Identification

Name
Paclitaxel
Accession Number
DB01229  (APRD00259, DB05261, DB05927, DB05526)
Type
Small Molecule
Groups
Approved, Vet Approved
Description

Paclitaxel is a mitotic inhibitor used in cancer chemotherapy. It was discovered in a US National Cancer Institute program at the Research Triangle Institute in 1967 when Monroe E. Wall and Mansukh C. Wani isolated it from the bark of the Pacific yew tree, Taxus brevifolia and named it taxol. Later it was discovered that endophytic fungi in the bark synthesize paclitaxel. When it was developed commercially by Bristol-Myers Squibb (BMS), the generic name was changed to paclitaxel and the BMS compound is sold under the trademark Taxol. In this formulation, paclitaxel is dissolved in Kolliphor EL and ethanol, as a delivery agent. A newer formulation, in which paclitaxel is bound to albumin, is sold under the trademark Abraxane. [Wikipedia]

Structure
Thumb
Synonyms
  • (2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
  • 5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
  • Paclitaxel
  • Taxol A
External IDs
ABI-007 / BMS 181339-01 / BMS-181339-01 / DHP 107 / MBT 0206 / MBT-0206 / NK 105 / NSC-125973 / QW-8184
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AbraxaneInjection, powder, lyophilized, for suspension100 mg/20mLIntravenousAbraxis Bio Science, Llc2005-02-10Not applicableUs
AbraxaneInjection, powder, for suspension5 mg/mlIntravenousCelgene Europe Limited2008-01-11Not applicableEu
AbraxaneInjection, powder, for suspension5 mg/mlIntravenousCelgene Europe Limited2008-01-11Not applicableEu
Abraxane for Injectable SuspensionPowder, for suspension100 mgIntravenousCelgene2006-08-31Not applicableCanada
Aj-paclitaxelSolution6 mgIntravenousAgila Jamp Canada IncNot applicableNot applicableCanada
PaclitaxelInjection6 mg/mLIntravenousWG Critical Care, LLC2013-07-11Not applicableUs
PaclitaxelInjection6 mg/mLIntravenousWG Critical Care, LLC2013-07-11Not applicableUs
PaclitaxelInjection6 mg/mLIntravenousWG Critical Care, LLC2013-07-11Not applicableUs
PaclitaxelLiquid6 mgIntravenousIvax Pharmaceuticals IncorporatedNot applicableNot applicableCanada
Paclitaxel for InjectionSolution6 mgIntravenousTevaNot applicableNot applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-paclitaxel InjectableSolution6 mgIntravenousApotex Corporation2005-02-07Not applicableCanada
PaclitaxelInjection, solution6 mg/mLIntravenousActavis Pharma Company2015-01-05Not applicableUs
PaclitaxelInjection, solution30 mg/5mLIntravenousBreckenridge Pharmaceutical, Inc.2016-09-30Not applicableUs
PaclitaxelInjection, solution6 mg/mLIntravenousSagent Pharmaceuticals2011-09-27Not applicableUs
PaclitaxelInjection, solution, concentrate6 mg/mLIntravenousTeva Parenteral Medicines, Inc.2008-10-23Not applicableUs
PaclitaxelInjection100 mg/16.7mLIntravenousPfizer Laboratories Div Pfizer Inc.2011-09-30Not applicableUs
PaclitaxelInjection100 mg/16.7mLIntravenousMylan Institutional2011-09-30Not applicableUs
PaclitaxelInjection, solution, concentrate6 mg/mLIntravenousTeva Parenteral Medicines, Inc.2009-11-03Not applicableUs
PaclitaxelInjection, solution6 mg/mLIntravenousSandoz2008-01-02Not applicableUs
PaclitaxelInjection, solution, concentrate6 mg/mLIntravenousTeva Parenteral Medicines, Inc.2009-09-16Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
PaxeneInjection, solution, concentrate6 mg/mlIntravenousNorton Healthcare Ltd.1999-07-19Not applicableEu
PaxeneInjection, solution, concentrate6 mg/mlIntravenousNorton Healthcare Ltd.1999-07-19Not applicableEu
PaxeneInjection, solution, concentrate6 mg/mlIntravenousNorton Healthcare Ltd.1999-07-19Not applicableEu
PaxeneInjection, solution, concentrate6 mg/mlIntravenousNorton Healthcare Ltd.1999-07-19Not applicableEu
International/Other Brands
Onxol / Paxceed / Taxol
Categories
UNII
P88XT4IS4D
CAS number
33069-62-4
Weight
Average: 853.9061
Monoisotopic: 853.330955345
Chemical Formula
C47H51NO14
InChI Key
RCINICONZNJXQF-MZXODVADSA-N
InChI
InChI=1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1
IUPAC Name
(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-bis(acetyloxy)-1,9-dihydroxy-15-{[(2R,3S)-2-hydroxy-3-phenyl-3-(phenylformamido)propanoyl]oxy}-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0³,¹⁰.0⁴,⁷]heptadec-13-en-2-yl benzoate
SMILES
[H][[email protected]]12[[email protected]](OC(=O)C3=CC=CC=C3)[[email protected]]3(O)C[[email protected]](OC(=O)[[email protected]](O)[[email protected]@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([[email protected]@H](OC(C)=O)C(=O)[[email protected]]1(C)[[email protected]@H](O)C[[email protected]]1OC[[email protected]@]21OC(C)=O)C3(C)C

Pharmacology

Indication

Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Structured Indications
Pharmacodynamics

Paclitaxel is a taxoid antineoplastic agent indicated as first-line and subsequent therapy for the treatment of advanced carcinoma of the ovary, and other various cancers including breast cancer. Paclitaxel is a novel antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions. In addition, paclitaxel induces abnormal arrays or "bundles" of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis.

Mechanism of action

Paclitaxel interferes with the normal function of microtubule growth. Whereas drugs like colchicine cause the depolymerization of microtubules in vivo, paclitaxel arrests their function by having the opposite effect; it hyper-stabilizes their structure. This destroys the cell's ability to use its cytoskeleton in a flexible manner. Specifically, paclitaxel binds to the β subunit of tubulin. Tubulin is the "building block" of mictotubules, and the binding of paclitaxel locks these building blocks in place. The resulting microtubule/paclitaxel complex does not have the ability to disassemble. This adversely affects cell function because the shortening and lengthening of microtubules (termed dynamic instability) is necessary for their function as a transportation highway for the cell. Chromosomes, for example, rely upon this property of microtubules during mitosis. Further research has indicated that paclitaxel induces programmed cell death (apoptosis) in cancer cells by binding to an apoptosis stopping protein called Bcl-2 (B-cell leukemia 2) and thus arresting its function.

TargetActionsOrganism
AApoptosis regulator Bcl-2
inhibitor
Human
ATubulin beta-1 chain
inhibitor
Human
UNuclear receptor subfamily 1 group I member 2
inducer
Human
AMicrotubule-associated protein 4Not AvailableHuman
AMicrotubule-associated protein 2Not AvailableHuman
AMicrotubule-associated protein tauNot AvailableHuman
Absorption

When a 24 hour infusion of 135 mg/m^2 is given to ovarian cancer patients, the maximum plasma concentration (Cmax) is 195 ng/mL, while the AUC is 6300 ng•h/mL.

Volume of distribution
  • 227 to 688 L/m^2 [apparent volume of distribution at steady-state, 24 hour infusion]
Protein binding

89%-98% bound to plasma protein. The presence of cimetidine, ranitidine, dexamethasone, or diphenhydramine did not affect protein binding of paclitaxel.

Metabolism

Hepatic. In vitro studies with human liver microsomes and tissue slices showed that paclitaxel was metabolized primarily to 6a-hydrox-ypaclitaxel by the cytochrome P450 isozyme CYP2C8; and to two minor metabolites, 3’-p-hydroxypaclitaxel and 6a, 3’-p-dihydroxypaclitaxel, by CYP3A4.

Route of elimination

In 5 patients administered a 225 or 250 mg/m2 dose of radiolabeled paclitaxel as a 3-hour infusion, a mean of 71% of the radioactivity was excreted in the feces in 120 hours, and 14% was recovered in the urine.

Half life

When a 24 hour infusion of 135 mg/m^2 is given to ovarian cancer patients, the elimination half=life is 52.7 hours.

Clearance
  • 21.7 L/h/m2 [Dose 135 mg/m2, infusion duration 24 h]
  • 23.8 L/h/m2 [Dose 175 mg/m2, infusion duration 24 h]
  • 7 L/h/m2 [Dose 135 mg/m2, infusion duration 3 h]
  • 12.2 L/h/m2 [Dose 175 mg/m2, infusion duration 3 h]
Toxicity

Rat (ipr) LD50=32530 µg/kg. Symptoms of overdose include bone marrow suppression, peripheral neurotoxicity, and mucositis. Overdoses in pediatric patients may be associated with acute ethanol toxicity.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Paclitaxel Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
10-hydroxycamptothecinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with 10-hydroxycamptothecin.Investigational
2-(4-Chlorophenyl)-5-QuinoxalinecarboxamideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide.Experimental
2-chloroethyl-3-sarcosinamide-1-nitrosoureaThe risk or severity of adverse effects can be increased when Paclitaxel is combined with 2-chloroethyl-3-sarcosinamide-1-nitrosourea.Investigational
2-MethoxyestradiolThe risk or severity of adverse effects can be increased when Paclitaxel is combined with 2-Methoxyestradiol.Investigational
3-MethoxybenzamideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with 3-Methoxybenzamide.Experimental
3,3'-diindolylmethaneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with 3,3'-diindolylmethane.Investigational
3,4-Dihydroxybenzoic AcidThe risk or severity of adverse effects can be increased when Paclitaxel is combined with 3,4-Dihydroxybenzoic Acid.Experimental
6-O-benzylguanineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with 6-O-benzylguanine.Investigational
7-HydroxystaurosporineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with 7-Hydroxystaurosporine.Experimental, Investigational
8-azaguanineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with 8-azaguanine.Experimental
9-aminocamptothecinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with 9-aminocamptothecin.Investigational
AbirateroneThe serum concentration of Paclitaxel can be increased when it is combined with Abiraterone.Approved
AcebutololThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Acebutolol.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Paclitaxel.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Paclitaxel.Experimental
AclarubicinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Aclarubicin.Investigational
Acridine CarboxamideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Acridine Carboxamide.Investigational
ActeosideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Acteoside.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Paclitaxel.Approved
AfimoxifeneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Afimoxifene.Investigational
AfliberceptThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Aflibercept.Approved
AlatrofloxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Alatrofloxacin.Withdrawn
AlbendazoleThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Albendazole.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Aldesleukin.Approved
AlectinibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Alectinib.Approved
AlemtuzumabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Alemtuzumab.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Aliskiren.Approved, Investigational
AlitretinoinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Alitretinoin.Approved, Investigational
AltretamineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Altretamine.Approved
AlvocidibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Alvocidib.Experimental, Investigational
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Paclitaxel.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Amiloride.Approved
AminoglutethimideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Aminoglutethimide.Approved, Investigational
Aminolevulinic acidThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Aminolevulinic acid.Approved
AmiodaroneThe metabolism of Paclitaxel can be decreased when combined with Amiodarone.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Amlodipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Paclitaxel.Approved, Illicit
AmonafideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Amonafide.Investigational
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Paclitaxel.Approved, Investigational
AmrubicinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Amrubicin.Approved, Investigational
AmsacrineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Amsacrine.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Amyl Nitrite.Approved
AnagrelideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Anagrelide.Approved
AnastrozoleThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Anastrozole.Approved, Investigational
AnecortaveThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Anecortave.Investigational
annamycinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with annamycin.Investigational
AP 12009The risk or severity of adverse effects can be increased when Paclitaxel is combined with AP 12009.Investigational
AP24534The risk or severity of adverse effects can be increased when Paclitaxel is combined with AP24534.Investigational
ApaziquoneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Apaziquone.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Paclitaxel.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Apraclonidine.Approved
AprepitantThe serum concentration of Paclitaxel can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Paclitaxel.Approved, Investigational
Arotinoid acidThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Arotinoid acid.Experimental
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Paclitaxel.Approved, Investigational
Arsanilic acidThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Arsanilic acid.Experimental, Vet Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Arsenic trioxide.Approved, Investigational
AsparaginaseThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Asparaginase.Approved
AtazanavirThe serum concentration of Paclitaxel can be increased when it is combined with Atazanavir.Approved, Investigational
AtazanavirThe metabolism of Paclitaxel can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Atenolol.Approved
AtezolizumabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Atezolizumab.Approved
AtomoxetineThe metabolism of Paclitaxel can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Atorvastatin.Approved
AxitinibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Axitinib.Approved, Investigational
AzacitidineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Azacitidine.Approved, Investigational
AzathioprineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Azathioprine.Approved
Azelaic AcidThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Azelaic Acid.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Azilsartan medoxomil.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Paclitaxel.Experimental
BarbitalBarbital may increase the hypotensive activities of Paclitaxel.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Paclitaxel.Approved
BatimastatThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Batimastat.Experimental
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Paclitaxel.Investigational
BelinostatThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Belinostat.Approved, Investigational
BelotecanThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Belotecan.Investigational
BenazeprilThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Benazepril.Approved, Investigational
BendamustineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Bendamustine.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Bendroflumethiazide.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Paclitaxel.Approved, Withdrawn
BesifloxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Besifloxacin.Approved
BetaxololThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Betaxolol.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Paclitaxel.Approved, Investigational
BexaroteneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Bexarotene.Approved, Investigational
BexaroteneThe serum concentration of Bexarotene can be increased when it is combined with Paclitaxel.Approved, Investigational
BicalutamideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Bicalutamide.Approved
BinetrakinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Binetrakin.Investigational
BisoprololThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Bisoprolol.Approved
BizelesinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Bizelesin.Investigational
BleomycinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Bleomycin.Approved
BlinatumomabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Blinatumomab.Approved
BoceprevirThe metabolism of Paclitaxel can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Paclitaxel can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Paclitaxel.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Paclitaxel.Approved
BretyliumThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Brimonidine.Approved
BroxuridineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Broxuridine.Investigational
Bryostatin 1The risk or severity of adverse effects can be increased when Paclitaxel is combined with Bryostatin 1.Investigational
BSI-201The risk or severity of adverse effects can be increased when Paclitaxel is combined with BSI-201.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Paclitaxel.Approved, Investigational
BuserelinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Buserelin.Approved
BusulfanThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Busulfan.Approved, Investigational
Buthionine SulfoximineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Buthionine Sulfoximine.Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Cabazitaxel.Approved
CabergolineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Cabergoline.Approved
CabozantinibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Cabozantinib.Approved
CalcipotriolThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Calcipotriol.Approved
CamptothecinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Camptothecin.Experimental
CanagliflozinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Canagliflozin.Approved
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Candesartan cilexetil.Approved
CanertinibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Canertinib.Investigational
CapecitabineThe metabolism of Paclitaxel can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Captopril.Approved
CarbamazepineThe metabolism of Paclitaxel can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Paclitaxel.Approved
CarboplatinCarboplatin may increase the myelosuppressive activities of Paclitaxel.Approved
CarboquoneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Carboquone.Experimental
CarboxyamidotriazoleThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Carboxyamidotriazole.Investigational
CarfilzomibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Carfilzomib.Approved
CarmofurThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Carmofur.Withdrawn
CarmustineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Carmustine.Approved
CarteololThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Carteolol.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Carvedilol.Approved, Investigational
CatumaxomabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Catumaxomab.Approved, Investigational
CediranibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Cediranib.Investigational
CelecoxibThe metabolism of Paclitaxel can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Paclitaxel can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Paclitaxel.Withdrawn
CetuximabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Cetuximab.Approved
ChlorambucilThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Chlorambucil.Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Chlorotrianisene.Investigational, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Paclitaxel.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Chlorthalidone.Approved
CholecalciferolThe metabolism of Paclitaxel can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholesterolThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Cholesterol.Experimental, Investigational
Cholic AcidPaclitaxel may decrease the excretion rate of Cholic Acid which could result in a higher serum level.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Paclitaxel.Approved, Investigational
CinoxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ciprofloxacin.Approved, Investigational
CisplatinCisplatin may increase the myelosuppressive activities of Paclitaxel.Approved
CladribineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Cladribine.Approved, Investigational
ClarithromycinThe metabolism of Paclitaxel can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Paclitaxel can be decreased when combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Clofarabine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Paclitaxel.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Clonidine.Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Paclitaxel.Approved
ClotrimazoleThe metabolism of Paclitaxel can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Clozapine.Approved
CobicistatThe metabolism of Paclitaxel can be decreased when combined with Cobicistat.Approved
CobimetinibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Cobimetinib.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Paclitaxel.Approved
CombretastatinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Combretastatin.Investigational
ConivaptanThe serum concentration of Paclitaxel can be increased when it is combined with Conivaptan.Approved, Investigational
CordycepinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Cordycepin.Investigational
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Paclitaxel.Approved
Coumermycin A1The risk or severity of adverse effects can be increased when Paclitaxel is combined with Coumermycin A1.Experimental
CrenolanibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Crenolanib.Investigational
CrisaboroleThe metabolism of Paclitaxel can be decreased when combined with Crisaborole.Approved
CrizotinibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Crizotinib.Approved
CurcuminThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Curcumin.Investigational
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Paclitaxel.Approved, Investigational
CyclosporineThe metabolism of Paclitaxel can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Paclitaxel.Experimental
Cyproterone acetateThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Cyproterone acetate.Approved, Investigational
CytarabineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Cytarabine.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Paclitaxel.Approved
DabrafenibThe serum concentration of Paclitaxel can be decreased when it is combined with Dabrafenib.Approved
DacarbazineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Dacarbazine.Approved, Investigational
DactinomycinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Dactinomycin.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Dapagliflozin.Approved
DaratumumabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Daratumumab.Approved
DarunavirThe metabolism of Paclitaxel can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Paclitaxel can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Daunorubicin.Approved
DecitabineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Decitabine.Approved, Investigational
DeferasiroxThe serum concentration of Paclitaxel can be decreased when it is combined with Deferasirox.Approved, Investigational
DegarelixThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Degarelix.Approved
DelavirdineThe metabolism of Paclitaxel can be decreased when combined with Delavirdine.Approved
DemecolcineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Demecolcine.Experimental
Denileukin diftitoxThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Denileukin diftitox.Approved, Investigational
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Paclitaxel.Approved
DeoxyspergualinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Deoxyspergualin.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Paclitaxel.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Paclitaxel.Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Dexmedetomidine.Approved, Vet Approved
DexrazoxaneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Dexrazoxane.Approved, Withdrawn
DianhydrogalactitolThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Dianhydrogalactitol.Investigational
DiclofenamideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Diclofenamide.Approved
DidoxThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Didox.Investigational
DienogestThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Dienogest.Approved
diethylnorspermineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with diethylnorspermine.Investigational
DiethylstilbestrolThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Diethylstilbestrol.Approved, Investigational
DigitoxinDigitoxin may decrease the cardiotoxic activities of Paclitaxel.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Paclitaxel.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Paclitaxel.Approved
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Paclitaxel.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Paclitaxel.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Paclitaxel.Experimental
DihydroergotamineThe metabolism of Paclitaxel can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Paclitaxel can be decreased when combined with Diltiazem.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Dipyridamole.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Docetaxel.Approved, Investigational
Dolastatin 10The risk or severity of adverse effects can be increased when Paclitaxel is combined with Dolastatin 10.Investigational
DosulepinThe metabolism of Paclitaxel can be decreased when combined with Dosulepin.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Doxazosin.Approved
DoxifluridineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Doxifluridine.Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Paclitaxel.Approved, Investigational
DoxorubicinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Paclitaxel can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Paclitaxel can be decreased when combined with Dronedarone.Approved
DuligotuzumabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Duligotuzumab.Investigational
DuloxetinePaclitaxel may increase the orthostatic hypotensive activities of Duloxetine.Approved
EcabetThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ecabet.Approved, Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Paclitaxel.Approved
EdrecolomabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Edrecolomab.Experimental, Investigational
EfaproxiralThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Efaproxiral.Investigational
EfatutazoneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Efatutazone.Investigational
EfavirenzThe metabolism of Paclitaxel can be decreased when combined with Efavirenz.Approved, Investigational
EflornithineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Eflornithine.Approved, Withdrawn
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Paclitaxel.Approved, Investigational
EG009The risk or severity of adverse effects can be increased when Paclitaxel is combined with EG009.Investigational
ElotuzumabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Elotuzumab.Approved
ElsamitrucinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Elsamitrucin.Investigational
EltrombopagThe serum concentration of Paclitaxel can be increased when it is combined with Eltrombopag.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Paclitaxel.Approved
EndostatinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Endostatin.Investigational
EnoxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Enoxacin.Approved, Investigational
EnrofloxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Enrofloxacin.Vet Approved
EntinostatThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Entinostat.Investigational
EnzalutamideThe serum concentration of Paclitaxel can be decreased when it is combined with Enzalutamide.Approved
Epigallocatechin GallateThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Epigallocatechin Gallate.Investigational
EpirubicinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Epirubicin.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Eplerenone.Approved
EpofolateThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Epofolate.Investigational
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Paclitaxel.Approved
EprosartanThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Eprosartan.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Paclitaxel.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Paclitaxel.Approved
EribulinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Eribulin.Approved, Investigational
ErlotinibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Erlotinib.Approved, Investigational
ErythromycinThe metabolism of Paclitaxel can be decreased when combined with Erythromycin.Approved, Vet Approved
EsmololThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Esmolol.Approved
EstramustineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Estramustine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Etacrynic acid.Approved
EtanidazoleThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Etanidazole.Investigational
Ethiodized oilThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ethiodized oil.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ethyl carbamate.Withdrawn
EtoglucidThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Etoglucid.Experimental
EtoposideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Etoposide.Approved
EtravirineThe metabolism of Paclitaxel can be decreased when combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Paclitaxel.Approved
ExatecanThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Exatecan.Investigational
ExemestaneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Exemestane.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when Paclitaxel is combined with exisulind.Investigational
FelodipineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Felodipine.Approved, Investigational
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Paclitaxel.Approved
FenretinideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Fenretinide.Investigational
FiacitabineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Fiacitabine.Investigational
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Paclitaxel.Approved, Investigational
FingolimodPaclitaxel may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FleroxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Fleroxacin.Approved
FloxuridineThe metabolism of Paclitaxel can be decreased when combined with Floxuridine.Approved
FluconazoleThe metabolism of Paclitaxel can be decreased when combined with Fluconazole.Approved
FludarabineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Fludarabine.Approved
FlumequineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Flumequine.Withdrawn
FluorouracilThe metabolism of Paclitaxel can be decreased when combined with Fluorouracil.Approved
FlutamideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Flutamide.Approved
FluvastatinThe metabolism of Paclitaxel can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Paclitaxel can be decreased when combined with Fluvoxamine.Approved, Investigational
FormestaneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Formestane.Approved, Investigational, Withdrawn
FormycinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Formycin.Experimental
FosamprenavirThe metabolism of Paclitaxel can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Paclitaxel can be increased when it is combined with Fosaprepitant.Approved
FosbretabulinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Fosbretabulin.Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Fosinopril.Approved
FosphenytoinThe metabolism of Paclitaxel can be increased when combined with Fosphenytoin.Approved
FotemustineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Fotemustine.Experimental, Investigational
FulvestrantThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Fulvestrant.Approved, Investigational
FumagillinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Fumagillin.Experimental
FurosemideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Paclitaxel can be increased when it is combined with Fusidic Acid.Approved
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Paclitaxel.Investigational
Gallium nitrateThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Gallium nitrate.Approved, Investigational
GarenoxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Gatifloxacin.Approved, Investigational
GefitinibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Gefitinib.Approved, Investigational
GeldanamycinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Geldanamycin.Experimental, Investigational
GemcitabineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Gemcitabine.Approved
GemfibrozilThe metabolism of Paclitaxel can be decreased when combined with Gemfibrozil.Approved
GemifloxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Gemifloxacin.Approved, Investigational
Gemtuzumab ozogamicinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Gemtuzumab ozogamicin.Approved
GenisteinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Genistein.Investigational
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Paclitaxel.Investigational
Ginsenoside CThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ginsenoside C.Nutraceutical
GitoformateGitoformate may decrease the cardiotoxic activities of Paclitaxel.Experimental
GoserelinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Goserelin.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Grepafloxacin.Investigational, Withdrawn
GS 0573The risk or severity of adverse effects can be increased when Paclitaxel is combined with GS 0573.Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Guanfacine.Approved, Investigational
GusperimusThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Gusperimus.Investigational
HadacidinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Hadacidin.Experimental
HalofuginoneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Halofuginone.Investigational, Vet Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Paclitaxel.Approved, Vet Approved
Hepatitis A VaccineThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Paclitaxel.Approved
Hepatitis B Vaccine (Recombinant)The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Paclitaxel.Approved, Withdrawn
HexestrolThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Hexestrol.Withdrawn
HexobarbitalHexobarbital may increase the hypotensive activities of Paclitaxel.Approved
HydralazineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Paclitaxel.Approved, Investigational
Hydroxyprogesterone caproateThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Hydroxyprogesterone caproate.Approved
HydroxyureaThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Hydroxyurea.Approved
HypericinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Hypericin.Investigational
IbrutinibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ibrutinib.Approved
IdarubicinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Idarubicin.Approved
IdelalisibThe serum concentration of Paclitaxel can be increased when it is combined with Idelalisib.Approved
IfosfamideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ifosfamide.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Paclitaxel.Approved, Investigational
ImatinibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Paclitaxel.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Paclitaxel.Approved
ImiquimodThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Imiquimod.Approved, Investigational
IndapamideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Indapamide.Approved
IndinavirThe metabolism of Paclitaxel can be decreased when combined with Indinavir.Approved
IndirubinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Indirubin.Investigational
Indole-3-carbinolThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Indole-3-carbinol.Investigational
IndoraminThe risk or severity of adverse effects can be increased when Indoramin is combined with Paclitaxel.Withdrawn
InfigratinibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Infigratinib.Investigational
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with Paclitaxel.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Paclitaxel.Investigational
IniparibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Iniparib.Experimental, Investigational
Interferon Alfa-2b, RecombinantThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Interferon Alfa-2b, Recombinant.Approved
Interferon beta-1aThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Interferon beta-1a.Approved, Investigational
IobenguaneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Iobenguane.Approved, Investigational
IpilimumabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ipilimumab.Approved
IrbesartanThe metabolism of Paclitaxel can be decreased when combined with Irbesartan.Approved, Investigational
IrinotecanThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Irinotecan.Approved, Investigational
IrofulvenThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Irofulven.Investigational
IrsogladineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Irsogladine.Investigational
IsavuconazoniumThe metabolism of Paclitaxel can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Paclitaxel.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Paclitaxel.Approved, Vet Approved
IsosorbideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Isosorbide.Approved, Investigational
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe metabolism of Paclitaxel can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Paclitaxel can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Paclitaxel can be increased when it is combined with Ivacaftor.Approved
IxabepiloneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ixabepilone.Approved, Investigational
IxazomibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ixazomib.Approved
KetoconazoleThe metabolism of Paclitaxel can be decreased when combined with Ketoconazole.Approved, Investigational
KOS-1584The risk or severity of adverse effects can be increased when Paclitaxel is combined with KOS-1584.Investigational
KRN-7000The risk or severity of adverse effects can be increased when Paclitaxel is combined with KRN-7000.Investigational
L-alanosineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with L-alanosine.Investigational
LabetalolThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Labetalol.Approved
LacidipineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Paclitaxel.Approved, Investigational
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Paclitaxel.Experimental
LanreotideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Lanreotide.Approved
LapatinibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Lapatinib.Approved, Investigational
LCL-161The risk or severity of adverse effects can be increased when Paclitaxel is combined with LCL-161.Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Paclitaxel.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Leflunomide.Approved, Investigational
LenalidomideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Lenalidomide.Approved
LentinanThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Lentinan.Experimental, Investigational
LenvatinibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Lenvatinib.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Paclitaxel.Approved, Investigational
LetrozoleThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Letrozole.Approved, Investigational
LeuprolideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Leuprolide.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Paclitaxel.Approved, Investigational
LevodopaPaclitaxel may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Levofloxacin.Approved, Investigational
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Paclitaxel.Approved, Investigational
LiarozoleThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Liarozole.Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Lisinopril.Approved, Investigational
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Paclitaxel.Approved, Investigational
LobeglitazoneThe metabolism of Paclitaxel can be decreased when combined with Lobeglitazone.Approved, Investigational
LofexidineThe risk or severity of adverse effects can be increased when Lofexidine is combined with Paclitaxel.Approved, Investigational
LomefloxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Lomefloxacin.Approved, Investigational
LometrexolThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Lometrexol.Investigational
LomustineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Lomustine.Approved
LonidamineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Lonidamine.Approved, Investigational
LopinavirThe metabolism of Paclitaxel can be decreased when combined with Lopinavir.Approved
LosartanThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Losartan.Approved
LovastatinThe metabolism of Paclitaxel can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Paclitaxel can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Paclitaxel can be increased when it is combined with Lumacaftor.Approved
LurtotecanThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Lurtotecan.Investigational
LycopeneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Lycopene.Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Paclitaxel.Illicit, Investigational, Withdrawn
MafosfamideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Mafosfamide.Investigational
ManidipineThe metabolism of Paclitaxel can be decreased when combined with Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Mannitol.Approved, Investigational
MannosulfanThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Mannosulfan.Experimental
MasitinibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Masitinib.Investigational, Vet Approved
MasoprocolThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Masoprocol.Approved, Investigational
MaxacalcitolThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Maxacalcitol.Approved, Investigational
MebendazoleThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Mebendazole.Approved, Vet Approved
MecamylamineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Mecamylamine.Approved
MechlorethamineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Mechlorethamine.Approved
MedrogestoneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Medrogestone.Approved
Medroxyprogesterone acetateThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Medroxyprogesterone acetate.Approved, Investigational
Megestrol acetateThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Megestrol acetate.Approved, Vet Approved
MelphalanThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Melphalan.Approved
MequinolThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Mequinol.Approved
MercaptopurineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Mercaptopurine.Approved
MerestinibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Merestinib.Investigational
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Paclitaxel.Investigational, Withdrawn
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Paclitaxel.Experimental
MethazolamideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Paclitaxel.Approved
MethotrexateThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Methotrexate.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Methyclothiazide.Approved
Methyl aminolevulinateThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Methyl aminolevulinate.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Methyldopa.Approved
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Paclitaxel.Approved
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Paclitaxel.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Methylprednisolone.Approved, Vet Approved
MethylselenocysteineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Methylselenocysteine.Investigational
MethyltestosteroneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Methyltestosterone.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Paclitaxel.Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Paclitaxel.Experimental
MetipranololThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Metolazone.Approved
MetoprineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Metoprine.Experimental
MetoprololThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Metoprolol.Approved, Investigational
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Paclitaxel.Experimental
MidostaurinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Midostaurin.Approved
MifepristoneThe serum concentration of Paclitaxel can be increased when it is combined with Mifepristone.Approved, Investigational
MiltefosineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Miltefosine.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Minoxidil.Approved
MisonidazoleThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Misonidazole.Investigational
MitobronitolThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Mitobronitol.Experimental
MitoguazoneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Mitoguazone.Investigational
MitolactolThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Mitolactol.Investigational
MitomycinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Mitomycin.Approved
MitotaneThe serum concentration of Paclitaxel can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Mitoxantrone.Approved, Investigational
MizoribineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Mizoribine.Investigational
MLN576The risk or severity of adverse effects can be increased when Paclitaxel is combined with MLN576.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Moexipril.Approved
MolgramostimThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Molgramostim.Investigational
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Paclitaxel.Approved, Investigational
motexafin gadoliniumThe risk or severity of adverse effects can be increased when Paclitaxel is combined with motexafin gadolinium.Investigational
MoxifloxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Moxifloxacin.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Moxonidine is combined with Paclitaxel.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Mycophenolic acid.Approved
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Paclitaxel.Approved, Investigational
NadifloxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Nadifloxacin.Investigational
NadololThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Nadolol.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Nalidixic Acid.Approved, Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Paclitaxel.Approved
NamitecanThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Namitecan.Investigational
NatalizumabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Natalizumab.Approved, Investigational
NavitoclaxThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Navitoclax.Investigational
NebivololThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Nebivolol.Approved, Investigational
NebularineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Nebularine.Experimental
NecitumumabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Necitumumab.Approved
NedaplatinNedaplatin may increase the myelosuppressive activities of Paclitaxel.Approved, Investigational
NefazodoneThe metabolism of Paclitaxel can be decreased when combined with Nefazodone.Approved, Withdrawn
NelarabineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Nelarabine.Approved, Investigational
NelfinavirThe metabolism of Paclitaxel can be decreased when combined with Nelfinavir.Approved
NesiritideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Paclitaxel can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Paclitaxel can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Paclitaxel can be decreased when combined with Nicardipine.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Paclitaxel.Approved, Investigational
NicorandilNicorandil may increase the hypotensive activities of Paclitaxel.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Nifedipine.Approved
NiguldipineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Niguldipine.Experimental
NilotinibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Nilotinib.Approved, Investigational
NilutamideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Nilutamide.Approved
NilvadipineThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Paclitaxel.Approved, Investigational
NimodipineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Nimodipine.Approved
NimustineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Nimustine.Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Paclitaxel.Approved
NiraparibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Niraparib.Approved, Investigational
NisoldipineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Nisoldipine.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Paclitaxel.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Paclitaxel.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Nitroprusside.Approved
NivolumabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Nivolumab.Approved
nocodazoleThe risk or severity of adverse effects can be increased when Paclitaxel is combined with nocodazole.Experimental
NolatrexedThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Nolatrexed.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Norfloxacin.Approved
NOV-002NOV-002 may increase the myelosuppressive activities of Paclitaxel.Investigational
ObinutuzumabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Obinutuzumab.Approved
OblimersenThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Oblimersen.Experimental, Investigational
OBP-801The risk or severity of adverse effects can be increased when Paclitaxel is combined with OBP-801.Investigational
OctreotideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Octreotide.Approved, Investigational
OfatumumabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ofatumumab.Approved
OfloxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ofloxacin.Approved
OglufanideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Oglufanide.Investigational
OlaparibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Olaparib.Approved
OleandrinOleandrin may decrease the cardiotoxic activities of Paclitaxel.Experimental, Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Olmesartan.Approved, Investigational
OltiprazThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Oltipraz.Investigational
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Omacetaxine mepesuccinate.Approved
OmeprazoleThe metabolism of Paclitaxel can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OnapristoneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Onapristone.Investigational
OprelvekinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Oprelvekin.Approved, Investigational
OsimertinibThe serum concentration of Paclitaxel can be increased when it is combined with Osimertinib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Paclitaxel.Approved
OxaliplatinOxaliplatin may increase the myelosuppressive activities of Paclitaxel.Approved, Investigational
Oxolinic acidThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Oxolinic acid.Experimental
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Paclitaxel.Approved
Paclitaxel poliglumexThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Paclitaxel poliglumex.Experimental, Investigational
PalbociclibThe serum concentration of Paclitaxel can be increased when it is combined with Palbociclib.Approved
PalifosfamideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Palifosfamide.Investigational
PamidronateThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pamidronate.Approved
PanitumumabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Panitumumab.Approved, Investigational
PanobinostatThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Panobinostat.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Papaverine.Approved
PatupiloneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Patupilone.Experimental, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Paclitaxel.Approved
PazufloxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pefloxacin.Approved
PegaspargaseThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pegaspargase.Approved, Investigational
PembrolizumabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pembrolizumab.Approved
PemetrexedThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pemetrexed.Approved, Investigational
PenbutololThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Penbutolol.Approved, Investigational
PenclomedineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Penclomedine.Investigational
PentobarbitalThe metabolism of Paclitaxel can be increased when combined with Pentobarbital.Approved, Vet Approved
PentostatinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pentostatin.Approved, Investigational
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Paclitaxel.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Perindopril.Approved
PertuzumabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pertuzumab.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Paclitaxel.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Phenelzine.Approved
Phenethyl IsothiocyanateThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Phenethyl Isothiocyanate.Investigational
PhenobarbitalThe metabolism of Paclitaxel can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Phenoxybenzamine.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Phentolamine.Approved
Phenylacetic acidThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Phenylacetic acid.Approved
Phenylbutyric acidThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Phenylbutyric acid.Approved, Investigational
PhenytoinThe metabolism of Paclitaxel can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Paclitaxel.Approved, Investigational
PindololThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pindolol.Approved
PinometostatThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pinometostat.Investigational
PioglitazoneThe metabolism of Paclitaxel can be decreased when combined with Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pipamperone.Approved, Investigational
PipobromanThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pipobroman.Approved
PirarubicinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pirarubicin.Investigational
PirfenidoneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pirfenidone.Approved, Investigational
PirlindoleThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pirlindole.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Paclitaxel.Approved
PixantroneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pixantrone.Approved, Investigational
PlevitrexedThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Plevitrexed.Investigational
PlicamycinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Plicamycin.Approved, Investigational, Withdrawn
PodofiloxThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Podofilox.Approved
PodophyllinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Podophyllin.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pomalidomide.Approved
PonatinibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ponatinib.Approved
Porfimer sodiumThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Porfimer sodium.Approved, Investigational
porfiromycinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with porfiromycin.Investigational
PosaconazoleThe metabolism of Paclitaxel can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PralatrexateThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pralatrexate.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pramipexole.Approved, Investigational
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Paclitaxel.Approved
PrazosinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Prazosin.Approved
PrednimustineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Prednimustine.Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Prednisone.Approved, Vet Approved
PrimidoneThe metabolism of Paclitaxel can be increased when combined with Primidone.Approved, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Procarbazine.Approved
PropofolThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Propranolol.Approved, Investigational
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Paclitaxel.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Paclitaxel.Approved
PrulifloxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Prulifloxacin.Investigational
PuromycinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Puromycin.Experimental
PyrazoloacridineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pyrazoloacridine.Investigational
PyrimethamineThe metabolism of Paclitaxel can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuetiapineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Quetiapine.Approved
QuinacrineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Quinacrine.Approved, Investigational
QuinaprilThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Quinapril.Approved, Investigational
QuinineThe metabolism of Paclitaxel can be decreased when combined with Quinine.Approved
RabeprazoleThe metabolism of Paclitaxel can be decreased when combined with Rabeprazole.Approved, Investigational
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Rabies virus inactivated antigen, A.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Paclitaxel.Approved
RabusertibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Rabusertib.Investigational
Radium Ra 223 DichlorideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Radium Ra 223 Dichloride.Approved, Investigational
RaltitrexedThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Raltitrexed.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ramipril.Approved
RamucirumabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ramucirumab.Approved, Investigational
RanibizumabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ranibizumab.Approved
RanimustineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ranimustine.Experimental
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Paclitaxel.Approved, Investigational
RanpirnaseThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ranpirnase.Investigational
RasagilineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Rasagiline.Approved
RegorafenibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Regorafenib.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Remifentanil.Approved
ReserpineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Reserpine.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Resveratrol.Approved, Experimental, Investigational
Rhodamine 6GThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Rhodamine 6G.Experimental
RidaforolimusThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ridaforolimus.Investigational
RifabutinThe metabolism of Paclitaxel can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Paclitaxel can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Paclitaxel can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Paclitaxel.Approved, Investigational
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Paclitaxel.Investigational
RiociguatThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Riociguat.Approved
RisperidonePaclitaxel may increase the hypotensive activities of Risperidone.Approved, Investigational
RituximabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Rituximab.Approved
RoflumilastRoflumilast may increase the immunosuppressive activities of Paclitaxel.Approved
RolapitantThe serum concentration of Paclitaxel can be increased when it is combined with Rolapitant.Approved
RomidepsinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Romidepsin.Approved, Investigational
RopiniroleThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ropivacaine.Approved
RoquinimexThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Roquinimex.Investigational
RosiglitazoneThe metabolism of Paclitaxel can be decreased when combined with Rosiglitazone.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Paclitaxel.Approved
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Paclitaxel.Approved
RotigotineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Rotigotine.Approved
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Paclitaxel.Approved
RubitecanThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Rubitecan.Investigational
RucaparibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Rucaparib.Approved, Investigational
RufloxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Rufloxacin.Experimental
RuxolitinibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ruxolitinib.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Sacubitril.Approved
SalirasibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Salirasib.Investigational
Salmonella typhi ty21a live antigenThe therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Paclitaxel.Approved
SaquinavirThe metabolism of Paclitaxel can be decreased when combined with Saquinavir.Approved, Investigational
SaracatinibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Saracatinib.Investigational
SatraplatinSatraplatin may increase the myelosuppressive activities of Paclitaxel.Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Paclitaxel.Approved
SecobarbitalThe metabolism of Paclitaxel can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Selegiline.Approved, Investigational, Vet Approved
SeliciclibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Seliciclib.Investigational
SemaxanibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Semaxanib.Investigational
SemustineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Semustine.Experimental, Investigational
SeocalcitolThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Seocalcitol.Experimental, Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe metabolism of Paclitaxel can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Paclitaxel.Approved
SiltuximabThe serum concentration of Paclitaxel can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Paclitaxel can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Paclitaxel.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Paclitaxel.Approved
SirolimusThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Sirolimus.Approved, Investigational
SitafloxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Sitafloxacin.Experimental, Investigational
SizofiranThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Sizofiran.Investigational
SoblidotinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Soblidotin.Investigational
Sodium NitriteThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Sodium Nitrite.Approved
SonidegibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Sonidegib.Approved, Investigational
SorafenibThe risk or severity of adverse effects can be increased when Sorafenib is combined with Paclitaxel.Approved, Investigational
SotalolThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Sotalol.Approved
SparfloxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Sparfloxacin.Approved, Investigational
Sparfosic acidThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Sparfosic acid.Experimental
SparsomycinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Sparsomycin.Experimental
SpironolactoneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Spironolactone.Approved
squalamineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with squalamine.Investigational
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Paclitaxel.Investigational
SRT501The risk or severity of adverse effects can be increased when Paclitaxel is combined with SRT501.Investigational
St. John's WortThe serum concentration of Paclitaxel can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Paclitaxel can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Streptokinase.Approved, Investigational
StreptozocinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Streptozocin.Approved
SufentanilThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Sufentanil.Approved, Investigational
SulfadiazineThe metabolism of Paclitaxel can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Paclitaxel can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Paclitaxel can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulforaphaneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Sulforaphane.Investigational
SulindacThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Sulindac.Approved
SunitinibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Sunitinib.Approved, Investigational
SuraminThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Suramin.Approved, Investigational
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Paclitaxel.Approved, Investigational
TalaporfinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Talaporfin.Investigational
TalazoparibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Talazoparib.Investigational
TamoxifenThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Tamoxifen.Approved
TamsulosinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Tamsulosin.Approved, Investigational
TaselisibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Taselisib.Investigational
TaurolidineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Taurolidine.Investigational
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Paclitaxel.Investigational
TegafurThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Tegafur.Approved
TelaprevirThe metabolism of Paclitaxel can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Paclitaxel can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Telmisartan.Approved, Investigational
TemafloxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Temafloxacin.Withdrawn
TemoporfinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Temoporfin.Approved, Investigational
TemozolomideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Temozolomide.Approved, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Temsirolimus.Approved
TeniposideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Teniposide.Approved
TerazosinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Terazosin.Approved
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Paclitaxel.Experimental
TeriflunomideThe serum concentration of Paclitaxel can be increased when it is combined with Teriflunomide.Approved
TestolactoneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Testolactone.Approved, Investigational
TezacitabineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Tezacitabine.Investigational
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Paclitaxel.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Paclitaxel.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Paclitaxel.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Thioridazine.Approved, Withdrawn
ThiotepaThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Thiotepa.Approved
ThymalfasinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Thymalfasin.Approved, Investigational
TiazofurineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Tiazofurine.Experimental
TiboloneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Tibolone.Approved, Investigational
TicagrelorThe metabolism of Paclitaxel can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Paclitaxel can be decreased when combined with Ticlopidine.Approved
TimololThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Timolol.Approved
TioguanineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Tioguanine.Approved
Tiomolibdate ionThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Tiomolibdate ion.Investigational
TipifarnibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Tipifarnib.Investigational
TirapazamineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Tirapazamine.Investigational
TivozanibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Tivozanib.Investigational
TizanidineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Paclitaxel can be decreased when it is combined with Tocilizumab.Approved
TofacitinibPaclitaxel may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolazolineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Tolazoline.Approved, Vet Approved
TolbutamideThe metabolism of Paclitaxel can be decreased when combined with Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Tolcapone.Approved, Withdrawn
TopiroxostatThe metabolism of Paclitaxel can be decreased when combined with Topiroxostat.Approved, Investigational
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Paclitaxel.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Torasemide.Approved
ToremifeneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Toremifene.Approved, Investigational
TositumomabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Tositumomab.Approved, Investigational
ToyocamycinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Toyocamycin.Experimental
TrabectedinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Trabectedin.Approved, Investigational
TrametinibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Trametinib.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Trandolapril.Approved
TranylcypromineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Tranylcypromine.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Paclitaxel.Approved, Investigational
TrastuzumabThe serum concentration of Paclitaxel can be decreased when it is combined with Trastuzumab.Approved, Investigational
Trastuzumab emtansineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Trastuzumab emtansine.Approved
TrebananibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Trebananib.Investigational
TremelimumabThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Tremelimumab.Investigational
TreosulfanThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Treosulfan.Investigational
TretazicarThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Tretazicar.Investigational
TretinoinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Triamterene.Approved
TriaziquoneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Triaziquone.Experimental
TrifluridineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Trifluridine.Approved
TrilostaneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Trilostane.Approved, Investigational, Vet Approved, Withdrawn
TrimethoprimThe metabolism of Paclitaxel can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrimetrexateThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Trimetrexate.Approved, Investigational
TriptolideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Triptolide.Investigational
TriptorelinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Triptorelin.Approved, Vet Approved
TrofosfamideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Trofosfamide.Investigational
TrovafloxacinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Trovafloxacin.Approved, Investigational, Withdrawn
TroxacitabineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Troxacitabine.Investigational
TubercidinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Tubercidin.Experimental
UbenimexThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ubenimex.Experimental, Investigational
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Paclitaxel.Approved, Experimental
Uracil mustardThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Uracil mustard.Approved
VadimezanThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Vadimezan.Investigational
Valproic AcidThe metabolism of Paclitaxel can be decreased when combined with Valproic Acid.Approved, Investigational
ValrubicinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Valrubicin.Approved
ValsartanThe metabolism of Paclitaxel can be decreased when combined with Valsartan.Approved, Investigational
VandetanibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Vandetanib.Approved
VapreotideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Vapreotide.Approved, Investigational
VeliparibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Veliparib.Investigational
VemurafenibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Vemurafenib.Approved
VenetoclaxThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Venetoclax.Approved
VenlafaxineThe metabolism of Paclitaxel can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Paclitaxel can be decreased when combined with Verapamil.Approved
VerteporfinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Verteporfin.Approved, Investigational
VesnarinoneThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Vesnarinone.Investigational
VinblastineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Vinblastine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Paclitaxel.Approved, Investigational
VincristineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Vincristine.Approved, Investigational
VindesineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Vindesine.Approved, Investigational
VinflunineThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Vinflunine.Approved
VinorelbinePaclitaxel may increase the neurotoxic activities of Vinorelbine.Approved, Investigational
VintafolideThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Vintafolide.Investigational
VismodegibThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Vismodegib.Approved
Vitamin AThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Vitamin A.Approved, Nutraceutical, Vet Approved
VoriconazoleThe metabolism of Paclitaxel can be decreased when combined with Voriconazole.Approved, Investigational
VorinostatThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Vorinostat.Approved, Investigational
VorozoleThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Vorozole.Experimental
Yellow fever vaccineThe therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Paclitaxel.Approved
ZafirlukastThe metabolism of Paclitaxel can be decreased when combined with Zafirlukast.Approved, Investigational
ZiprasidoneThe metabolism of Paclitaxel can be decreased when combined with Ziprasidone.Approved
ZorubicinThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Zorubicin.Experimental
Zoster vaccineThe therapeutic efficacy of Zoster vaccine can be decreased when used in combination with Paclitaxel.Approved
Zuretinol acetateThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Zuretinol acetate.Investigational
Food Interactions
  • Avoid echinacea.
  • Avoid grapefruit and grapefruit juice due to potential increase of paclitaxel.

References

Synthesis Reference

Hendricus B. A. de Bont, Ruben G. G. Leenders, Johan W. Scheeren, Hidde J. Haisma, Dick de Vos, "Paclitaxel prodrugs, method for preparation as well as their use in selective chemotherapy." U.S. Patent US5760072, issued September, 1989.

US5760072
General References
  1. Wall ME, Wani MC: Camptothecin and taxol: discovery to clinic--thirteenth Bruce F. Cain Memorial Award Lecture. Cancer Res. 1995 Feb 15;55(4):753-60. [PubMed:7850785]
  2. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT: Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc. 1971 May 5;93(9):2325-7. [PubMed:5553076]
  3. Fuchs DA, Johnson RK: Cytologic evidence that taxol, an antineoplastic agent from Taxus brevifolia, acts as a mitotic spindle poison. Cancer Treat Rep. 1978 Aug;62(8):1219-22. [PubMed:688258]
  4. Saville MW, Lietzau J, Pluda JM, Feuerstein I, Odom J, Wilson WH, Humphrey RW, Feigal E, Steinberg SM, Broder S, et al.: Treatment of HIV-associated Kaposi's sarcoma with paclitaxel. Lancet. 1995 Jul 1;346(8966):26-8. [PubMed:7603142]
  5. Authors unspecified: ABI 007. Drugs R D. 2004;5(3):155-9. [PubMed:15139776]
  6. Gaitanis A, Staal S: Liposomal doxorubicin and nab-paclitaxel: nanoparticle cancer chemotherapy in current clinical use. Methods Mol Biol. 2010;624:385-92. doi: 10.1007/978-1-60761-609-2_26. [PubMed:20217610]
External Links
Human Metabolome Database
HMDB15360
KEGG Drug
D00491
KEGG Compound
C07394
PubChem Compound
36314
PubChem Substance
46506910
ChemSpider
10368587
BindingDB
50001839
ChEBI
45863
ChEMBL
CHEMBL428647
Therapeutic Targets Database
DNC001411
PharmGKB
PA450761
IUPHAR
2770
Guide to Pharmacology
GtP Drug Page
HET
TA1
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Paclitaxel
ATC Codes
L01CD01 — Paclitaxel
AHFS Codes
  • 10:00.00 — Antineoplastic Agents
PDB Entries
1jff / 2hxf / 2hxh / 2p4n / 2wbe / 3dco / 3edl / 3iz0 / 3j6g / 3j6p
show 34 more
FDA label
Download (220 KB)
MSDS
Download (74 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Not Yet RecruitingTreatmentSquamous Cell Carcinoma (SCC)1
0RecruitingTreatmentAdenocarcinoma of the Pancreas1
0RecruitingTreatmentAnaplastic Thyroid Cancers1
0RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
0TerminatedTreatmentAdenocarcinoma of the Pancreas1
0TerminatedTreatmentStage I Non-Small Cell Lung Cancer / Stage II Non-Small Cell Lung Cancer1
0Unknown StatusTreatmentCancer, Breast1
0Unknown StatusTreatmentPancreatic Adenocarcinoma Locally Advanced / Pancreatic Adenocarcinoma Metastatic / Pancreatic Adenocarcinoma Resectable1
1Active Not RecruitingTreatmentAdenocarcinoma of the Cervix / Adenosquamous carcinoma of the cervix / Cervical Squamous Cell Carcinoma / Stage IB Cervical Cancer / Stage IIA Cervical Cancer / Stage IIB Cervical Cancer / Stage IIIA Cervical Cancer / Stage IIIB Cervical Cancer / Stage IVA Cervical Cancer1
1Active Not RecruitingTreatmentAdenocarcinoma of the Pancreas / Pancreatic Adenocarcinoma Metastatic1
1Active Not RecruitingTreatmentAdenocarcinomas / Neoplasms, Pancreatic1
1Active Not RecruitingTreatmentAdult Solid Neoplasm1
1Active Not RecruitingTreatmentAdvanced Breast Cancer1
1Active Not RecruitingTreatmentAdvanced Cancers1
1Active Not RecruitingTreatmentAdvanced Malignancies / Cancer, Advanced1
1Active Not RecruitingTreatmentAdvanced Ovarian Cancer / Carboplatin / Paclitaxel / Triple Negative Metastatic Breast Cancer1
1Active Not RecruitingTreatmentAdvanced Pancreatic Cancer1
1Active Not RecruitingTreatmentAdvanced Solid Tumors2
1Active Not RecruitingTreatmentAdvanced Solid Tumors / Neoplasms1
1Active Not RecruitingTreatmentBRCA-mutated Solid Tumor / Triple Negative Metastatic Breast Cancer1
1Active Not RecruitingTreatmentBreast Cancer - Female / Unspecified Adult Solid Tumor - Protocol Specific1
1Active Not RecruitingTreatmentCancer, Advanced2
1Active Not RecruitingTreatmentCancer, Breast1
1Active Not RecruitingTreatmentCancer, Breast / Cancer, Ovarian / Carcinoma, Colorectal / Carcinoma, Pancreatic / Melanoma / Non-Small Cell Lung Carcinoma (NSCLC) / Prostate Cancer / Renal Cell Adenocarcinoma / Tumors, Solid1
1Active Not RecruitingTreatmentCancer, Breast / Metastatic Breast Cancer (MBC) / Triple Negative Breast Cancer (TNBC)1
1Active Not RecruitingTreatmentCancer, Ovarian / Fallopian Tube Cancer / No Prior Chemotherapy / Primary Peritoneal Cancer1
1Active Not RecruitingTreatmentCancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cancer1
1Active Not RecruitingTreatmentCancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cancer / Primary Peritoneal Carcinoma1
1Active Not RecruitingTreatmentCancer, Ovarian / Peritoneal Cavity Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1Active Not RecruitingTreatmentCancers2
1Active Not RecruitingTreatmentEndometrial Adenocarcinomas / Endometrial Adenosquamous Carcinoma / Endometrial Clear Cell Adenocarcinoma / Endometrial Mucinous Adenocarcinoma / Endometrial Serous Adenocarcinoma / Endometrial Transitional Cell Carcinoma / Endometrial Undifferentiated Carcinoma / Endometrioid Adenocarcinoma / Recurrent Uterine Corpus Carcinoma / Stage III Uterine Corpus Cancer / Stage IIIA Uterine Corpus Cancer / Stage IIIB Uterine Corpus Cancer / Stage IIIC Uterine Corpus Cancer / Stage IV Uterine Corpus Cancer / Stage IVA Uterine Corpus Cancer / Stage IVB Uterine Corpus Cancer / Uterine Carcinosarcoma1
1Active Not RecruitingTreatmentEsophageal Cancers1
1Active Not RecruitingTreatmentFallopian Tube Carcinosarcoma / Fallopian Tube Clear Cell Adenocarcinoma / Fallopian Tube Endometrioid Adenocarcinoma / Fallopian Tube Mucinous Adenocarcinoma / Fallopian Tube Serous Neoplasm / Fallopian Tube Transitional Cell Carcinoma / Ovarian Brenner Tumor / Ovarian Carcinosarcoma / Ovarian Clear Cell Adenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Mixed Epithelial Tumor / Ovarian Mucinous Adenocarcinoma / Ovarian Seromucinous Tumor / Ovarian Serous Adenocarcinoma / Ovarian Transitional Cell Carcinoma / Primary Peritoneal Serous Adenocarcinoma / Stage IIA Fallopian Tube Cancer / Stage IIA Ovarian Cancer / Stage IIB Fallopian Tube Cancer / Stage IIB Ovarian Cancer / Stage IIC Fallopian Tube Cancer / Stage IIC Ovarian Cancer / Stage IIIA Fallopian Tube Cancer / Stage IIIA Ovarian Cancer / Stage IIIA Primary Peritoneal Cancer / Stage IIIB Fallopian Tube Cancer / Stage IIIB Ovarian Cancer / Stage IIIB Primary Peritoneal Cancer / Stage IIIC Fallopian Tube Cancer / Stage IIIC Ovarian Cancer / Stage IIIC Primary Peritoneal Cancer / Stage IV Fallopian Tube Cancer / Stage IV Ovarian Cancer / Stage IV Primary Peritoneal Cancer / Undifferentiated Fallopian Tube Carcinoma / Undifferentiated Ovarian Carcinoma1
1Active Not RecruitingTreatmentGastro-esophageal Junction Adenocarcinoma / Hepatocellular,Carcinoma / Tumors, Solid1
1Active Not RecruitingTreatmentHer2-Positive Breast Cancer / Male Breast Cancer / Recurrent Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer1
1Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)4
1Active Not RecruitingTreatmentLung Cancers1
1Active Not RecruitingTreatmentMale Breast Cancer / Recurrent Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer1
1Active Not RecruitingTreatmentMalignant Neoplasm of Pancreas2
1Active Not RecruitingTreatmentNeoplasms, Breast1
1Active Not RecruitingTreatmentNeoplasms / Solid Cancers1
1Active Not RecruitingTreatmentNon-hematologic Malignancies1
1Active Not RecruitingTreatmentOncology, Medical1
1Active Not RecruitingTreatmentPancreatic Cancer Metastatic1
1Active Not RecruitingTreatmentTriple Negative Breast Neoplasms1
1Active Not RecruitingTreatmentTumors, Solid2
1CompletedNot AvailableBone Diseases / Neoplasms1
1CompletedNot AvailableCancer, Ovarian / Head and Neck Carcinoma / Lung Cancers / Neurotoxicity1
1CompletedNot AvailableCancers1
1CompletedBasic ScienceLung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers1
1CompletedOtherSolid Malignancies1
1CompletedSupportive CareUnspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentAbdominal wall neoplasm / Carcinoma NOS1
1CompletedTreatmentAbdominal wall neoplasm / Fallopian Tube Neoplasms / Lung Cancer Non-Small Cell Cancer (NSCLC) / Neoplasms, Ovarian / Pancreatic Ductal Carcinoma / Transitional Cell Carcinoma / Tumor Virus Infections / Urinary Bladder Neoplasms1
1CompletedTreatmentAdenocarcinoma of the Cervix / Adenosquamous carcinoma of the cervix / Cervical Squamous Cell Carcinoma / Cervical Squamous Cell Carcinoma, Not Otherwise Specified / Recurrent Cervical Carcinoma / Stage IVB Cervical Cancer1
1CompletedTreatmentAdenocarcinomas1
1CompletedTreatmentAdenocarcinomas / Lung Cancer Non-Small Cell Cancer (NSCLC)1
1CompletedTreatmentAdenocarcinomas / Malignant Neoplasm of Pancreas / Neoplasms, Pancreatic1
1CompletedTreatmentAdult Grade III Lymphomatoid Granulomatosis / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Contiguous Stage II Adult Burkitt Lymphoma / Contiguous Stage II Adult Diffuse Large Cell Lymphoma / Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Contiguous Stage II Adult Lymphoblastic Lymphoma / Contiguous Stage II Grade 1 Follicular Lymphoma / Contiguous Stage II Grade 2 Follicular Lymphoma / Contiguous Stage II Grade 3 Follicular Lymphoma / Contiguous Stage II Mantle Cell Lymphoma / Contiguous Stage II Marginal Zone Lymphoma / Contiguous Stage II Small Lymphocytic Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Burkitt Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Noncontiguous Stage II Small Lymphocytic Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Splenic Marginal Zone Lymphoma / Stage I Adult Burkitt Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Mixed Cell Lymphoma / Stage I Adult Diffuse Small Cleaved Cell Lymphoma / Stage I Adult Immunoblastic Large Cell Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage I Grade 1 Follicular Lymphoma / Stage I Grade 2 Follicular Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Marginal Zone Lymphoma / Stage I Small Lymphocytic Lymphoma / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Small Lymphocytic Lymphoma / Unspecified Adult Solid Tumor, Protocol Specific / Waldenstrom's Macroglobulinemia (WM)1
1CompletedTreatmentAdult Solid Neoplasm / Estrogen Receptor Negative / Estrogen Receptor Positive / HER2/Neu Negative / Male Breast Carcinoma / Progesterone Receptor Negative / Recurrent Breast Carcinoma / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer / Triple-Negative Breast Carcinoma1
1CompletedTreatmentAdult Solid Neoplasm / Estrogen Receptor Negative / HER2/Neu Negative / Male Breast Carcinoma / Progesterone Receptor Negative / Recurrent Breast Carcinoma / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer / Triple-Negative Breast Carcinoma1
1CompletedTreatmentAdult Solid Neoplasm / Brca1 Mutation Carrier / Brca2 Mutation Carrier / Hereditary Breast and Ovarian Cancer Syndrome1
1CompletedTreatmentAdult Solid Neoplasm / Recurrent Breast Carcinoma / Stage IV Breast Cancer1
1CompletedTreatmentAdvanced Adult Primary Liver Cancer / Anaplastic Thyroid Cancers / Bone Metastases / Carcinoma of the Appendix / Distal Urethral Cancer / Fallopian Tube Cancer / Gastrinoma / Glucagonoma / Hepatic Metastases / Inflammatory carcinoma of the breast / Insulinoma / Localized Unresectable Adult Primary Liver Cancer / Lung Cancer Metastatic / Male Breast Cancer / Malignant Pericardial Effusion / Malignant Pleural Effusions / Metastases to skin / Metastatic Gastrointestinal Carcinoid Tumor / Metastatic Parathyroid Cancer / Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter / Newly Diagnosed Carcinoma of Unknown Primary / Occult Non-small Cell Lung Cancer / Pancreatic Polypeptide Tumor / Primary Peritoneal Cavity Cancer / Proximal Urethral Cancer / Pulmonary Carcinoid Tumor / Recurrent Adenoid Cystic Carcinoma of the Oral Cavity / Recurrent Adrenocortical Carcinoma / Recurrent Adult Primary Liver Cancer / Recurrent Anal Cancer / Recurrent Bladder Cancer / Recurrent Breast Cancer / Recurrent Carcinoma of Unknown Primary / Recurrent Cervical Cancer / Recurrent Colon Cancer / Recurrent Endometrial Carcinoma / Recurrent Esophageal Cancer / Recurrent Extrahepatic Bile Duct Cancer / Recurrent Gallbladder Cancer / Recurrent Gastric Cancer / Recurrent Gastrointestinal Carcinoid Tumor / Recurrent Islet Cell Carcinoma / Recurrent Malignant Testicular Germ Cell Tumor / Recurrent Mucoepidermoid Carcinoma of the Oral Cavity / Recurrent Non-small Cell Lung Cancer / Recurrent Ovarian Epithelial Cancer / Recurrent Pancreatic Cancer / Recurrent Parathyroid Cancer / Recurrent Prostate Cancer / Recurrent Rectal Cancer / Recurrent Renal Cell Cancer / Recurrent Salivary Gland Cancer / Recurrent Small Intestine Cancer / Recurrent Squamous Cell Carcinoma of the Larynx / Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity / Recurrent Squamous Cell Carcinoma of the Nasopharynx / Recurrent Squamous Cell Carcinoma of the Oropharynx / Recurrent Thyroid Cancer / Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter / Recurrent Urethral Cancer / Recurrent Vaginal Cancer / Recurrent Vulvar Cancer / Small Intestine Adenocarcinoma / Somatostatinoma / Stage III Adenoid Cystic Carcinoma of the Oral Cavity / Stage III Adrenocortical Carcinoma / Stage III Bladder Cancer / Stage III Cervical Cancer / Stage III Colon Cancer / Stage III Endometrial Carcinoma / Stage III Esophageal Cancer / Stage III Follicular Thyroid Cancer / Stage III Gastric Cancer / Stage III Malignant Testicular Germ Cell Tumor / Stage III Mucoepidermoid Carcinoma of the Oral Cavity / Stage III Ovarian Epithelial Cancer / Stage III Pancreatic Cancer / Stage III Papillary Thyroid Cancer / Stage III Prostate Cancer / Stage III Rectal Cancer / Stage III Renal Cell Cancer / Stage III Salivary Gland Cancer / Stage III Squamous Cell Carcinoma of the Larynx / Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage III Squamous Cell Carcinoma of the Nasopharynx / Stage III Squamous Cell Carcinoma of the Oropharynx / Stage III Vaginal Cancer / Stage III Vulvar Cancer / Stage IIIA Anal Cancer / Stage IIIA Breast Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Anal Cancer / Stage IIIB Breast Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IV Adenoid Cystic Carcinoma of the Oral Cavity / Stage IV Adrenocortical Carcinoma / Stage IV Anal Cancer / Stage IV Bladder Cancer / Stage IV Breast Cancer / Stage IV Colon Cancer / Stage IV Endometrial Carcinoma / Stage IV Esophageal Cancer / Stage IV Follicular Thyroid Cancer / Stage IV Gastric Cancer / Stage IV Mucoepidermoid Carcinoma of the Oral Cavity / Stage IV Non-Small Cell Lung Cancer / Stage IV Ovarian Epithelial Cancer / Stage IV Pancreatic Cancer / Stage IV Papillary Thyroid Cancer / Stage IV Prostate Cancer / Stage IV Rectal Cancer / Stage IV Renal Cell Cancer / Stage IV Salivary Gland Cancer / Stage IV Squamous Cell Carcinoma of the Larynx / Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IV Squamous Cell Carcinoma of the Nasopharynx / Stage IV Squamous Cell Carcinoma of the Oropharynx / Stage IVA Cervical Cancer / Stage IVA Vaginal Cancer / Stage IVB Cervical Cancer / Stage IVB Vaginal Cancer / Stage IVB Vulvar Cancer / Thyroid Gland Medullary Carcinoma / Unresectable Extrahepatic Bile Duct Cancer / Unresectable Gallbladder Cancer / Urethral Cancer Associated With Invasive Bladder Cancer / WDHA Syndrome1
1CompletedTreatmentAdvanced Cancers2
1CompletedTreatmentAdvanced Cancers / Liver Cancer / Tumors, Solid1
1CompletedTreatmentAdvanced Malignant Solid Tumors1
1CompletedTreatmentAdvanced Melanoma1
1CompletedTreatmentAdvanced Solid Malignancies / Malignancies, Hematologic1
1CompletedTreatmentAdvanced Solid Tumors3
1CompletedTreatmentAdvanced Solid Tumors / Cancer, Ovarian / Lung Cancer Small Cell Lung Cancer (SCLC)1
1CompletedTreatmentAdvanced Solid Tumors / Cancers / Tumors1
1CompletedTreatmentAdvanced Solid Tumors / Metastatic Solid Tumors1
1CompletedTreatmentAdvanced Solid Tumours2
1CompletedTreatmentBladder Cancers / Brain and Central Nervous System Tumors / Cancer, Breast / Cancer, Ovarian / Esophageal Cancers / Extragonadal Germ Cell Tumor / Lung Cancers / Malignant Neoplasm of Stomach / Prostate Cancer1
1CompletedTreatmentBladder Cancers / Cervical Cancers / Endometrial Cancers / Vaginal Cancers1
1CompletedTreatmentBladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter2
1CompletedTreatmentBrain and Central Nervous System Tumors / Cancer, Breast / Cancer, Ovarian / Lung Cancers / Malignant Lymphomas / Melanoma (Skin) / Renal Cancers / Small Intestine Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentBreast Cancer, Non-small Lung Cancer1
1CompletedTreatmentBrenner Tumor / Fallopian Tube Cancer / Ovarian Carcinosarcoma / Ovarian Clear Cell Cystadenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Mixed Epithelial Carcinoma / Ovarian Mucinous Cystadenocarcinoma / Ovarian Serous Cystadenocarcinoma / Ovarian Undifferentiated Adenocarcinoma / Primary Peritoneal Cavity Cancer / Stage II Ovarian Epithelial Cancer / Stage III Ovarian Epithelial Cancer / Stage IV Ovarian Epithelial Cancer1
1CompletedTreatmentBrenner Tumor / Fallopian Tube Cancer / Ovarian Clear Cell Cystadenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Mixed Epithelial Carcinoma / Ovarian Mucinous Cystadenocarcinoma / Ovarian Serous Cystadenocarcinoma / Ovarian Undifferentiated Adenocarcinoma / Primary Peritoneal Cavity Cancer / Stage II Ovarian Epithelial Cancer / Stage III Ovarian Epithelial Cancer / Stage IV Ovarian Epithelial Cancer1
1CompletedTreatmentBrenner Tumor / Ovarian Clear Cell Cystadenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Mixed Epithelial Carcinoma / Ovarian Mucinous Cystadenocarcinoma / Ovarian Serous Cystadenocarcinoma / Ovarian Undifferentiated Adenocarcinoma / Stage III Ovarian Epithelial Cancer / Stage IV Ovarian Epithelial Cancer1
1CompletedTreatmentCancer, Advanced2
1CompletedTreatmentCancer, Breast12
1CompletedTreatmentCancer, Breast / Cancer, Ovarian / Cancers / Malignant Lymphomas / Renal Cell Adenocarcinoma1
1CompletedTreatmentCancer, Breast / Cancer, Ovarian / Colorectal Cancers / Head and Neck Carcinoma / Lung Cancers / Malignant Neoplasm of Pancreas / Melanoma (Skin) / Prostate Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentCancer, Breast / Cancer, Ovarian / Lung Cancers / Malignant Neoplasm of Colon / Malignant Neoplasm of Stomach / Tumors, Solid1
1CompletedTreatmentCancer, Breast / Metastatic Breast Cancer, Locally Advanced Breast Cancer1
1CompletedTreatmentCancer, Breast / Metastatic Cancers1
1CompletedTreatmentCancer, Breast / Metastatic Cancers / Neoplasms1
1CompletedTreatmentCancer, Breast / Tumors, Solid1
1CompletedTreatmentCancer, Ovarian2
1CompletedTreatmentCancer, Ovarian / Endometrial Cancers1
1CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Malignant Peritoneal Neoplasm1
1CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Peritoneal Cavity Cancer2
1CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cancer1
1CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer1
1CompletedTreatmentCancer, Ovarian / Primary Peritoneal Cavity Cancer3
1CompletedTreatmentCancer, Ovarian / Tumors, Solid1
1CompletedTreatmentCancers4
1CompletedTreatmentCancers / Chronic Lung Diseases1
1CompletedTreatmentCancers / Endometrial Carcinoma / Lung Cancer Non-Small Cell Cancer (NSCLC) / Ovarian Carcinoma1
1CompletedTreatmentCervical Cancers1
1CompletedTreatmentChemotherapeutic Agent Toxicity / Endometrial Adenocarcinomas / Fallopian Tube Carcinoma / Gastrointestinal Complications / Malignant Ovarian Mixed Epithelial Tumor / Neurotoxicity Syndrome / Ovarian Brenner Tumor / Ovarian Clear Cell Cystadenocarcinoma / Ovarian Mucinous Cystadenocarcinoma / Ovarian Serous Cystadenocarcinoma / Primary Peritoneal Carcinoma / Stage II Ovarian Cancer / Stage III Ovarian Cancer / Stage IV Ovarian Cancer / Undifferentiated Ovarian Carcinoma1
1CompletedTreatmentColorectal Cancers / Lung Cancers / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentEndometrial Adenosquamous Carcinoma / Endometrial Clear Cell Adenocarcinoma / Endometrial Mixed Adenocarcinoma / Endometrial Serous Adenocarcinoma / Endometrial Squamous Cell Carcinoma / Endometrial Undifferentiated Carcinoma / Recurrent Uterine Corpus Carcinoma / Stage IIIA Uterine Corpus Cancer / Stage IIIC Uterine Corpus Cancer / Stage IVA Uterine Corpus Cancer / Stage IVB Uterine Corpus Cancer1
1CompletedTreatmentEndometrial Cancers1
1CompletedTreatmentEndometrial Clear Cell Adenocarcinoma / Endometrial Serous Adenocarcinoma / Stage III Uterine Corpus Cancer / Stage IV Uterine Corpus Cancer1
1CompletedTreatmentEsophageal Cancers2
1CompletedTreatmentEsophagus Disorders / Squamous Carcinoma of Esophagus1
1CompletedTreatmentFallopian Tube Carcinoma / Infectious Disorder / Neutropenias / Ovarian Carcinosarcoma / Primary Peritoneal Carcinoma / Stage III Ovarian Cancer / Stage IV Ovarian Cancer1
1CompletedTreatmentGenital Neoplasms, Female1
1CompletedTreatmentHER-2 Gene Amplification1
1CompletedTreatmentHER-2 Positive Breast Cancer / Metastatic Breast Cancer (MBC)1
1CompletedTreatmentHER2-Negative Breast Cancer / Human Epidermal Growth Factor 2 Negative Carcinoma of Breast / Male Breast Cancer / Recurrent Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer1
1CompletedTreatmentHead and Neck Carcinoma4
1CompletedTreatmentLeukemias / Malignant Lymphomas / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentLiver Metastasis / Melanoma1
1CompletedTreatmentLocally Advanced, Metastatic Solid Tumors1
1CompletedTreatmentLocally Advanced/Metastatic Her2 Non Overexpressing Breast Cancer / Locally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer / Primary Peritoneal Cancer or Endometrial Cancer1
1CompletedTreatmentLocally Recurrent and Metastatic Breast Cancer1
1CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)7
1CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Ovarian Epithelial Cancer1
1CompletedTreatmentLung Cancers7
1CompletedTreatmentLung Cancers / Metastatic Cancers1
1CompletedTreatmentMale Breast Cancer / Recurrent Breast Cancer / Recurrent Endometrial Carcinoma / Recurrent Gastric Cancer / Recurrent Non-small Cell Lung Cancer / Recurrent Ovarian Epithelial Cancer / Recurrent Small Cell Lung Cancer1
1CompletedTreatmentMalignant Diseases1
1CompletedTreatmentMalignant Lymphomas / Small Intestine Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentMalignant Lymphomas / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentMalignant Neoplasm of Pancreas1
1CompletedTreatmentMalignant Ovarian Mixed Epithelial Tumor / Ovarian Brenner Tumor / Ovarian Clear Cell Cystadenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Mucinous Cystadenocarcinoma / Ovarian Serous Cystadenocarcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Undifferentiated Ovarian Carcinoma1
1CompletedTreatmentMalignant Peritoneal Neoplasm1
1CompletedTreatmentMelanoma1
1CompletedTreatmentMetastatic Breast Cancer (MBC)2
1CompletedTreatmentMetastatic or Locally Advanced Solid Tumors1
1CompletedTreatmentNeoplasm Metastases / Neoplasms1
1CompletedTreatmentNeoplasms11
1CompletedTreatmentNeoplasms, Breast1
1CompletedTreatmentNeoplasms, Breast Neoplasms, Head and Neck Neoplasms1
1CompletedTreatmentNeoplasms, Breast / Solid Tumor Cancers1
1CompletedTreatmentNeoplasms, Ovarian2
1CompletedTreatmentNon Small Cell Lung Carcinoma (NSCLC)1
1CompletedTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
1CompletedTreatmentNon-Squamous Non-Small Cell Lung Cancer1
1CompletedTreatmentOvarian Sarcoma / Ovarian Stromal Cancer / Recurrent Endometrial Carcinoma / Recurrent Ovarian Epithelial Cancer / Recurrent Ovarian Germ Cell Tumor / Stage III Endometrial Carcinoma / Stage III Ovarian Epithelial Cancer / Stage III Ovarian Germ Cell Tumor / Stage IV Endometrial Carcinoma / Stage IV Ovarian Epithelial Cancer / Stage IV Ovarian Germ Cell Tumor / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentPancreatic Cancer Metastatic1
1CompletedTreatmentProstate Cancer2
1CompletedTreatmentRecurrent Ovarian Cancer1
1CompletedTreatmentSolid Cancers3
1CompletedTreatmentSquamous Cell Carcinoma of Esophagus1
1CompletedTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
1CompletedTreatmentStage IIIA Non-Small Cell Lung Cancer1
1CompletedTreatmentTumors1
1CompletedTreatmentTumors, Solid4
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific22
1Not Yet RecruitingOtherNeoplasms, Advanced Solid1
1Not Yet RecruitingTreatmentAdvanced Stage Solid Tumors1
1Not Yet RecruitingTreatmentCancer of Breast / Cancer, Breast1
1Not Yet RecruitingTreatmentCancer, Ovarian1
1Not Yet RecruitingTreatmentCancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cancer1
1Not Yet RecruitingTreatmentGastrooesophageal Cancer1
1Not Yet RecruitingTreatmentMalignant Neoplasm of Pancreas1
1Not Yet RecruitingTreatmentNeoplasms, Breast1
1RecruitingNot AvailableMalignant Neoplasm of Pancreas1
1RecruitingNot AvailablePancreatic Cancer Metastatic1
1RecruitingDiagnosticEsophageal Cancers1
1RecruitingDiagnosticMetastatic Breast Cancer (MBC) / Neoplasms, Breast / Rb+ Breast Cancer1
1RecruitingOtherAdvanced Solid Tumors, Neoplasms, Advanced Solid1
1RecruitingTreatmentAdenocarcinoma of the Pancreas / Adult Solid Neoplasm / Advanced Malignant Solid Neoplasm / ALK positive / Pancreatic Adenocarcinoma Metastatic / Solid Neoplasms / Stage III Pancreatic Cancer / Stage IV Pancreatic Cancer1
1RecruitingTreatmentAbdominal wall neoplasm / Carcinoma, Squamous Cell of Head and Neck / Esophagogastric Junction Neoplasms / Fallopian Tube Neoplasms / Neoplasms, Ovarian / Pancreatic Ductal Carcinoma / Small Cell Lung Carcinoma / Squamous Cell Carcinoma of Esophagus / Stomach Neoplasms / Triple Negative Breast Neoplasms1
1RecruitingTreatmentAdenocarcinoma of the Pancreas1
1RecruitingTreatmentAdenocarcinoma of the Pancreas / Head and Neck Squamous Cell Carcinoma (HNSCC) / Non-Resectable Cholangiocarcinoma / Pancreatic Adenocarcinoma Metastatic / Recurrent Gallbladder Carcinoma / Recurrent Non-Small Cell Lung Carcinoma / Stage III Pancreatic Cancer / Stage IIIA Gallbladder Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Gallbladder Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IV Gallbladder Cancer / Stage IV Non-Small Cell Lung Cancer / Stage IV Pancreatic Cancer / Unresectable Gallbladder Carcinoma / Unresectable Pancreatic Cancer1
1RecruitingTreatmentAdenocarcinoma of the Pancreas / Locally Advanced Solid Tumors / Metastatic Solid Tumors1
1RecruitingTreatmentAdenocarcinoma of the Pancreas / Malignant Neoplasm of Pancreas1
1RecruitingTreatmentAdenocarcinoma of the Pancreas / Pancreatic Adenocarcinoma Metastatic / Stage IV Pancreatic Cancer / Unresectable Pancreatic Carcinoma1
1RecruitingTreatmentAdenocarcinomas of the Gastroesophageal Junction / Gastric Adenocarcinoma / Gastrooesophageal Cancer / Neoplasms, Esophageal / Squamous Cell Carcinoma (SCC)1
1RecruitingTreatmentAdvanced Breast Cancer1
1RecruitingTreatmentAdvanced Cancers1
1RecruitingTreatmentAdvanced Malignant Solid Neoplasm / BRCA Rearrangement / BRCA1 Gene Mutation / Brca2 Gene Mutation / Deleterious BRCA1 Gene Mutation / Deleterious BRCA2 Gene Mutation / Metastatic Malignant Solid Neoplasm / Solid Neoplasms / Unresectable Solid Neoplasm1
1RecruitingTreatmentAdvanced Nonhaematologic Malignancies1
1RecruitingTreatmentAdvanced Nonhematologic Malignancies1
1RecruitingTreatmentAdvanced Solid Tumors1
1RecruitingTreatmentBladder Carcinoma / Carcinoma of Unknown Primary Origin / Carcinoma, Breast / Endometrial Carcinoma / Lung, Carcinoma / Malignant Head and Neck Neoplasm / Melanoma / Neoplasms, Ovarian / Oesophageal Carcinoma / Ovarian Carcinoma / Renal Pelvis and Ureter Urothelial Carcinoma / Testicular Lymphoma / Urethral Carcinoma1
1RecruitingTreatmentBreast Adenocarcinoma / Cancer, Breast / Human Epidermal Growth Factor 2 Negative Carcinoma of Breast / Recurrent Breast Carcinoma / Stage IV Breast Cancer1
1RecruitingTreatmentBreast Cancer Triple Negative / Cancer, Ovarian / Cervical Cancers / Endometrial Cancers / Tumors, Solid1
1RecruitingTreatmentBreastcancer1
1RecruitingTreatmentCancer Ovaries / Cancer Peritoneal / Fallopian Tube Cancer1
1RecruitingTreatmentCancer of Pancreas / Cancer of the Pancreas / Malignant Neoplasm of Pancreas1
1RecruitingTreatmentCancer, Advanced2
1RecruitingTreatmentCancer, Advanced / Lung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers / Metastatic Lung Cancer / Non-Squamous Non-Small Cell Neoplasm of Lung / Squamous Cell Carcinoma of Lung1
1RecruitingTreatmentCancer, Breast / Colorectal Cancers / Esophagogastric Cancer / Lung Cancer Non-Small Cell Cancer (NSCLC) / Malignant Neoplasm of Pancreas / Tumors1
1RecruitingTreatmentCancer, Breast / Endometrial Cancers / Head and Neck (HNSCC) / Lung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancer Small Cell Lung Cancer (SCLC) / Ovary Cancer1
1RecruitingTreatmentCancer, Ovarian3
1RecruitingTreatmentCancer, Ovarian / Endometrial Cancers1
1RecruitingTreatmentCancers1
1RecruitingTreatmentCarcinoma, Breast / Metastatic Breast Cancer (MBC)1
1RecruitingTreatmentCarcinoma, Small Cell1
1RecruitingTreatmentDiseases of Oesophagus Stomach and Duodenum1
1RecruitingTreatmentEndometrial Cancers / Endometrial Carcinoma / Neoplasms, Endometrial1
1RecruitingTreatmentEsophageal Cancers / Gastrooesophageal Cancer / Malignant Neoplasm of Stomach1
1RecruitingTreatmentEsophageal Cancers / Lung Cancers1
1RecruitingTreatmentEsophagogastric Adenocarcinoma1
1RecruitingTreatmentEstrogen Receptor Negative / HER2/Neu Negative / Progesterone Receptor Negative / Recurrent Breast Carcinoma / Stage III Breast Cancer / Stage III Breast Cancer AJCC V7 / Stage IIIA Breast Cancer / Stage IIIA Breast Cancer AJCC v7 / Stage IIIB Breast Cancer / Stage IIIB Breast Cancer AJCC v7 / Stage IIIC Breast Cancer / Stage IIIC Breast Cancer AJCC v7 / Stage IV Breast Cancer / Stage IV Breast Cancer AJCC v6 and v7 / Triple-Negative Breast Carcinoma1
1RecruitingTreatmentEstrogen Receptor Negative / HER2/Neu Negative / Progesterone Receptor Negative / Recurrent Breast Carcinoma / Stage IV Breast Cancer / Triple-Negative Breast Carcinoma1
1RecruitingTreatmentFallopian Tube Carcinoma / Primary Peritoneal Carcinoma / Recurrent Endometrial Cancer / Recurrent Ovarian Cancer1
1RecruitingTreatmentFallopian Tubes / High Grade Serous Ovarian / Primary Peritoneal Cancer1
1RecruitingTreatmentFumarate Hydratase (FH)-Deficient Tumors / Lung Cancer Non-Small Cell Cancer (NSCLC) / Mesothelioma / Renal Cell Adenocarcinoma / Succinate Dehydrogenase (SDH)-Deficient Gastrointestinal Stromal Tumors (GIST) / Succinate Dehydrogenase (SDH)-Deficient Non-gastrointestinal Stromal Tumors / Triple-Negative Breast Cancer (TNBC) / Tumors Harboring Amplifications in the cMyc Gene / Tumors Harboring Isocitrate Dehydrogenase-1 (IDH1) and IDH2 Mutations / Tumors, Solid1
1RecruitingTreatmentKRAS Activating Mutation / Recurrent Non-Small Cell Lung Carcinoma / Stage III Non-Small Cell Lung Cancer / Stage III Non-Small Cell Lung Cancer AJCC v7 / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer AJCC v7 / Stage IIIb Non-small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer AJCC v71
1RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancer Small Cell Lung Cancer (SCLC) / Tumors, Solid1
1RecruitingTreatmentMalignant Neoplasm of Pancreas3
1RecruitingTreatmentMetastatic Breast Cancer (MBC)1
1RecruitingTreatmentMetastatic Breast Cancer (MBC) / Recurrent Breast Cancer1
1RecruitingTreatmentMetastatic Pancreatic Ductal Adenocarcinoma1
1RecruitingTreatmentNeoplasms, Breast / Neoplasms, Pancreatic1
1RecruitingTreatmentNeoplasms, Gynecologic1
1RecruitingTreatmentOncology, Medical1
1RecruitingTreatmentOvarian Carcinosarcoma1
1RecruitingTreatmentOvarian Epithelial Cancer1
1RecruitingTreatmentPancreatic Cancer Stage III / Pancreatic Cancer Stage IV1
1RecruitingTreatmentRecurrent Salivary Gland Cancer / Recurrent Squamous Cell Carcinoma of the Hypopharynx / Recurrent Squamous Cell Carcinoma of the Larynx / Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity / Recurrent Squamous Cell Carcinoma of the Nasopharynx / Recurrent Squamous Cell Carcinoma of the Oropharynx / Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Recurrent Verrucous Carcinoma of the Larynx / Recurrent Verrucous Carcinoma of the Oral Cavity / Salivary Gland Squamous Cell Carcinoma / Tongue Cancer1
1RecruitingTreatmentRecurrent and Metastatic Gastric Cancer1
1RecruitingTreatmentRefractory Cancer1
1RecruitingTreatmentStage II Non-Small Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer1
1RecruitingTreatmentStage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
1RecruitingTreatmentTumors, Solid2
1SuspendedTreatmentAdenosquamous carcinoma of the cervix / Cervical Adenosarcoma / Cervical Carcinosarcoma / Cervical Squamous Cell Carcinoma, Not Otherwise Specified / Endometrial Clear Cell Adenocarcinoma / Endometrial Endometrioid Adenocarcinoma / Endometrial Mixed Adenocarcinoma / Endometrial Mucinous Adenocarcinoma / Endometrial Squamous Cell Carcinoma / Endometrial Transitional Cell Carcinoma / Endometrial Undifferentiated Carcinoma / Fallopian Tube Adenocarcinoma / Fallopian Tube Clear Cell Adenocarcinoma / Fallopian Tube Mucinous Adenocarcinoma / Fallopian Tube Serous Adenocarcinoma / Fallopian Tube Transitional Cell Carcinoma / Malignant Ovarian Epithelial Tumor / Malignant Peritoneal Neoplasm / Ovarian Carcinosarcoma / Ovarian Clear Cell Adenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Mucinous Adenocarcinoma / Ovarian Serous Adenocarcinoma / Ovarian Transitional Cell Carcinoma / Primary Peritoneal Serous Adenocarcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Melanoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Stage IV Skin Melanoma / Undifferentiated Fallopian Tube Carcinoma / Undifferentiated Ovarian Carcinoma / Uterine Corpus Carcinosarcoma1
1SuspendedTreatmentCancers1
1SuspendedTreatmentStage IIA Non-small Cell Lung Cancer / Stage IIB Non-small Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer1
1TerminatedNot AvailableNon-hematologic Malignancies / Pharmacokinetics of ASP98531
1TerminatedTreatmentAbdominal wall neoplasm / Fallopian Tube Neoplasms / Neoplasms, Ovarian1
1TerminatedTreatmentAdenocarcinoma of the Lung / Bronchoalveolar Cell Lung Cancer / Large Cell Lung Cancer / Squamous Cell Carcinoma of Lung / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer1
1TerminatedTreatmentAdenocarcinoma of the Lung / Bronchoalveolar Cell Lung Cancer / Large Cell Lung Cancer / Stage II Non-Small Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer1
1TerminatedTreatmentAdvanced Aggressive Non-Hodgkin's Lymphoma / Advanced Hodgkin's Lymphoma / Advanced Indolent Non-Hodgkin's Lymphoma / Advanced Pancreatic Adenocarcinoma / Advanced Solid Tumors / Advanced Triple-Negative Breast Cancer / Advanced Urothelial Carcinoma1
1TerminatedTreatmentAdvanced Solid Cancers1
1TerminatedTreatmentBenign Neoplasm of Pancreas / Mucinous Cystadenocarcinoma of Pancreas / Mucinous Cystadenoma of Pancreas / Mucinous Cystic Tumor With Moderate Dysplasia1
1TerminatedTreatmentBrain and Central Nervous System Tumors1
1TerminatedTreatmentCancer, Advanced1
1TerminatedTreatmentCancer, Ovarian1
1TerminatedTreatmentCancer, Ovarian / Primary Peritoneal Cavity Cancer1
1TerminatedTreatmentCancer: Solid Tumors1
1TerminatedTreatmentCholestasis / Neoplasms, Pancreatic1
1TerminatedTreatmentEstrogen Receptor Negative / HER2/Neu Negative / Progesterone Receptor Negative / Stage IIA Breast Cancer / Stage IIB Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Triple-Negative Breast Carcinoma1
1TerminatedTreatmentFallopian Tube Neoplasms / Neoplasms / Neoplasms, Ovarian / Primary Peritoneal Neoplasms1
1TerminatedTreatmentHead and Neck Carcinoma1
1TerminatedTreatmentHodgkins Disease (HD) / Non-Hodgkin's Lymphoma (NHL)1
1TerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Recurrent Anal Cancer / Recurrent Breast Cancer / Recurrent Esophageal Cancer / Recurrent Gastric Cancer / Recurrent Metastatic Squamous Neck Cancer With Occult Primary / Recurrent Non-small Cell Lung Cancer / Recurrent Ovarian Epithelial Cancer / Recurrent Salivary Gland Cancer / Recurrent Squamous Cell Carcinoma of the Hypopharynx / Recurrent Squamous Cell Carcinoma of the Larynx / Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity / Recurrent Squamous Cell Carcinoma of the Nasopharynx / Recurrent Squamous Cell Carcinoma of the Oropharynx / Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Recurrent Verrucous Carcinoma of the Larynx / Recurrent Verrucous Carcinoma of the Oral Cavity / Salivary Gland Squamous Cell Carcinoma / Stage IV Anal Cancer / Stage IV Breast Cancer / Stage IV Esophageal Cancer / Stage IV Gastric Cancer / Stage IV Non-Small Cell Lung Cancer / Stage IV Ovarian Epithelial Cancer / Stage IV Salivary Gland Cancer / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Larynx / Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IV Squamous Cell Carcinoma of the Nasopharynx / Stage IV Squamous Cell Carcinoma of the Oropharynx / Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IV Verrucous Carcinoma of the Larynx / Stage IV Verrucous Carcinoma of the Oral Cavity / Unspecified Adult Solid Tumor, Protocol Specific1
1TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
1TerminatedTreatmentNeoplasms1
1TerminatedTreatmentNeoplasms, Advanced or Metastatic1
1TerminatedTreatmentProstate Cancer1
1TerminatedTreatmentStages II-III Breast Cancer1
1TerminatedTreatmentTumors, Solid3
1Unknown StatusTreatmentAdvanced Solid Tumors1
1Unknown StatusTreatmentCancer of the Esophagus, Gastroesophageal Junction or Stomach1
1Unknown StatusTreatmentCancer, Breast1
1Unknown StatusTreatmentCervical Cancers1
1Unknown StatusTreatmentDrug/Agent Toxicity by Tissue/Organ / Unspecified Adult Solid Tumor, Protocol Specific1
1Unknown StatusTreatmentHead and Neck Carcinoma1
1Unknown StatusTreatmentMalignant Lymphomas2
1Unknown StatusTreatmentMelanoma1
1Unknown StatusTreatmentMetastatic Non-hematologic Malignancies1
1Unknown StatusTreatmentProstate Cancer1
1Unknown StatusTreatmentUnspecified Adult Solid Tumor, Protocol Specific2
1WithdrawnTreatmentAdenocarcinoma of the Lung / Large Cell Lung Cancer / Squamous Cell Carcinoma of Lung / Stage IIA Non-small Cell Lung Cancer / Stage IIB Non-small Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer1
1WithdrawnTreatmentCancer of Cervix / Tumors1
1WithdrawnTreatmentCancer, Breast1
1WithdrawnTreatmentCancer, Ovarian / Endometrial Cancers / Recurrent Endometrial Cancer / Recurrent Ovarian Cancer1
1WithdrawnTreatmentCancers / Lung Cancer Non-Small Cell Cancer (NSCLC) / Ovarian Epithelial Cancer1
1WithdrawnTreatmentDuct Cell Adenocarcinoma of the Pancreas / Recurrent Pancreatic Cancer / Stage III Pancreatic Cancer / Stage IV Pancreatic Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1WithdrawnTreatmentEpithelial Ovarian Carcinoma / Ovarian Carcinoma, Stage 3 or 4 / Primary Peritoneal Carcinoma1
1WithdrawnTreatmentEsophageal Cancers1
1WithdrawnTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Non-Squamous Non-Small Cell Lung Cancer1
1WithdrawnTreatmentMelanoma1
1WithdrawnTreatmentNeoplasms1
1WithdrawnTreatmentOvarian Papillary Serous Carcinoma / Ovarian Serous Cystadenocarcinoma / Recurrent Fallopian Tube Cancer / Recurrent Ovarian Epithelial Cancer / Recurrent Ovarian Germ Cell Tumor / Recurrent Primary Peritoneal Cavity Cancer1
1WithdrawnTreatmentTumors1
1WithdrawnTreatmentTumors, Solid2
1WithdrawnTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1, 2Active Not RecruitingTreatmentAdenocarcinoma of the Lung / Bronchioloalveolar Carcinoma / Large Cell Lung Carcinoma / Lung Adenocarcinoma, Mixed Subtype / Minimally Invasive Lung Adenocarcinoma / Squamous Cell Lung Carcinoma / Stage III Non-Small Cell Lung Cancer / Stage III Non-Small Cell Lung Cancer AJCC v7 / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer AJCC v7 / Stage IIIb Non-small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer AJCC v71
1, 2Active Not RecruitingTreatmentAdenocarcinoma of the Pancreas1
1, 2Active Not RecruitingTreatmentAdvanced Breast Cancer / Advanced Malignant Solid Tumors / Neoplasms, Breast1
1, 2Active Not RecruitingTreatmentCancer, Advanced / Cancer, Breast / Lung Cancer Small Cell Lung Cancer (SCLC) / Malignant Neoplasm of Pancreas / Ovarian / Sarcomas1
1, 2Active Not RecruitingTreatmentCancer, Breast3
1, 2Active Not RecruitingTreatmentCancer, Ovarian1
1, 2Active Not RecruitingTreatmentCancers / Clinical Oncology / Dermatofibrosarcoma / Ewing's Sarcoma (ES) / Ewing's Tumor / Fibrosarcomas malignant / Histiocytoma / Malignant Melanoma / Melanoma / Neoplasia / Neoplasms / Neuroblastomas / Oncology, Medical / Osteosarcoma Tumor / Pediatrics, Osteosarcoma / Rhabdomyosarcomas / Sarcoma, Osteogenic / Sarcoma, Spindle Cell / Sarcomas, Epitheliod / Soft Tissue Sarcoma (STS) / Tumors1
1, 2Active Not RecruitingTreatmentCervix Carcinoma Recurrent / Metastatic Carcinoma to the Uterine Cervix / Recurrent Carcinoma Cervix1
1, 2Active Not RecruitingTreatmentMalignant Neoplasm of Stomach1
1, 2Active Not RecruitingTreatmentMetastatic Breast Cancer (MBC)1
1, 2Active Not RecruitingTreatmentMetastatic Breast Cancer (MBC) / Recurrent Breast Cancer1
1, 2Active Not RecruitingTreatmentMetastatic Cancers1
1, 2Active Not RecruitingTreatmentMetastatic Pancreas Adenocarcinoma1
1, 2Active Not RecruitingTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
1, 2Active Not RecruitingTreatmentOvarian Carcinoma1
1, 2Active Not RecruitingTreatmentPancreatic Acinar Cell Carcinoma / Pancreatic Adenocarcinoma Metastatic / Pancreatic Ductal Adenocarcinoma / Stage III Pancreatic Cancer / Stage III Pancreatic Cancer AJCC v6 and v7 / Stage IV Pancreatic Cancer / Stage IV Pancreatic Cancer AJCC v6 and v7 / Unresectable Pancreatic Carcinoma1
1, 2Active Not RecruitingTreatmentPancreatic Cancer, Adult1
1, 2Active Not RecruitingTreatmentPlatinum Resistant Ovarian Cancer1
1, 2Active Not RecruitingTreatmentRecurrent Fallopian Tube Cancer / Recurrent Ovarian Epithelial Cancer / Recurrent Primary Peritoneal Cavity Cancer1
1, 2Active Not RecruitingTreatmentResectable Pancreatic Adenocarcinoma1
1, 2Active Not RecruitingTreatmentStage III Ovarian Cancer / Stage IV Ovarian Cancer / Uterine Cancers1
1, 2CompletedTreatmentAdvanced Gastric Cancer1
1, 2CompletedTreatmentAdvanced Melanoma / B-cell Malignancy, Low-grade / Cancer, Ovarian / Malignant Solid Tumours / Triple Negative Breast Cancer (TNBC)1
1, 2CompletedTreatmentAdvanced or Metastatic Breast Cancer / Advanced or Metastatic Solid Tumors1
1, 2CompletedTreatmentAnaplastic Thyroid Cancers1
1, 2CompletedTreatmentBladder Cancers2
1, 2CompletedTreatmentBladder Cancers / Cancer, Ovarian / Fallopian Tube Cancer / Ovarian Epithelial Cancer1
1, 2CompletedTreatmentBladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter1
1, 2CompletedTreatmentBladder Urothelial Carcinoma / Stage I Bladder Cancer / Stage II Bladder Cancer / Stage III Bladder Cancer1
1, 2CompletedTreatmentBrain and Central Nervous System Tumors / Cancer, Ovarian / Extragonadal Germ Cell Tumor / Teratoma / Testicular germ cell tumour1
1, 2CompletedTreatmentCancer, Breast12
1, 2CompletedTreatmentCancer, Breast / Male Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer1
1, 2CompletedTreatmentCancer, Breast / Neoplasms, Breast1
1, 2CompletedTreatmentCancer, Breast / Neoplasms / Neoplasms, Breast1
1, 2CompletedTreatmentCancer, Ovarian2
1, 2CompletedTreatmentCancer, Ovarian / Extragonadal Germ Cell Tumor / Testicular germ cell tumour1
1, 2CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer1
1, 2CompletedTreatmentCancer, Ovarian / Testicular germ cell tumour1
1, 2CompletedTreatmentCancer, Ovarian / Tumors, Solid1
1, 2CompletedTreatmentCancers1
1, 2CompletedTreatmentCarcinoma of Unknown Primary / Head and Neck Carcinoma1
1, 2CompletedTreatmentCervical Cancers1
1, 2CompletedTreatmentCoronary Artery Restenosis1
1, 2CompletedTreatmentDrug/Agent Toxicity by Tissue/Organ / Lung Cancers / Radiation Toxicity1
1, 2CompletedTreatmentEsophageal Cancers1
1, 2CompletedTreatmentEsophageal Cancers / Toxicity1
1, 2CompletedTreatmentHER-2 Positive Advanced Gastric Cancer1
1, 2CompletedTreatmentHead and Neck Carcinoma1
1, 2CompletedTreatmentHead and Neck Carcinoma / Oral Complications1
1, 2CompletedTreatmentInoperable Locally Advanced Breast Cancer / Metastatic Breast Cancer (MBC)1
1, 2CompletedTreatmentLeukemias1
1, 2CompletedTreatmentLeukemias / Malignant Lymphomas / Sarcomas / Unspecified Adult Solid Tumor, Protocol Specific1
1, 2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)7
1, 2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers1
1, 2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Tumors, Solid1
1, 2CompletedTreatmentLung Cancers4
1, 2CompletedTreatmentMale Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer1
1, 2CompletedTreatmentMalignant Lymphomas1
1, 2CompletedTreatmentMalignant Neoplasm of Pancreas1
1, 2CompletedTreatmentMelanoma1
1, 2CompletedTreatmentMetastatic Breast Cancer (MBC)2
1, 2CompletedTreatmentMetastatic Cancers / Pancreatic Cancer Metastatic1
1, 2CompletedTreatmentNeoplasms, Esophageal2
1, 2CompletedTreatmentOvarian Epithelial Cancer Stage III / Stage IV Breast Cancer / Stage IV Ovarian Cancer1
1, 2CompletedTreatmentPancreatic Cancer Metastatic1
1, 2CompletedTreatmentPrimary Peritoneal Carcinoma1
1, 2CompletedTreatmentProstate Cancer3
1, 2CompletedTreatmentRecurrent Breast Cancer / Stage IIIB Breast Cancer / Stage IV Breast Cancer1
1, 2CompletedTreatmentRecurrent Non-small Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer1
1, 2CompletedTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
1, 2CompletedTreatmentStage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
1, 2CompletedTreatmentStage IV Gastric Cancer / Tumors, Solid1
1, 2CompletedTreatmentStage IV Non-Small Cell Lung Cancer1
1, 2CompletedTreatmentStage IV Pancreatic Cancer2
1, 2CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1, 2CompletedTreatmentUterine Cancers1
1, 2Not Yet RecruitingTreatmentAdvanced or Metastatic Biliary Tract Cancer (BTC) / Advanced or Metastatic Endometrial Cancer / Advanced or Metastatic Gastroesophageal Cancer (GC) / Advanced or Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) / Advanced or Metastatic Solid Tumors / Recurrent Ovarian Carcinoma1
1, 2Not Yet RecruitingTreatmentCancer, Ovarian2
1, 2Not Yet RecruitingTreatmentElderly Patients / Oesophagus Cancer1
1, 2Not Yet RecruitingTreatmentMalignant Neoplasm of Breast1
1, 2RecruitingPreventionLung Cancer Non-Small Cell Cancer (NSCLC)1
1, 2RecruitingTreatmentAdenocarcinoma of the Pancreas / Adenocarcinoma of Unknown Primary / Adult Cholangiocarcinoma / Carcinoma of Gallbladder / Gastric Adenocarcinoma / Malignant Gastrointestinal Neoplasm / Pancreatic Adenocarcinoma Metastatic / Stage III Ampulla of Vater Cancer / Stage III Pancreatic Cancer / Stage IIIA Gallbladder Cancer / Stage IIIA Gastric Cancer / Stage IIIB Gallbladder Cancer / Stage IIIB Gastric Cancer / Stage IV Ampulla of Vater Cancer / Stage IV Gallbladder Cancer / Stage IV Gastric Cancer / Stage IV Pancreatic Cancer1
1, 2RecruitingTreatmentAdenocarcinomas of the Gastroesophageal Junction / Gastric Cardia Adenocarcinoma / Stage IB Gastric Cancer / Stage IB Gastric Cancer AJCC v7 / Stage II Gastric Cancer / Stage II Gastric Cancer AJCC v7 / Stage IIA Gastric Cancer / Stage IIA Gastric Cancer AJCC v7 / Stage IIB Gastric Cancer / Stage IIB Gastric Cancer AJCC v7 / Stage IIIA Gastric Cancer / Stage IIIA Gastric Cancer AJCC v7 / Stage IIIB Gastric Cancer / Stage IIIB Gastric Cancer AJCC v71
1, 2RecruitingTreatmentAdvanced Gastric Adenocarcinoma1
1, 2RecruitingTreatmentAdvanced Ovarian Cancer / Fallopian Tube Cancer / Malignant Peritoneal Neoplasm1
1, 2RecruitingTreatmentAdvanced Ovarian Cancer / Ovarian Cancer Stage IIIB / Ovarian Cancer Stage IIIC / Peritoneal Carcinomatosis1
1, 2RecruitingTreatmentAdvanced or Metastatic Colorectal Cancer (CRC) / Advanced or Metastatic Solid Tumor That Progressed on Previous Therapy With a Programmed Cell Death Ligand 1 (PD-L1) Inhibitor / Advanced or Metastatic Solid Tumor That Progressed on Previous Therapy With a Programmed Cell Death Protein 1 (PD-1) Inhibitor / Advanced or Metastatic Solid Tumors / Non-Small Cell Lung Cancer (NSCLC; Squamous or Nonsquamous) / Pancreatic Ductal Adenocarcinoma (PDAC)1
1, 2RecruitingTreatmentBreast Adenocarcinoma / Estrogen Receptor Positive / HER2/Neu Negative / Recurrent Breast Carcinoma / Stage IIB Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer1
1, 2RecruitingTreatmentBreast Cancer, Male / Cancer, Breast / Her2-Positive Breast Cancer / Malignant Neoplasm of Female Breast1
1, 2RecruitingTreatmentCancer, Advanced1
1, 2RecruitingTreatmentCancer, Breast3
1, 2RecruitingTreatmentCancer, Breast / Cellular Diagnosis, Ovarian Epithelial Cancer / Tumors, Solid1
1, 2RecruitingTreatmentCancer, Breast / Ductal Carcinoma / Invasive Breast Carcinoma / Invasive Ductal Breast Carcinoma1
1, 2RecruitingTreatmentCancer, Ovarian / Fallopian Tube Cancer / Malignant Neoplasms of Female Genital Organs / Primary Peritoneal Carcinoma1
1, 2RecruitingTreatmentCancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer1
1, 2RecruitingTreatmentCancers2
1, 2RecruitingTreatmentCervical Carcinoma / Endometrial Carcinoma / Fallopian Tube Carcinoma / Ovarian Carcinoma / Primary Peritoneal Carcinoma1
1, 2RecruitingTreatmentColorectal Adenocarcinoma (CRC) / Gastric Adenocarcinoma / Renal Cell Adenocarcinoma / Transitional Cell Carcinoma1
1, 2RecruitingTreatmentCutaneous Malignant Melanoma1
1, 2RecruitingTreatmentEsophageal Cancers1
1, 2RecruitingTreatmentFallopian Tube Carcinosarcoma / Fallopian Tube Clear Cell Adenocarcinoma / Fallopian Tube Endometrioid Adenocarcinoma / Fallopian Tube Serous Neoplasm / High Grade Ovarian Serous Adenocarcinoma / Ovarian Carcinosarcoma / Ovarian Clear Cell Adenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Primary Peritoneal Serous Adenocarcinoma / Stage III Fallopian Tube Cancer / Stage III Ovarian Cancer / Stage III Primary Peritoneal Cancer / Stage IIIA Fallopian Tube Cancer / Stage IIIA Ovarian Cancer / Stage IIIA Primary Peritoneal Cancer / Stage IIIB Fallopian Tube Cancer / Stage IIIB Ovarian Cancer / Stage IIIB Primary Peritoneal Cancer / Stage IIIC Fallopian Tube Cancer / Stage IIIC Ovarian Cancer / Stage IIIC Primary Peritoneal Cancer / Stage IV Fallopian Tube Cancer / Stage IV Ovarian Cancer / Stage IV Primary Peritoneal Cancer1
1, 2RecruitingTreatmentGastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma1
1, 2RecruitingTreatmentINOPERABLE STAGE IIIA/B NON-SMALL CELL LUNG CANCER / STAGE IIIA/B NSCLC / INOPERABLE LUNG CANCER1
1, 2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)3
1, 2RecruitingTreatmentLung Cancers1
1, 2RecruitingTreatmentMalignant Neoplasm of Pancreas2
1, 2RecruitingTreatmentMetastatic Breast Cancer (MBC)1
1, 2RecruitingTreatmentNeoplasms Metastasis / Neoplasms, Esophageal / Stomach Neoplasms1
1, 2RecruitingTreatmentPancreatic Adenocarcinoma Metastatic2
1, 2RecruitingTreatmentPancreatic Adenocarcinoma Metastatic / Pancreatic Cancer Metastatic1
1, 2RecruitingTreatmentPancreatic Cancer (Unresectable)1
1, 2RecruitingTreatmentPancreatic Cancer Metastatic1
1, 2RecruitingTreatmentPancreatic Neoplasms (Locally Advanced Non-metastatic)1
1, 2RecruitingTreatmentSquamous Cell Carcinoma of Esophagus1
1, 2RecruitingTreatmentTriple Negative Breast Cancer (TNBC)1
1, 2SuspendedTreatmentAcinar Cell Adenocarcinoma of the Pancreas / Duct Cell Adenocarcinoma of the Pancreas / Stage IV Pancreatic Cancer1
1, 2SuspendedTreatmentFallopian Tube Cancer / Ovarian Epithelial Cancer / Primary Peritoneal Cancer1
1, 2SuspendedTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC) / Human Papillomavirus Infections / Salivary Gland Squamous Cell Carcinoma / Stage IVA Hypopharyngeal Squamous Cell Carcinoma / Stage IVA Laryngeal Squamous Cell Carcinoma / Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma / Stage IVA Major Salivary Gland Carcinoma / Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVA Oropharyngeal Carcinoma / Stage IVA Oropharyngeal Carcinoma AJCC v7 / Stage IVA Oropharyngeal Squamous Cell Carcinoma / Stage IVB Hypopharyngeal Squamous Cell Carcinoma / Stage IVB Laryngeal Squamous Cell Carcinoma / Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma / Stage IVB Major Salivary Gland Carcinoma / Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVB Oropharyngeal Carcinoma / Stage IVB Oropharyngeal Carcinoma AJCC v7 / Stage IVB Oropharyngeal Squamous Cell Carcinoma / Tongue Carcinoma1
1, 2SuspendedTreatmentPancreatic Adenocarcinoma Metastatic / Recurrent Pancreatic Carcinoma / Stage III Pancreatic Cancer / Stage IV Pancreatic Cancer1
1, 2TerminatedNot AvailableLung Cancer Non-Small Cell Cancer (NSCLC)1
1, 2TerminatedTreatmentAdenocarcinoma of the Esophagus / Adenocarcinomas of the Gastroesophageal Junction1
1, 2TerminatedTreatmentAdenocarcinomas / Tumors / Unknown Primary Tumors1
1, 2TerminatedTreatmentAdvanced Squamous Non-Small Cell Lung Cancer1
1, 2TerminatedTreatmentBasaloid Squamous Cell Carcinoma / Carcinoma, Adenosquamous Cell / Carcinoma, Undifferentiated / Squamous Cell Carcinoma of the Head and Neck (SCCHN)1
1, 2TerminatedTreatmentCancer, Breast2
1, 2TerminatedTreatmentCancer, Breast / Lung Cancers / Unspecified Adult Solid Tumor, Protocol Specific1
1, 2TerminatedTreatmentCancer, Ovarian1
1, 2TerminatedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Intestinal Obstruction / Malignant Peritoneal Neoplasm1
1, 2TerminatedTreatmentGlioblastoma Multiforme / Neoplasms, Brain1
1, 2TerminatedTreatmentHER2-Negative Breast Cancer / Inflammatory carcinoma of the breast / Male Breast Cancer / Recurrent Breast Cancer / Stage IV Breast Cancer1
1, 2TerminatedTreatmentLocally Advanced Non-Small Cell Lung Cancer1
1, 2TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Non-Small Cell Lunch Cancer1
1, 2TerminatedTreatmentLung Cancers5
1, 2TerminatedTreatmentMalignant Neoplasm of Pancreas1
1, 2TerminatedTreatmentMetastatic Breast Cancer (MBC)1
1, 2TerminatedTreatmentNeoplasm Metastases / Neoplasms, Breast1
1, 2TerminatedTreatmentNeoplasms1
1, 2TerminatedTreatmentNon-Squamous Non-Small Cell Lung Cancer / Squamous Non-Small Cell Lung Cancer1
1, 2TerminatedTreatmentPancreatic Cancer Metastatic1
1, 2TerminatedTreatmentRelapsed Or Refractory Multiple Myeloma1
1, 2TerminatedTreatmentStage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer1
1, 2TerminatedTreatmentStage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
1, 2TerminatedTreatmentStage IV (Metastatic) Breast Cancer1
1, 2Unknown StatusSupportive CareDrug/Agent Toxicity by Tissue/Organ / Head and Neck Carcinoma / Radiation Toxicity1
1, 2Unknown StatusTreatmentAdvanced Metastatic Gastric Cancer / Recurrent Gastric Cancer1
1, 2Unknown StatusTreatmentBladder Cancers1
1, 2Unknown StatusTreatmentBrain and Central Nervous System Tumors / Cancer, Ovarian / Extragonadal Germ Cell Tumor / Testicular germ cell tumour1
1, 2Unknown StatusTreatmentCancer, Breast3
1, 2Unknown StatusTreatmentCancer, Breast / Malignant Neoplasm of Stomach / Unspecified Adult Solid Tumor, Protocol Specific1
1, 2Unknown StatusTreatmentCancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer1
1, 2Unknown StatusTreatmentEsophageal Cancers1
1, 2Unknown StatusTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1, 2Unknown StatusTreatmentLung Cancers1
1, 2Unknown StatusTreatmentMalignant Neoplasm of Pancreas1
1, 2Unknown StatusTreatmentNasopharyngeal Carcinoma1
1, 2Unknown StatusTreatmentRecurrent Platinum-resistant Ovarian Cancer1
1, 2Unknown StatusTreatmentStage IV Pancreatic Cancer1
1, 2WithdrawnTreatmentCancer, Breast1
1, 2WithdrawnTreatmentLung Cancers1
1, 2WithdrawnTreatmentMalignant Neoplasm of Stomach1
2Active Not RecruitingNot AvailablePeritoneal Carcinomatosis1
2Active Not RecruitingBasic ScienceStage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer1
2Active Not RecruitingOtherCancer, Breast / Locally Advanced Malignant Neoplasm1
2Active Not RecruitingOtherLung Cancer Non-Small Cell Cancer (NSCLC)1
2Active Not RecruitingPreventionCancer, Ovarian / Endometrial Cancers / Uterine Cervical Cancer1
2Active Not RecruitingSupportive CareCancer, Breast1
2Active Not RecruitingTreatmentAdenocarcinoma Of Esophagus / Adenocarcinomas of the Gastroesophageal Junction / Recurrent Esophageal Carcinoma / Squamous Cell Carcinoma of Esophagus / Stage IV Esophageal Cancer1
2Active Not RecruitingTreatmentAdenocarcinoma of the Lung / Adenosquamous Lung Carcinoma / Bronchioloalveolar Carcinoma / Large Cell Lung Carcinoma / Non-Small Cell Lung Carcinoma (NSCLC) / Recurrent Non-Small Cell Lung Carcinoma / Squamous Cell Lung Carcinoma / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer1
2Active Not RecruitingTreatmentAdenocarcinoma of the Lung / Adenosquamous Lung Carcinoma / Bronchioloalveolar Carcinoma / Malignant Pericardial Effusion / Malignant Pleural Effusions / Minimally Invasive Lung Adenocarcinoma / Stage IIIb Non-small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer AJCC v7 / Stage IV Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer AJCC v71
2Active Not RecruitingTreatmentAdenocarcinoma of the Lung / Lung Cancer Non-Small Cell Cancer (NSCLC)1
2Active Not RecruitingTreatmentAdenocarcinomas of the Gastroesophageal Junction / Esophageal Cancers1
2Active Not RecruitingTreatmentAdenocarcinomas of the Gastroesophageal Junction / Gastric Adenocarcinoma1
2Active Not RecruitingTreatmentAdenocarcinomas of the Gastroesophageal Junction / Metastatic Gastric Adenocarcinoma1
2Active Not RecruitingTreatmentAdvanced Breast Cancer / Cancer, Breast1
2Active Not RecruitingTreatmentAdvanced Pancreatic Cancer1
2Active Not RecruitingTreatmentBiliary Tract Cancer1
2Active Not RecruitingTreatmentBladder Cancers1
2Active Not RecruitingTreatmentBladder Carcinoma / Transitional Cell Carcinoma1
2Active Not RecruitingTreatmentCancer, Breast23
2Active Not RecruitingTreatmentCancer, Breast / Carcinoma of the Breast1
2Active Not RecruitingTreatmentCancer, Breast / Neoplasms, Breast1
2Active Not RecruitingTreatmentCancer, Ovarian4
2Active Not RecruitingTreatmentCancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cancer1
2Active Not RecruitingTreatmentCancers1
2Active Not RecruitingTreatmentCarcinoma, Breast / Fallopian Tube Cancer / Malignant Peritoneal Neoplasm / Ovarian Carcinoma1
2Active Not RecruitingTreatmentCervical Cancer, Cancer, Metastatic Cancers / Cervical Cancers1
2Active Not RecruitingTreatmentCervical Cancers2
2Active Not RecruitingTreatmentCholangiocarcinomas1
2Active Not RecruitingTreatmentEndometrial Adenocarcinomas / Endometrial Adenosquamous Carcinoma / Endometrial Clear Cell Adenocarcinoma / Endometrial Serous Adenocarcinoma / Recurrent Uterine Corpus Carcinoma / Stage IIIA Uterine Corpus Cancer / Stage IIIB Uterine Corpus Cancer / Stage IIIC Uterine Corpus Cancer / Stage IVA Uterine Corpus Cancer / Stage IVB Uterine Corpus Cancer1
2Active Not RecruitingTreatmentEndometrial Cancers1
2Active Not RecruitingTreatmentEsophageal Cancers1
2Active Not RecruitingTreatmentEstrogen Receptor-negative Breast Cancer / Estrogen Receptor-Positive Breast Cancer / HER2-Negative Breast Cancer / Her2-Positive Breast Cancer / Male Breast Cancer / Progesterone Receptor-negative Breast Cancer / Progesterone Receptor-positive Breast Cancer / Recurrent Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer / Triple-Negative Breast Cancer (TNBC)1
2Active Not RecruitingTreatmentEstrogen Receptor-negative Breast Cancer / HER2-Negative Breast Cancer / Progesterone Receptor-negative Breast Cancer / Recurrent Breast Cancer / Stage IV Breast Cancer / Triple-Negative Breast Cancer (TNBC)1
2Active Not RecruitingTreatmentEstrogen Receptor-negative Breast Cancer / HER2-Negative Breast Cancer / Progesterone Receptor-negative Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Triple-Negative Breast Cancer (TNBC)1
2Active Not RecruitingTreatmentFallopian Tube Cancer / Ovarian Epithelial Cancer / Primary Peritoneal Carcinoma1
2Active Not RecruitingTreatmentFallopian Tube Clear Cell Adenocarcinoma / Fallopian Tube Endometrioid Adenocarcinoma / Fallopian Tube Mucinous Adenocarcinoma / Fallopian Tube Serous Adenocarcinoma / Fallopian Tube Transitional Cell Carcinoma / Malignant Ovarian Mixed Epithelial Tumor / Ovarian Brenner Tumor / Ovarian Clear Cell Adenocarcinoma / Ovarian Clear Cell Cystadenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Mucinous Adenocarcinoma / Ovarian Mucinous Cystadenocarcinoma / Ovarian Seromucinous Carcinoma / Ovarian Serous Adenocarcinoma / Ovarian Serous Cystadenocarcinoma / Ovarian Transitional Cell Tumor / Primary Peritoneal Serous Adenocarcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Undifferentiated Fallopian Tube Carcinoma / Undifferentiated Ovarian Carcinoma1
2Active Not RecruitingTreatmentGastrointestinal Neuroendocrine Carcinomas1
2Active Not RecruitingTreatmentGerm Cell Tumors1
2Active Not RecruitingTreatmentHER2-Positive Early Stage Breast Cancer1
2Active Not RecruitingTreatmentHead and Neck Carcinoma2
2Active Not RecruitingTreatmentHead and Neck Carcinoma / Squamous Cell Carcinoma (SCC)1
2Active Not RecruitingTreatmentHead and Neck Carcinoma / Squamous Cell Carcinoma of the Head and Neck (SCCHN)2
2Active Not RecruitingTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC)1
2Active Not RecruitingTreatmentHemangiosarcoma / Paclitaxel1
2Active Not RecruitingTreatmentHuman Papilloma Virus Infection / Stage III Squamous Cell Carcinoma of the Hypopharynx / Stage III Squamous Cell Carcinoma of the Larynx / Stage III Squamous Cell Carcinoma of the Oropharynx / Stage III Verrucous Carcinoma of the Larynx / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Verrucous Carcinoma of the Larynx / Stage IVA Squamous Cell Carcinoma of the Larynx / Stage IVA Squamous Cell Carcinoma of the Oropharynx / Stage IVA Verrucous Carcinoma of the Larynx / Stage IVB Squamous Cell Carcinoma of the Larynx / Stage IVB Squamous Cell Carcinoma of the Oropharynx / Stage IVB Verrucous Carcinoma of the Larynx / Stage IVC Squamous Cell Carcinoma of the Larynx / Stage IVC Squamous Cell Carcinoma of the Oropharynx / Stage IVC Verrucous Carcinoma of the Larynx1
2Active Not RecruitingTreatmentHuman Papilloma Virus Infection / Stage III Squamous Cell Carcinoma of the Oropharynx / Stage IVA Squamous Cell Carcinoma of the Oropharynx / Stage IVB Squamous Cell Carcinoma of the Oropharynx1
2Active Not RecruitingTreatmentInflammatory carcinoma of the breast / Male Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer1
2Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)8
2Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers1
2Active Not RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC)3
2Active Not RecruitingTreatmentLung Cancers4
2Active Not RecruitingTreatmentMale Breast Cancer / Metastases to skin / Recurrent Breast Cancer / Stage IV Breast Cancer1
2Active Not RecruitingTreatmentMalignant Melanoma1
2Active Not RecruitingTreatmentMalignant Neoplasm of Pancreas2
2Active Not RecruitingTreatmentMalignant Neoplasm of Stomach1
2Active Not RecruitingTreatmentMalignant Solid Tumours1
2Active Not RecruitingTreatmentMalignant Tumor of the Breast / Neoplasms, Breast1
2Active Not RecruitingTreatmentMelanoma1
2Active Not RecruitingTreatmentMelanoma (Skin)1
2Active Not RecruitingTreatmentMetastatic Breast Cancer (MBC)7
2Active Not RecruitingTreatmentMetastatic Breast Cancer (MBC) / Metastatic Breastcancer1
2Active Not RecruitingTreatmentMetastatic Malignant Neoplasm in the Brain / Recurrent Non-Small Cell Lung Carcinoma / Stage IIA Non-Small Cell Lung Carcinoma / Stage IIB Non-Small Cell Lung Carcinoma / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2Active Not RecruitingTreatmentMetastatic Melanoma / Mucosal Melanoma / Recurrent Melanoma / Stage IV Cutaneous Melanoma AJCC v6 and v7 / Stage IV Skin Melanoma / Stage IV Uveal Melanoma1
2Active Not RecruitingTreatmentMetastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma / Recurrent Metastatic Squamous Neck Cancer With Occult Primary / Recurrent Salivary Gland Cancer / Recurrent Squamous Cell Carcinoma of the Hypopharynx / Recurrent Squamous Cell Carcinoma of the Larynx / Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity / Recurrent Squamous Cell Carcinoma of the Nasopharynx / Recurrent Squamous Cell Carcinoma of the Oropharynx / Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Recurrent Verrucous Carcinoma of the Larynx / Recurrent Verrucous Carcinoma of the Oral Cavity / Salivary Gland Squamous Cell Carcinoma / Stage IV Salivary Gland Cancer / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Larynx / Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IV Squamous Cell Carcinoma of the Nasopharynx / Stage IV Squamous Cell Carcinoma of the Oropharynx / Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IV Verrucous Carcinoma of the Larynx / Stage IV Verrucous Carcinoma of the Oral Cavity / Tongue Cancer / Untreated Metastatic Squamous Neck Cancer With Occult Primary1
2Active Not RecruitingTreatmentNasopharyngeal Carcinoma1
2Active Not RecruitingTreatmentNeoplasms, Breast1
2Active Not RecruitingTreatmentNeoplasms, Head and Neck1
2Active Not RecruitingTreatmentNeoplasms, Ovarian1
2Active Not RecruitingTreatmentNeoplasms, Pancreatic1
2Active Not RecruitingTreatmentOvarian Sex-cord Stromal Tumor1
2Active Not RecruitingTreatmentPancreatic Acinar Cell Carcinoma / Pancreatic Ductal Adenocarcinoma / Recurrent Pancreatic Carcinoma / Stage IV Pancreatic Cancer1
2Active Not RecruitingTreatmentPancreatic Cancer Metastatic2
2Active Not RecruitingTreatmentRecurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma3
2Active Not RecruitingTreatmentRecurrent Non-Small Cell Lung Carcinoma / Stage IV Non-Small Cell Lung Cancer1
2Active Not RecruitingTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
2Active Not RecruitingTreatmentStage III Melanoma / Stage IV Melanoma / Unresectable Melanoma1
2Active Not RecruitingTreatmentStage III Non-Small Cell Lung Cancer / Stage III Non-Small Cell Lung Cancer AJCC v7 / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer AJCC v7 / Stage IIIb Non-small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer AJCC v71
2Active Not RecruitingTreatmentThyroid Gland Undifferentiated (Anaplastic) Carcinoma1
2Active Not RecruitingTreatmentUntreated Stage III Melanoma or Stage IV Melanoma1
2Active Not RecruitingTreatmentUrothelial Cancer1
2CompletedSupportive CareCancer, Ovarian / Lung Cancers / Neurotoxicity1
2CompletedTreatmentAbdominal wall neoplasm / Cancer, Ovarian / Fallopian Tube Cancer1
2CompletedTreatmentAbdominal wall neoplasm / Cancer, Ovarian / Fallopian Tube Neoplasms2
2CompletedTreatmentAbdominal wall neoplasm / Fallopian Tube Neoplasms / Neoplasms, Ovarian1
2CompletedTreatmentAcinar Cell Adenocarcinoma of the Pancreas / Duct Cell Adenocarcinoma of the Pancreas / Recurrent Pancreatic Cancer / Stage III Pancreatic Cancer / Stage IV Pancreatic Cancer1
2CompletedTreatmentAdenocarcinoma of Colon / Adenocarcinoma of Rectum / Metastatic Disease1
2CompletedTreatmentAdenocarcinoma of the Cervix / Adenosquamous carcinoma of the cervix / Cervical Small Cell Carcinoma / Cervical Squamous Cell Carcinoma / Recurrent Cervical Carcinoma1
2CompletedTreatmentAdenocarcinoma of the Cervix / Adenosquamous carcinoma of the cervix / Cervical Squamous Cell Carcinoma / Recurrent Cervical Carcinoma / Stage IVA Cervical Cancer / Stage IVB Cervical Cancer1
2CompletedTreatmentAdenocarcinoma of the Lung1
2CompletedTreatmentAdenocarcinoma of the Lung / Adenosquamous Cell Lung Cancer / Bronchoalveolar Cell Lung Cancer / Large Cell Lung Cancer / Recurrent Non-small Cell Lung Cancer / Squamous Cell Carcinoma of Lung / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2CompletedTreatmentAdenocarcinoma of the Lung / Adenosquamous Cell Lung Cancer / Bronchoalveolar Cell Lung Cancer / Large Cell Lung Cancer / Squamous Cell Carcinoma of Lung / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer1
2CompletedTreatmentAdenocarcinoma of the Pancreas / Stage II Pancreatic Cancer / Stage III Pancreatic Cancer1
2CompletedTreatmentAdenocarcinoma, Bronchiolo-Alveolar1
2CompletedTreatmentAdenocarcinomas / Esophageal Cancers / Gastro-esophageal Junction Cancer / Squamous Cell Carcinoma (SCC)1
2CompletedTreatmentAdenocarcinomas / Lung Cancer Non-Small Cell Cancer (NSCLC)1
2CompletedTreatmentAdenosquamous Cell Lung Cancer / Drug/Agent Toxicity by Tissue/Organ / Hemoptysis / Squamous Cell Carcinoma of Lung / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2CompletedTreatmentAdult Type Ovarian Granulosa Cell Tumor / Ovarian Gynandroblastoma / Ovarian Sertoli-Leydig Cell Tumors / Ovarian Sex Cord Tumor With Annular Tubules / Ovarian Steroid Cell Tumor1
2CompletedTreatmentAdvanced Non-Small Cell Lung Cancer / Lung Cancer Non-Small Cell Cancer (NSCLC) / Recurrent Non-small Cell Lung Cancer1
2CompletedTreatmentAdvanced Solid Tumors1
2CompletedTreatmentAdvanced or Metastatic Non-Small Cell Lung Cancer1
2CompletedTreatmentAdvanced/Metastatic Non-Small Cell Lung Cancer1
2CompletedTreatmentBladder Cancers3
2CompletedTreatmentBladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter2
2CompletedTreatmentBladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter / Urethral Cancer2
2CompletedTreatmentBladder Cancers / Urethral Cancer2
2CompletedTreatmentBrain and Central Nervous System Tumors2
2CompletedTreatmentBrain and Central Nervous System Tumors / Cancer, Ovarian / Extragonadal Germ Cell Tumor / Teratoma / Testicular germ cell tumour2
2CompletedTreatmentBreast Cancer Invasive Nos1
2CompletedTreatmentBrenner Tumor / Fallopian Tube Cancer / Ovarian Clear Cell Cystadenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Mixed Epithelial Carcinoma / Ovarian Mucinous Cystadenocarcinoma / Ovarian Serous Cystadenocarcinoma / Ovarian Undifferentiated Adenocarcinoma / Peritoneal Cavity Cancer / Recurrent Ovarian Epithelial Cancer / Stage III Ovarian Epithelial Cancer / Stage IV Ovarian Epithelial Cancer1
2CompletedTreatmentBrenner Tumor / Fallopian Tube Cancer / Ovarian Clear Cell Cystadenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Mucinous Cystadenocarcinoma / Ovarian Serous Cystadenocarcinoma / Ovarian Undifferentiated Adenocarcinoma / Stage III Ovarian Epithelial Cancer / Stage IV Ovarian Epithelial Cancer1
2CompletedTreatmentCancer of Gastrointestinal Tract / Colorectal Cancers1
2CompletedTreatmentCancer of Head and Neck1
2CompletedTreatmentCancer, Breast53
2CompletedTreatmentCancer, Breast / Cancer, Ovarian / Lung Cancers1
2CompletedTreatmentCancer, Breast / Cardiac Toxicity1
2CompletedTreatmentCancer, Breast / Effects of Chemotherapy / HER-2 Positive Breast Cancer1
2CompletedTreatmentCancer, Breast / ErbB1 Expressing / ErbB2 Overexpressing / Inflammatory / Neoplasms, Breast / Newly Diagnosed1
2CompletedTreatmentCancer, Breast / HER2 Positive1
2CompletedTreatmentCancer, Breast / HER2-Negative Breast Cancer1
2CompletedTreatmentCancer, Breast / Locally Advanced / Stage IIB Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IV Breast Cancer1
2CompletedTreatmentCancer, Breast / Metastatic Breast Cancer (MBC)1
2CompletedTreatmentCancer, Breast / Metastatic Breast Cancer (MBC) / Stage IV Breast Cancer / Triple Negative Breast Cancer (TNBC)1
2CompletedTreatmentCancer, Breast / Metastatic Breast Cancer (MBC) / Tumors, Solid1
2CompletedTreatmentCancer, Breast / Neoplasms Metastasis1
2CompletedTreatmentCancer, Breast / Neoplasms, Breast2
2CompletedTreatmentCancer, Breast / Stage I Breast Carcinoma / Stage II Breast Cancer1
2CompletedTreatmentCancer, Ovarian16
2CompletedTreatmentCancer, Ovarian / Clear Cell Mullerian Tumor / Fallopian Tube Cancer / Papillary Serous Mullerian Tumor / Primary Peritoneal Cancer1
2CompletedTreatmentCancer, Ovarian / Endometrial Cancers / Fallopian Tube Cancer / Sarcomas1
2CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Malignant Tumor of Peritoneum1
2CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Metastatic Cancers / Peritoneal Cavity Cancer1
2CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Peritoneal Cavity Cancer3
2CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cancer1
2CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer1
2CompletedTreatmentCancer, Ovarian / Neoplasms, Ovarian1
2CompletedTreatmentCancer, Ovarian / Testicular germ cell tumour1
2CompletedTreatmentCancers / Cervix Diseases / Neoplasms, Ovarian / Ovarian Epithelial Cancer / Primary Peritoneal Carcinoma / Tumors / Uterine Diseases1
2CompletedTreatmentCancers / Tumors1
2CompletedTreatmentCarcinoma NOS1
2CompletedTreatmentCarcinoma NOS / Non-Squamous Non-Small-Cell Lung Cancer1
2CompletedTreatmentCarcinoma of Unknown Primary1
2CompletedTreatmentCarcinoma of Unknown Primary Origin1
2CompletedTreatmentCarcinoma of Unknown Primary / Lung Cancers1
2CompletedTreatmentCarcinoma, Squamous Cell of the Head and Neck1
2CompletedTreatmentCervical Cancers4
2CompletedTreatmentCervical Cancers / Vaginal Cancers1
2CompletedTreatmentChemotherapeutic Agent Toxicity / Head and Neck Carcinoma / Mucositis / Radiation Toxicity / Xerostomia1
2CompletedTreatmentChildhood Extracranial Germ Cell Tumor / Childhood Extragonadal Germ Cell Tumor / Childhood Malignant Ovarian Germ Cell Tumor / Childhood Malignant Testicular Germ Cell Tumor / Ovarian Choriocarcinoma / Ovarian Embryonal Carcinoma / Ovarian Yolk Sac Tumor / Recurrent Childhood Malignant Germ Cell Tumor / Recurrent Malignant Testicular Germ Cell Tumor / Recurrent Ovarian Germ Cell Tumor / Testicular Choriocarcinoma / Testicular Choriocarcinoma and Embryonal Carcinoma / Testicular Choriocarcinoma and Yolk Sac Tumor / Testicular Embryonal Carcinoma / Testicular Embryonal Carcinoma and Yolk Sac Tumor / Testicular Yolk Sac Tumor1
2CompletedTreatmentCiliary Body and Choroid Melanoma, Medium/Large Size / Extraocular Extension Melanoma / Iris Melanoma / Metastatic Intraocular Melanoma / Recurrent Intraocular Melanoma1
2CompletedTreatmentCiliary Body and Choroid Melanoma, Medium/Large Size / Extraocular Extension Melanoma / Iris Melanoma / Recurrent Intraocular Melanoma / Recurrent Melanoma / Stage IV Melanoma1
2CompletedTreatmentColorectal Cancers1
2CompletedTreatmentConcomitant Radiochemotherapy / NSCLC Stage IIIB1
2CompletedTreatmentConcurrent Chemoradiotherapy / Esophageal Cancers / Oxaliplatin / Paclitaxel1
2CompletedTreatmentDistal Urethral Cancer / Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter / Proximal Urethral Cancer / Recurrent Bladder Cancer / Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter / Recurrent Urethral Cancer / Regional Transitional Cell Cancer of the Renal Pelvis and Ureter / Stage III Bladder Cancer / Stage IV Bladder Cancer / Transitional Cell Carcinoma of the Bladder / Urethral Cancer Associated With Invasive Bladder Cancer1
2CompletedTreatmentDrug/Agent Toxicity by Tissue/Organ / Lung Cancers1
2CompletedTreatmentER Positive, Her2 Negative Breast Cancer Patients / Triple Negative Breast Cancer Patients1
2CompletedTreatmentEarly Triple Negative Breast Cancer1
2CompletedTreatmentEndometrial Adenocarcinomas / Endometrial Adenosquamous Cell Carcinoma / Endometrial Clear Cell Carcinoma / Endometrial Papillary Serous Carcinoma / Stage I Endometrial Carcinoma / Stage II Endometrial Carcinoma / Stage III Endometrial Carcinoma / Stage IV Endometrial Carcinoma1
2CompletedTreatmentEndometrial Cancers6
2CompletedTreatmentEndometrial Carcinoma1
2CompletedTreatmentEsophageal Cancers13
2CompletedTreatmentEsophageal Cancers / Malignant Neoplasm of Stomach9
2CompletedTreatmentEsophagus Cancer1
2CompletedTreatmentEstrogen Receptor Negative / HER2/Neu Negative / Male Breast Carcinoma / Progesterone Receptor Negative / Stage IIA Breast Cancer / Stage IIB Breast Cancer / Stage IIIA Breast Cancer / Triple-Negative Breast Carcinoma1
2CompletedTreatmentEstrogen Receptor-negative Breast Cancer / Estrogen Receptor-Positive Breast Cancer / Her2-Positive Breast Cancer / Progesterone Receptor-negative Breast Cancer / Progesterone Receptor-positive Breast Cancer / Stage IA Breast Cancer / Stage IB Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer1
2CompletedTreatmentEstrogen Receptor-Positive Breast Cancer / Her2-Positive Breast Cancer / Stage IA Breast Cancer / Stage IB Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer1
2CompletedTreatmentFallopian Tube Cancer / Malignant Peritoneal Neoplasm / Ovarian Epithelial Cancer1
2CompletedTreatmentFallopian Tube Carcinoma / Primary Peritoneal Carcinoma / Recurrent Ovarian Carcinoma1
2CompletedTreatmentGastro-oesophageal Junction Cancer / Malignant Neoplasm of Stomach1
2CompletedTreatmentGerm Cell Neoplasms / Testicular Cancer1
2CompletedTreatmentHER2-positive, Newly Diagnosed, Primary Breast Cancer, Neoadjuvant Therapy, Trastuzumab1
2CompletedTreatmentHead and Neck Carcinoma18
2CompletedTreatmentHead and Neck Carcinoma / Lung Cancers1
2CompletedTreatmentHead and Neck Carcinoma / Precancerous Conditions1
2CompletedTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC) / Platinum Pre-treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma1
2CompletedTreatmentHer2-Positive Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Kaposi s Sarcoma (KS)1
2CompletedTreatmentInflammatory carcinoma of the breast / Invasive Ductal Breast Carcinoma / Mucinous Breast Cancer / Tubular Breast Carcinoma1
2CompletedTreatmentInflammatory carcinoma of the breast / Locally Advanced Breast Cancer (LABC)1
2CompletedTreatmentIntraocular Melanoma1
2CompletedTreatmentLeukemia, Mast-Cell1
2CompletedTreatmentLeukemias / Malignant Lymphomas1
2CompletedTreatmentLocally Advanced Non-Small Cell Lung Cancer / Lung Cancer Non-Small Cell Cancer (NSCLC)1
2CompletedTreatmentLocally Recurrent and Metastatic Breast Cancer1
2CompletedTreatmentLocally Recurrent or Metastatic Breast Cancer1
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)33
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancer Small Cell Lung Cancer (SCLC) / Lung Cancers1
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers / Neoplasms Metastasis1
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers / Swallowing Disorders1
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Neoplasms, Lung2
2CompletedTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
2CompletedTreatmentLung Cancers34
2CompletedTreatmentMale Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer1
2CompletedTreatmentMalignant Lymphomas3
2CompletedTreatmentMalignant Lymphomas / Unspecified Adult Solid Tumor, Protocol Specific / Unspecified Childhood Solid Tumor, Protocol Specific1
2CompletedTreatmentMalignant Melanoma1
2CompletedTreatmentMalignant Neoplasm of Female Breast1
2CompletedTreatmentMalignant Neoplasm of Pancreas3
2CompletedTreatmentMalignant Neoplasm of Stomach4
2CompletedTreatmentMalignant Neoplasm of Stomach / Peritoneal Carcinomatosis1
2CompletedTreatmentMalignant Pleural Effusions / Recurrent Non-small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2CompletedTreatmentMalignant Pleural Effusions / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2CompletedTreatmentMelanoma2
2CompletedTreatmentMelanoma / Metastases1
2CompletedTreatmentMetastatic Breast Cancer (MBC)12
2CompletedTreatmentMetastatic Malignant Melanoma1
2CompletedTreatmentMetastatic Melanoma2
2CompletedTreatmentMetastatic Non-Small Cell Lung Cancer1
2CompletedTreatmentMetastatic Pancreatic Ductal Adenocarcinoma1
2CompletedTreatmentMetastatic Transitional Cell Cancer of the Renal Pelvis and Ureter / Recurrent Bladder Cancer / Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter / Squamous Cell Carcinoma of the Bladder / Stage IV Bladder Cancer / Transitional Cell Carcinoma of the Bladder1
2CompletedTreatmentMetastatic or Recurrent Squamous Cell Carcinoma of the Lung1
2CompletedTreatmentMixed Tumor, Mullerian1
2CompletedTreatmentMultiple Myeloma and Plasma Cell Neoplasm2
2CompletedTreatmentNasopharyngeal Neoplasms1
2CompletedTreatmentNeoplasm Metastases / Neoplasms, Breast1
2CompletedTreatmentNeoplasms, Breast9
2CompletedTreatmentNeoplasms, Colorectal1
2CompletedTreatmentNeoplasms, Germ Cell and Embryonal1
2CompletedTreatmentNeoplasms, Ovarian2
2CompletedTreatmentNeoplasms, Pancreatic1
2CompletedTreatmentNeuroendocrine Carcinomas1
2CompletedTreatmentNon Small Cell Lung Carcinoma (NSCLC)2
2CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
2CompletedTreatmentNon-Squamous Non-Small Cell Lung Cancer5
2CompletedTreatmentOvarian Carcinoma1
2CompletedTreatmentOvarian Clear Cell Cystadenocarcinoma / Stage III Ovarian Cancer / Stage IV Ovarian Cancer1
2CompletedTreatmentOvarian Epithelial Cancer1
2CompletedTreatmentOvarian Epithelial Cancer / Primary Peritoneal Cancer1
2CompletedTreatmentOvarian Epithelial Cancer / Primary Peritoneal Carcinoma1
2CompletedTreatmentOvary Cancer1
2CompletedTreatmentPancreatic Adenocarcinoma Advanced or Metastatic1
2CompletedTreatmentPancreatic Cancer Metastatic1
2CompletedTreatmentPenile Cancer1
2CompletedTreatmentPrimary Breast Cancer1
2CompletedTreatmentProstate Cancer10
2CompletedTreatmentRecurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma1
2CompletedTreatmentRecurrent Melanoma / Stage IV Melanoma1
2CompletedTreatmentRecurrent Non-small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer3
2CompletedTreatmentRecurrent Ovarian Cancer2
2CompletedTreatmentRenal Cancers1
2CompletedTreatmentResectable Pancreatic Cancers1
2CompletedTreatmentSarcomas4
2CompletedTreatmentSquamous Cell Carcinoma (SCC)2
2CompletedTreatmentSquamous Non Small Cell Lung Cancer2
2CompletedTreatmentStage III Ovarian Cancer / Stage IV Ovarian Cancer1
2CompletedTreatmentStomach and Gastro-Esophageal Junction (GEJ) Cancer1
2CompletedTreatmentTesticular Neoplasms1
2CompletedTreatmentTesticular germ cell tumour1
2CompletedTreatmentAdvanced thymic carcinoma / Thymic Carcinoma1
2CompletedTreatmentTransitional Cell Carcinoma2
2CompletedTreatmentTriple Negative Breast Cancer (TNBC)1
2CompletedTreatmentTumors1
2CompletedTreatmentUnilateral HER2 Positive Breast Cancer1
2CompletedTreatmentUnknown Primary Neoplasms1
2CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
2CompletedTreatmentUrologic Neoplasms2
2CompletedTreatmentUterine Cancers2
2CompletedTreatmentUterine Carcinosarcoma1
2CompletedTreatmentVulvar Cancers1
2Enrolling by InvitationTreatmentCancer, Ovarian1
2Not Yet RecruitingTreatmentAdenocarcinoma Of Esophagus1
2Not Yet RecruitingTreatmentAdenocarcinomas / Cancer of Pancreas / Cancer of the Pancreas / Malignant Neoplasm of Pancreas / Neoplasms, Pancreatic / Pancreas Neoplasms1
2Not Yet RecruitingTreatmentAdvanced Gastric Cancer1
2Not Yet RecruitingTreatmentAdvanced Newly Diagnosed or Recurrent High Grade Serous Carcinomas (HGSC)1
2Not Yet RecruitingTreatmentAdvanced Pancreatic Cancer1
2Not Yet RecruitingTreatmentBladder Cancers / Transitional Cell Carcinoma1
2Not Yet RecruitingTreatmentBreast Cancer Stage II / Breast Cancer Stage III / Cancer, Breast1
2Not Yet RecruitingTreatmentCancer, Breast / Triple Negative Breast Cancer (TNBC)1
2Not Yet RecruitingTreatmentCancer, Ovarian / Fallopian Tube Cancer / Ovarian Epithelial Cancer1
2Not Yet RecruitingTreatmentChildren / Nasopharyngeal Carcinoma1
2Not Yet RecruitingTreatmentEfficacy and Safety1
2Not Yet RecruitingTreatmentEsophageal Cancers1
2Not Yet RecruitingTreatmentEsophageal Cancers / Laryngeal Cancer / Lip Cancer / Oral Cancers / Oropharynx Cancers / Squamous Cell Carcinoma (SCC)1
2Not Yet RecruitingTreatmentEsophageal Cancers / Induction chemotherapy1
2Not Yet RecruitingTreatmentFallopian Tube Cancer / Ovarian Epithelial Cancer / Primary Peritoneal Cancer1
2Not Yet RecruitingTreatmentLocally Advanced Breast Cancer (LABC)1
2Not Yet RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2Not Yet RecruitingTreatmentMalignant Neoplasm of Breast1
2Not Yet RecruitingTreatmentPulmonary Large Cell Neuroendocrine Carcinoma1
2Not Yet RecruitingTreatmentRecurrent or Metastatic Breast Cancer1
2Not Yet RecruitingTreatmentStage IIIA Non-Small Cell Lung Cancer1
2Not Yet RecruitingTreatmentStage IIIC Fallopian Tube Cancer / Stage IIIC Ovarian Cancer / Stage IIIC Primary Peritoneal Cancer / Stage IV Fallopian Tube Cancer / Stage IV Ovarian Cancer / Stage IV Primary Peritoneal Cancer1
2Not Yet RecruitingTreatmentTransitional Cell Carcinoma1
2RecruitingBasic ScienceRecurrent Non-Small Cell Lung Carcinoma / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2RecruitingHealth Services ResearchLung Cancer Small Cell Lung Cancer (SCLC)1
2RecruitingTreatmentAdenocarcinoma Breast Stage IV1
2RecruitingTreatmentAdenocarcinoma of the Esophagus / Adenocarcinoma of the Gastric Cardia / Adenocarcinomas of the Gastroesophageal Junction / Stage IIIA Esophageal Cancer / Stage IIIB Esophageal Cancer / Stage IIIC Esophageal Cancer1
2RecruitingTreatmentAdenocarcinoma of the Pancreas1
2RecruitingTreatmentAdenocarcinoma of the Pancreas / Malignant Neoplasm of Pancreas / Pancreas Ductal Adenocarcinoma1
2RecruitingTreatmentAdenocarcinoma of the Pancreas / Resectable Pancreatic Cancers / Resectable Pancreatic Carcinoma1
2RecruitingTreatmentAdenocarcinoma of the Pancreas / Resectable Pancreatic Cancers / Unresectable Pancreatic Cancer1
2RecruitingTreatmentAdenocarcinoma of the Prostate1
2RecruitingTreatmentAdenocarcinomas of the Esophagogastric Junction1
2RecruitingTreatmentAdenocarcinomas of the Gastroesophageal Junction / Gastric Adenocarcinoma1
2RecruitingTreatmentAdenocarcinomas of the Gastroesophageal Junction / Malignant Neoplasm of Stomach1
2RecruitingTreatmentAdvanced Breast Cancer / Metastatic Breast Cancer (MBC)1
2RecruitingTreatmentAdvanced Gastric Adenocarcinoma2
2RecruitingTreatmentAdvanced Gastric Cancer1
2RecruitingTreatmentAdvanced Gastric or EGJ Cancer1
2RecruitingTreatmentAnal Basaloid Carcinoma / Anal Canal Cloacogenic Carcinoma / Anal Squamous Cell Carcinoma / Metastatic Anal Canal Carcinoma / Recurrent Anal Canal Carcinoma / Stage IIIB Anal Canal Cancer / Stage IV Anal Canal Cancer1
2RecruitingTreatmentAnaplastic Thyroid Carcinoma / Malignant Neoplasms of Thyroid and Other Endocrine Glands / Poorly Differentiated Thyroid Cancer1
2RecruitingTreatmentBRCA1 Hereditary Breast and Ovarian Cancer Syndrome1
2RecruitingTreatmentBladder Cancers / Transitional Cell Carcinoma1
2RecruitingTreatmentBreast - Female / Male Breast Cancer1
2RecruitingTreatmentBreast Adenocarcinoma / Breast Cancer Metastatic / Breast Cancer Stage II / Breast Cancer Stage III / Estrogen Receptor- Negative Breast Cancer / Estrogen Receptor-Positive Breast Cancer / HER2/Neu Negative / Invasive Adenocarcinoma of the Breast / Invasive Breast Carcinoma / Locally Advanced Breast Cancer (LABC) / Progesterone Receptor Negative / Progesterone Receptor Positive Tumor / Stage II Breast Cancer / Stage IIA Breast Cancer / Stage IIB Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Triple-Negative Breast Carcinoma1
2RecruitingTreatmentBreast Adenocarcinoma / Her2-Positive Breast Cancer / Inflammatory Breast Carcinoma / Recurrent Breast Cancer / Stage IIA Breast Cancer / Stage IIB Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer1
2RecruitingTreatmentBrenner Tumor / Malignant Ascites / Malignant Pleural Effusions / Ovarian Clear Cell Cystadenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Mixed Epithelial Carcinoma / Ovarian Serous Cystadenocarcinoma / Ovarian Undifferentiated Adenocarcinoma / Recurrent Fallopian Tube Cancer / Recurrent Ovarian Epithelial Cancer / Recurrent Ovarian Germ Cell Tumor / Recurrent Primary Peritoneal Cavity Cancer / Stage IIIA Fallopian Tube Cancer / Stage IIIA Ovarian Epithelial Cancer / Stage IIIA Ovarian Germ Cell Tumor / Stage IIIA Primary Peritoneal Cavity Cancer / Stage IIIB Fallopian Tube Cancer / Stage IIIB Ovarian Epithelial Cancer / Stage IIIB Ovarian Germ Cell Tumor / Stage IIIB Primary Peritoneal Cavity Cancer / Stage IIIC Fallopian Tube Cancer / Stage IIIC Ovarian Epithelial Cancer / Stage IIIC Ovarian Germ Cell Tumor / Stage IIIC Primary Peritoneal Cavity Cancer / Stage IV Fallopian Tube Cancer / Stage IV Ovarian Epithelial Cancer / Stage IV Ovarian Germ Cell Tumor / Stage IV Primary Peritoneal Cavity Cancer1
2RecruitingTreatmentCNS Germ Cell Tumor1
2RecruitingTreatmentCancer of Head and Neck / Cancers of the Head and Neck / Carcinoma, Squamous Cell of the Head and Neck / Head and Neck Carcinoma / Neoplasms, Head and Neck / Squamous Cell Carcinoma of the Head and Neck (SCCHN)1
2RecruitingTreatmentCancer of Stomach1
2RecruitingTreatmentCancer, Breast15
2RecruitingTreatmentCancer, Breast / Carcinoma, Breast / Malignant Neoplasm of Breast / Tumors, Breast1
2RecruitingTreatmentCancer, Breast / Estrogen Receptor Negative Neoplasm / HER-2 Positive Breast Cancer1
2RecruitingTreatmentCancer, Breast / Neoadjuvant Chemotherapy1
2RecruitingTreatmentCancer, Breast / Neoplasms Metastasis1
2RecruitingTreatmentCancer, Breast / Neoplasms, Breast1
2RecruitingTreatmentCancer, Ovarian4
2RecruitingTreatmentCancer, Ovarian / Childhood Germ Cell Tumor / Teratoma1
2RecruitingTreatmentCancer, Ovarian / Ovarian Cancer Metastatic1
2RecruitingTreatmentCancers of the Head and Neck / Head and Neck Carcinoma / Head and Neck Squamous Cell Carcinoma (HNSCC)1
2RecruitingTreatmentCancers of the Head and Neck / Lung Cancer Non-Small Cell Cancer (NSCLC) / Squamous Cell Carcinoma of Esophagus / Transitional Cell Carcinoma / Urinary Bladder Neoplasms1
2RecruitingTreatmentCarcinoma, Breast1
2RecruitingTreatmentCarcinoma, Ductal, Breast1
2RecruitingTreatmentCarcinoma, Non Small Cell Lung (NSCLC)1
2RecruitingTreatmentCervical Cancers1
2RecruitingTreatmentClear Cell Endometrial Cancer / Endometrial Cancers / Papillary Serous1
2RecruitingTreatmentDesmoid / Ewing's Sarcoma (ES) / Sarcomas / Tumor, Desmoplastic Small Round Cell, Adult / Tumor, Desmoplastic Small Round Cell, Childhood1
2RecruitingTreatmentDigestive System Neoplasms / Esophageal Cancers / Neoplasms / Neoplasms, Esophageal1
2RecruitingTreatmentEarly Primary Breast Cancer in the Elderly1
2RecruitingTreatmentEarly Stage Breast Cancer1
2RecruitingTreatmentEarly-Stage Breast Carcinoma / Estrogen Receptor Positive Tumor1
2RecruitingTreatmentEndometrial Adenocarcinomas / Endometrial Cancers1
2RecruitingTreatmentEndometrial Adenocarcinomas / Stage IA Uterine Corpus Cancer / Stage IB Uterine Corpus Cancer / Stage II Uterine Corpus Cancer / Stage IIIA Uterine Corpus Cancer / Stage IIIB Uterine Corpus Cancer / Stage IIIC Uterine Corpus Cancer / Stage IVA Uterine Corpus Cancer / Stage IVB Uterine Corpus Cancer1
2RecruitingTreatmentEndometrial Cancers2
2RecruitingTreatmentEndometrial Clear Cell Carcinoma / Ovarian Clear Cell Carcinoma1
2RecruitingTreatmentEpithelial Ovarian Carcinoma1
2RecruitingTreatmentEsophageal Cancer Stage III / Esophageal Cancer, Stage II1
2RecruitingTreatmentEsophageal Cancers1
2RecruitingTreatmentEsophageal Cancers / Gastrooesophageal Cancer1
2RecruitingTreatmentEsophageal Cancers / Malignant Neoplasm of Stomach1
2RecruitingTreatmentEstrogen Receptor Negative / Estrogen Receptor Positive / Estrogen Receptor-negative Breast Cancer / Estrogen Receptor-Positive Breast Cancer / HER2-Negative Breast Cancer / Her2-Positive Breast Cancer / HER2/Neu Negative / HER2/Neu Positive / Invasive Breast Carcinoma / Progesterone Receptor Negative / Progesterone Receptor Positive / Progesterone Receptor-negative Breast Cancer / Progesterone Receptor-positive Breast Cancer / Stage IA Breast Cancer / Stage II Breast Cancer / Stage IIA Breast Cancer / Stage IIB Breast Cancer / Stage III Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Triple-Negative Breast Cancer (TNBC) / Triple-Negative Breast Carcinoma1
2RecruitingTreatmentEstrogen Receptor Negative / HER2/Neu Negative / Inflammatory carcinoma of the breast / Progesterone Receptor Negative / Stage IIA Breast Cancer / Stage IIB Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Triple-Negative Breast Cancer (TNBC)1
2RecruitingTreatmentEstrogen Receptor Negative / HER2/Neu Negative / Invasive Breast Carcinoma / Progesterone Receptor Negative / Stage II Breast Cancer AJCC v6 and v7 / Stage IIA Breast Cancer / Stage IIA Breast Cancer AJCC v6 and v7 / Stage IIB Breast Cancer / Stage IIB Breast Cancer AJCC v6 and v7 / Stage III Breast Cancer AJCC V7 / Stage IIIA Breast Cancer / Stage IIIA Breast Cancer AJCC v7 / Stage IIIB Breast Cancer / Stage IIIB Breast Cancer AJCC v7 / Stage IIIC Breast Cancer / Stage IIIC Breast Cancer AJCC v7 / Triple-Negative Breast Carcinoma1
2RecruitingTreatmentEstrogen Receptor-negative Breast Cancer / HER2-Negative Breast Cancer / Progesterone Receptor-negative Breast Cancer / Stage IIA Breast Cancer / Stage IIB Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Triple-Negative Breast Cancer (TNBC)1
2RecruitingTreatmentEwing's Sarcoma (ES) / Rhabdomyosarcomas / Sarcoma, Osteogenic / Soft Tissue Sarcoma (STS)1
2RecruitingTreatmentFallopian Tube Cancer / Fallopian Tube Carcinoma / Ovarian Carcinoma / Ovarian Epithelial Cancer / Primary Peritoneal Carcinoma / Stage III Ovarian Cancer / Stage IV Ovarian Cancer1
2RecruitingTreatmentFallopian Tube Carcinoma / Ovarian Epithelial Cancer / Primary Peritoneal Cancer1
2RecruitingTreatmentFallopian Tube Transitional Cell Carcinoma / Malignant Ovarian Clear Cell Tumor / Malignant Ovarian Endometrioid Tumor / Malignant Ovarian Mixed Epithelial Tumor / Malignant Ovarian Serous Tumor / Ovarian Seromucinous Carcinoma / Ovarian Transitional Cell Carcinoma / Primary Peritoneal Serous Adenocarcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Undifferentiated Fallopian Tube Carcinoma / Undifferentiated Ovarian Carcinoma1
2RecruitingTreatmentGastro-esophageal Junction Adenocarcinoma / Malignant Neoplasm of Stomach1
2RecruitingTreatmentGastroesophageal Junction Cancer / Malignant Neoplasm of Stomach1
2RecruitingTreatmentGastrointestinal Stromal Tumors1
2RecruitingTreatmentGastrooesophageal Cancer1
2RecruitingTreatmentGerm Cell Tumors2
2RecruitingTreatmentGynecologic Malignancies1
2RecruitingTreatmentHER2 Negative Metastatic Breast Cancer1
2RecruitingTreatmentHER2 Positive Breast Cancers / Inflammatory carcinoma of the breast / Invasive Ductal Breast Carcinoma / Malignant Neoplasm of Female Breast / Mucinous Breast Cancer Stage II / Tubular Breast Cancer Stage II / Tubular Breast Cancer Stage III1
2RecruitingTreatmentHER2 Positive Breast Carcinoma / Stage IA Breast Cancer / Stage IB Breast Cancer / Stage IIA Breast Cancer / Stage IIB Breast Cancer1
2RecruitingTreatmentHER2 Positive Breast Carcinoma / Stage III Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer1
2RecruitingTreatmentHemangiosarcoma1
2RecruitingTreatmentHer2-Positive Breast Cancer2
2RecruitingTreatmentHigh Grade Malignant Neuroendocrine Carcinoma (Diagnosis)1
2RecruitingTreatmentInflammatory carcinoma of the breast1
2RecruitingTreatmentLocally Advanced Gastric Cancer1
2RecruitingTreatmentLocally Advanced Gastric Cancer / Metastatic Gastric Cancers1
2RecruitingTreatmentLocally Advanced Non-Small Cell Lung Cancer1
2RecruitingTreatmentLocally Advanced Pancreatic Adenocarcinoma1
2RecruitingTreatmentLung1
2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)11
2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers1
2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Non Small Cell Lung Cancer Recurrent / Non-Small Cell Carcinoma of Lung, TNM Stage 4 / Non-Small-Cell Lung Cancer Metastatic1
2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Squamous Cell Carcinoma (SCC)1
2RecruitingTreatmentLung Cancers1
2RecruitingTreatmentMalignant Neoplasm of Breast1
2RecruitingTreatmentMalignant Neoplasm of Pancreas2
2RecruitingTreatmentMalignant Neoplasm of Stomach2
2RecruitingTreatmentMalignant Neoplasms of Female Genital Organs1
2RecruitingTreatmentMelanoma1
2RecruitingTreatmentMetastatic Breast Cancer (MBC)3
2RecruitingTreatmentMetastatic Malignant Melanoma1
2RecruitingTreatmentMetastatic Triple Negative Breast Cancer1
2RecruitingTreatmentMetastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)1
2RecruitingTreatmentNasopharyngeal Neoplasms1
2RecruitingTreatmentNeoplasms, Breast2
2RecruitingTreatmentNeoplasms, Endometrial1
2RecruitingTreatmentNeoplasms, Esophageal2
2RecruitingTreatmentNeoplasms, Ovarian1
2RecruitingTreatmentNeoplasms, Ovarian / Ovarian Epithelial Cancer1
2RecruitingTreatmentOesophageal Carcinoma1
2RecruitingTreatmentOropharyngeal Squamous Cell Cancer1
2RecruitingTreatmentOvarian Granulosa Cell Tumor / Ovarian Gynandroblastoma / Ovarian Sertoli-Leydig Cell Tumors / Ovarian Sex Cord Tumor With Annular Tubules / Ovarian Sex Cord-Stromal Tumor / Ovarian Sex Cord-Stromal Tumor of Mixed or Unclassified Cell Types / Ovarian Steroid Cell Tumor1
2RecruitingTreatmentPancreatic Cancer Stage II1
2RecruitingTreatmentPancreatic Ductal Adenocarcinoma1
2RecruitingTreatmentPatients With Stage IV or Recurrent Adenocarcinoma of the Lung1
2RecruitingTreatmentPeritoneal Adhesion1
2RecruitingTreatmentRecurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma1
2RecruitingTreatmentRelapse/Refractory Multiple Myeloma1
2RecruitingTreatmentSalivary Gland Cancers1
2RecruitingTreatmentSquamous Cell Carcinoma of Esophagus3
2RecruitingTreatmentSquamous Cell Carcinoma of the Anus1
2RecruitingTreatmentStage IA Pancreatic Adenocarcinoma / Stage IB Pancreatic Adenocarcinoma / Stage IIA Pancreatic Adenocarcinoma / Stage IIB Pancreatic Adenocarcinoma1
2RecruitingTreatmentStage III Fallopian Tube Cancer / Stage III Ovarian Cancer / Stage III Primary Peritoneal Cancer / Stage IIIA Fallopian Tube Cancer / Stage IIIA Ovarian Cancer / Stage IIIA Primary Peritoneal Cancer / Stage IIIB Fallopian Tube Cancer / Stage IIIB Ovarian Cancer / Stage IIIB Primary Peritoneal Cancer / Stage IIIC Fallopian Tube Cancer / Stage IIIC Ovarian Cancer / Stage IIIC Primary Peritoneal Cancer / Stage IV Fallopian Tube Cancer / Stage IV Ovarian Cancer / Stage IV Primary Peritoneal Cancer1
2RecruitingTreatmentStage III Non-Small Cell Lung Cancer AJCC v7 / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer AJCC v7 / Stage IIIb Non-small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer AJCC v71
2RecruitingTreatmentTNBC - Triple-Negative Breast Cancer / Triple Negative Breast Cancer (TNBC)1
2RecruitingTreatmentTransitional Cell Carcinoma1
2RecruitingTreatmentTriple Negative Breast Cancer (TNBC)1
2RecruitingTreatmentTriple-Negative Breast Cancer (TNBC)1
2RecruitingTreatmentTumors, Solid1
2RecruitingTreatmentUnknown Primary Tumors1
2RecruitingTreatmentUnresectable Pancreatic Carcinoma1
2RecruitingTreatmentUntreated Metastatic Pancreatic Ductal Adenocarcinoma1
2SuspendedTreatmentAnaplastic Thyroid Cancers / Recurrent Thyroid Cancer1
2SuspendedTreatmentMelanoma (Skin)1
2TerminatedDiagnosticCancer, Breast1
2TerminatedPreventionHemodialysis Graft Dysfunction1
2TerminatedPreventionVascular Disease, Peripheral1
2TerminatedSupportive CareCancer, Ovarian / Cervical Cancers / Endometrial Cancers / Fallopian Tube Cancer / Neurotoxicity / Primary Peritoneal Cavity Cancer / Sarcomas1
2TerminatedTreatmentAdenocarcinoma of the Distal Esophagus / Adenocarcinoma of the Proximal Stomach / Adenocarcinomas of the Gastroesophageal Junction / Gastroesophageal Adenocarcinoma1
2TerminatedTreatmentAdenocarcinoma of the Esophagus / Esophageal Cancers / Squamous Cell Carcinoma (SCC)1
2TerminatedTreatmentAdenocarcinoma of the Lung / Bronchioloalveolar Carcinoma / Bronchioloalveolar Lung Carcinoma / Large Cell Lung Carcinoma / Recurrent Non-Small Cell Lung Carcinoma / Stage IV Non-Small Cell Lung Cancer1
2TerminatedTreatmentAdenocarcinoma of the Pancreas1
2TerminatedTreatmentAdenocarcinoma of the Pancreas / Stage III Pancreatic Cancer1
2TerminatedTreatmentAdvanced Non-Small Cell Lung Cancer1
2TerminatedTreatmentAdvanced Non-squamous NSCLC1
2TerminatedTreatmentBladder Cancers1
2TerminatedTreatmentBladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter / Urethral Cancer1
2TerminatedTreatmentBladder Cancers / Urothelial Cancer1
2TerminatedTreatmentBorderline Resectable Pancreatic Cancer1
2TerminatedTreatmentCancer, Breast10
2TerminatedTreatmentCancer, Breast / Locally Recurrent and Metastatic Breast Cancer / Neoplasms, Breast / Tumors, Breast1
2TerminatedTreatmentCancer, Breast / Recurrent Breast Cancer / Stage IV Breast Cancer1
2TerminatedTreatmentCancer, Ovarian2
2TerminatedTreatmentCancer, Ovarian / Childhood Germ Cell Tumor / Extragonadal Germ Cell Tumor / Testicular germ cell tumour1
2TerminatedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Malignant Peritoneal Neoplasm / Stage 3 Cancer / Stage 4 Cancer1
2TerminatedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Mixed Tumor, Mesodermal / Primary Peritoneal Carcinoma1
2TerminatedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Peritoneal Cavity Cancer1
2TerminatedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer1
2TerminatedTreatmentCancer, Ovarian / Malignant Peritoneal Neoplasm1
2TerminatedTreatmentCancer, Ovarian / Primary Peritoneal Cavity Cancer2
2TerminatedTreatmentCervical Cancers1
2TerminatedTreatmentCervical Cancers / Uterine Cancers1
2TerminatedTreatmentCutaneous Squamous Cell Carcinoma1
2TerminatedTreatmentDrug/Agent Toxicity by Tissue/Organ / Head and Neck Carcinoma / Oral Complications / Radiation Toxicity1
2TerminatedTreatmentEpithelial Ovarian Carcinoma1
2TerminatedTreatmentEsophageal Cancers1
2TerminatedTreatmentEsophageal Diseases1
2TerminatedTreatmentEsophagus Cancer / Gastroesophageal Junction Cancer / HER-2 Gene Amplification / Malignant Neoplasm of Stomach1
2TerminatedTreatmentEstrogen Receptor-Positive Breast Cancer / HER2-Negative Breast Cancer / Progesterone Receptor-positive Breast Cancer / Stage I Breast Carcinoma / Stage II Breast Cancer / Stage IIIA Breast Cancer1
2TerminatedTreatmentFallopian Tube Cancer / Ovarian Epithelial Cancer / Primary Peritoneal Cancer1
2TerminatedTreatmentFistula Stenosis1
2TerminatedTreatmentLocally Advanced HER2-negative Breast Cancer1
2TerminatedTreatmentLoco-regional Esophageal Cancer1
2TerminatedTreatmentLower Oesophagus Cancer / Oesophageal Junction Cancer / Stomach Neoplasms1
2TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)8
2TerminatedTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
2TerminatedTreatmentLung Cancers5
2TerminatedTreatmentMalignant Neoplasm of Pancreas1
2TerminatedTreatmentMalignant Neoplasm of Stomach1
2TerminatedTreatmentMalignant Ovarian Mixed Epithelial Tumor / Ovarian Clear Cell Cystadenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Mucinous Cystadenocarcinoma / Ovarian Serous Cystadenocarcinoma / Primary Peritoneal Carcinoma / Stage III Ovarian Cancer / Undifferentiated Ovarian Carcinoma1
2TerminatedTreatmentMelanoma2
2TerminatedTreatmentMelanoma (Skin)1
2TerminatedTreatmentMetastatic Breast Cancer (MBC)5
2TerminatedTreatmentMetastatic Cancer Pancreas1
2TerminatedTreatmentMetastatic, Gastric or Gastro-oesophageal Junction, Cancer1
2TerminatedTreatmentNeoplasms Metastasis / Neoplasms, Breast1
2TerminatedTreatmentNeoplasms, Breast1
2TerminatedTreatmentNeoplasms, Head and Neck / Squamous Cell Carcinoma (SCC)1
2TerminatedTreatmentNeoplasms, Ovarian1
2TerminatedTreatmentPancreatic Carcinoma Non-resectable / Stage IV Pancreatic Cancer1
2TerminatedTreatmentPatients With Advanced Ovarian Cancer Sensitive to Platinum-based Chemotherapy1
2TerminatedTreatmentPenile Squamous Cell Carcinoma Stage IV1
2TerminatedTreatmentProstate Cancer1
2TerminatedTreatmentProstatic Neoplasms1
2TerminatedTreatmentRecurrent Non-small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2TerminatedTreatmentRefractory Plasma Cell Myeloma1
2TerminatedTreatmentSarcomas1
2TerminatedTreatmentStage IB Esophageal Adenocarcinoma / Stage IIA Esophageal Adenocarcinoma / Stage IIB Esophageal Adenocarcinoma / Stage IIIA Esophageal Adenocarcinoma / Stage IIIB Esophageal Adenocarcinoma / Stage IIIC Esophageal Adenocarcinoma1
2TerminatedTreatmentTesticular Cancer1
2TerminatedTreatmentAdvanced thymic carcinoma / Thymic Carcinoma1
2TerminatedTreatmentTriple Negative Breast Cancer (TNBC)1
2TerminatedTreatmentTriple Negative Metastatic Breast Cancer1
2TerminatedTreatmentUrinary Bladder Neoplasms1
2TerminatedTreatmentUterine Cancers1
2TerminatedTreatmentUterine Neoplasms1
2Unknown StatusDiagnosticCancer, Breast1
2Unknown StatusDiagnosticLung Cancers1
2Unknown StatusSupportive CareNausea / Vomiting1
2Unknown StatusTreatmentAdenocarincoma of Pancreas / Stage III Pancreatic Cancer / Stage IVA Pancreatic Cancer / Stage IVB Pancreatic Cancer1
2Unknown StatusTreatmentAdrenocortical Carcinoma1
2Unknown StatusTreatmentAdvanced Gastric Cancer1
2Unknown StatusTreatmentAdvanced Pancreatic Cancer1
2Unknown StatusTreatmentBladder (Urothelial, Transitional Cell) Cancer / Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable / Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy) / Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive) / Bladder Cancers1
2Unknown StatusTreatmentBladder Cancers1
2Unknown StatusTreatmentCancer, Breast6
2Unknown StatusTreatmentCancer, Breast / Stage II Breast Cancer / Stage III Breast Cancer1
2Unknown StatusTreatmentCancer, Ovarian4
2Unknown StatusTreatmentCancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cancer1
2Unknown StatusTreatmentCancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer2
2Unknown StatusTreatmentCancer, Ovarian / Primary Peritoneal Cavity Cancer1
2Unknown StatusTreatmentCarcinoma NOS / Unknown Primary Neoplasms1
2Unknown StatusTreatmentCervical Cancers2
2Unknown StatusTreatmentEndometrial Cancers1
2Unknown StatusTreatmentEndometrial Serous Adenocarcinoma / Stage IIIA Uterine Corpus Cancer / Stage IIIB Uterine Corpus Cancer / Stage IIIC1 Uterine Corpus Cancer / Stage IIIC2 Uterine Corpus Cancer / Stage IVA Uterine Corpus Cancer / Stage IVB Uterine Corpus Cancer1
2Unknown StatusTreatmentErbB2-Positive Stage I-III Breast Cancer1
2Unknown StatusTreatmentEsophageal Cancers6
2Unknown StatusTreatmentGastric Adenocarcinoma1
2Unknown StatusTreatmentGastric Caner1
2Unknown StatusTreatmentHER-2 Positive Breast Cancer1
2Unknown StatusTreatmentHER2-Negative Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer1
2Unknown StatusTreatmentHead and Neck Carcinoma5
2Unknown StatusTreatmentHead and Neck Squamous Carcinoma / Nasopharyngeal Carcinoma1
2Unknown StatusTreatmentLiver Metastasis / Lung Cancer Non-Small Cell Cancer (NSCLC) / Malignant Neoplasm of Nasopharynx1
2Unknown StatusTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)3
2Unknown StatusTreatmentLung Cancers8
2Unknown StatusTreatmentMalignant Melanoma of Skin Stage III / Metastatic Melanoma1
2Unknown StatusTreatmentMalignant Neoplasm of Esophagus1
2Unknown StatusTreatmentMalignant Neoplasm of Stomach / Metastases to Perineum1
2Unknown StatusTreatmentMelanoma1
2Unknown StatusTreatmentNeoplasms, Head and Neck1
2Unknown StatusTreatmentPancreatic Ductal Carcinoma1
2Unknown StatusTreatmentProstate Cancer1
2Unknown StatusTreatmentProsthesis Survival1
2Unknown StatusTreatmentRecurrent Non-small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2Unknown StatusTreatmentSquamous Cell Carcinoma of Lung1
2Unknown StatusTreatmentStage I Breast Carcinoma / Stage II Breast Cancer1
2Unknown StatusTreatmentThyroid Cancers1
2Unknown StatusTreatmentTriple Negative Breast Cancer (TNBC)1
2Unknown StatusTreatmentUterine Cervical Cancer1
2WithdrawnNot AvailableLung Cancer Non-Small Cell Cancer (NSCLC) / Neoplasms, Lung1
2WithdrawnTreatmentArteriovenous Access Fistula Stenosis1
2WithdrawnTreatmentBladder Cancers / Urothelial Cancer1
2WithdrawnTreatmentCancer of Head and Neck1
2WithdrawnTreatmentCancer, Breast3
2WithdrawnTreatmentCancer, Breast / ER-Negative PR-Negative HER2-Negative Breast Cancer / ER-Negative PR-Negative HER2-Negative Breast Neoplasms / Triple Negative Breast Cancer (TNBC) / Triple Negative Breast Neoplasms / Triple-Negative Breast Cancer (TNBC) / Triple-Negative Breast Neoplasms1
2WithdrawnTreatmentCancer, Ovarian1
2WithdrawnTreatmentEsophageal Cancers / Gastrooesophageal Cancer / Her-2 Positive Gastric Cancer1
2WithdrawnTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2WithdrawnTreatmentLung Cancers1
2WithdrawnTreatmentMetastatic Melanoma1
2WithdrawnTreatmentNeoplasms, Breast3
2WithdrawnTreatmentProstate Cancer2
2WithdrawnTreatmentRecurrent Bladder Urothelial Carcinoma / Stage IV Bladder Urothelial Carcinoma1
2WithdrawnTreatmentUnknown Primary Tumors1
2, 3Active Not RecruitingTreatmentCancer, Breast1
2, 3Active Not RecruitingTreatmentHead and Neck Carcinoma1
2, 3CompletedTreatmentAdenocarcinoma of the Lung / Bronchoalveolar Cell Lung Cancer / Large Cell Lung Cancer / Recurrent Non-small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2, 3CompletedTreatmentCancer of the Breast / Cancer, Breast / Estrogen Receptor- Negative Breast Cancer / HER2- Negative Breast Cancer / Metastatic Breast Cancer (MBC) / Progesterone Receptor- Negative Breast Cancer / Recurrent Breast Cancer / Stage IV Breast Cancer / Triple-Negative Breast Cancer (TNBC) / Triple-negative Metastatic Breast Cancer / Tumors, Breast1
2, 3CompletedTreatmentCancer, Breast1
2, 3CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cancer1
2, 3CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer1
2, 3CompletedTreatmentHER-2 Positive Breast Cancer / Inflammatory carcinoma of breast stage IV / Inflammatory carcinoma of the breast / Invasive Ductal Breast Carcinoma / Malignant Neoplasm of Female Breast / Mucinous Breast Cancer Stage II / Tubular Breast Cancer Stage II / Tubular Breast Cancer Stage III1
2, 3CompletedTreatmentHead and Neck Carcinoma1
2, 3CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2, 3CompletedTreatmentLung Cancers2
2, 3CompletedTreatmentMalignant Neoplasm of Stomach1
2, 3Not Yet RecruitingTreatmentPrecancerous Type Pancreatic Cyst1
2, 3Not Yet RecruitingTreatmentRecurrent or Metastatic Breast Cancer1
2, 3RecruitingTreatmentCancer, Breast3
2, 3RecruitingTreatmentDialysis Access Dysfunction1
2, 3RecruitingTreatmentEndometrial Adenocarcinomas / Endometrial Clear Cell Adenocarcinoma / Endometrial Serous Adenocarcinoma / Endometrial Undifferentiated Carcinoma / Recurrent Uterine Corpus Carcinoma / Stage III Uterine Corpus Cancer / Stage IIIA Uterine Corpus Cancer / Stage IIIB Uterine Corpus Cancer / Stage IIIC Uterine Corpus Cancer / Stage IV Uterine Corpus Cancer / Stage IVA Uterine Corpus Cancer / Stage IVB Uterine Corpus Cancer1
2, 3RecruitingTreatmentEpstein-Barr Virus Infections / Stage II Nasopharyngeal Carcinoma / Stage III Nasopharyngeal Carcinoma / Stage IVA Nasopharyngeal Carcinoma / Stage IVB Nasopharyngeal Carcinoma1
2, 3RecruitingTreatmentEsophageal Cancers / Neoplasms, Esophageal1
2, 3RecruitingTreatmentFIGO Stages II to IV / Primary Malignant Neoplasm of Ovary1
2, 3RecruitingTreatmentInflammatory carcinoma of the breast / Invasive Ductal Breast Carcinoma / Mucinous Breast Cancer / Tubular Breast Carcinoma1
2, 3RecruitingTreatmentLow Grade Ovarian Serous Adenocarcinoma / Micropapillary Serous Carcinoma / Ovarian Serous Adenocarcinoma / Primary Peritoneal Serous Adenocarcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma1
2, 3RecruitingTreatmentMalignant Neoplasm of Esophagus1
2, 3SuspendedTreatmentDeleterious BRCA1 Gene Mutation / Deleterious BRCA2 Gene Mutation / Fallopian Tube Clear Cell Adenocarcinoma / Fallopian Tube Endometrioid Adenocarcinoma / Fallopian Tube Mucinous Adenocarcinoma / Fallopian Tube Serous Adenocarcinoma / Fallopian Tube Transitional Cell Carcinoma / Malignant Ovarian Mixed Epithelial Tumor / Ovarian Clear Cell Adenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Mucinous Adenocarcinoma / Ovarian Seromucinous Carcinoma / Ovarian Serous Adenocarcinoma / Ovarian Transitional Cell Carcinoma / Primary Peritoneal Serous Adenocarcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Undifferentiated Fallopian Tube Carcinoma / Undifferentiated Ovarian Carcinoma1
2, 3SuspendedTreatmentMetastatic Breast Cancer (MBC)1
2, 3SuspendedTreatmentSquamous Cell Carcinoma of Esophagus1
2, 3TerminatedTreatmentAnaplastic Thyroid Cancers1
2, 3TerminatedTreatmentCancer, Ovarian / Primary Peritoneal Cavity Cancer1
2, 3TerminatedTreatmentEsophageal Cancers1
2, 3TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2, 3TerminatedTreatmentStage IIIB or IV Non-Small Cell Lung Cancer1
2, 3Unknown StatusTreatmentCancer, Breast1
2, 3Unknown StatusTreatmentExtragonadal Germ Cell Tumor / Teratoma / Testicular germ cell tumour1
3Active Not RecruitingNot AvailableCancer, Breast1
3Active Not RecruitingTreatmentAbdominal wall neoplasm / Fallopian Tube Neoplasms / Genital Diseases, Female / Neoplasms, Ovarian / Ovarian Diseases1
3Active Not RecruitingTreatmentAdenocarcinoma Of Esophagus / Adenocarcinomas of the Gastroesophageal Junction / Stage IB Esophageal Cancer / Stage IB Esophageal Cancer AJCC v7 / Stage IIA Esophageal Cancer / Stage IIA Esophageal Cancer AJCC v7 / Stage IIB Esophageal Cancer / Stage IIB Esophageal Cancer AJCC v7 / Stage IIIA Esophageal Cancer / Stage IIIA Esophageal Cancer AJCC v7 / Stage IIIB Esophageal Cancer / Stage IIIB Esophageal Cancer AJCC v71
3Active Not RecruitingTreatmentAdenocarcinoma of the Cervix / Adenosquamous carcinoma of the cervix / Cervical Squamous Cell Carcinoma / Cervical Squamous Cell Carcinoma, Not Otherwise Specified / Chemotherapeutic Agent Toxicity / Cognitive Side Effects of Cancer Therapy / Psychological Impact of Cancer / Radiation Toxicity / Sexual Dysfunction and Infertility / Stage IB Cervical Cancer / Stage IIA Cervical Cancer / Stage IIB Cervical Cancer / Stage III Cervical Cancer / Stage IIIB Cervical Cancer / Stage IVA Cervical Cancer1
3Active Not RecruitingTreatmentAdenocarcinoma, Mucinous / Carcinoma, Undifferentiated / Clear Cell Adenocarcinoma / Fallopian Tube Clear Cell Adenocarcinoma / Fallopian Tube Endometrioid Adenocarcinoma / Fallopian Tube Mucinous Adenocarcinoma / Fallopian Tube Serous Adenocarcinoma / Malignant Ovarian Mixed Epithelial Tumor / Ovarian Brenner Tumor / Ovarian Clear Cell Adenocarcinofibroma / Ovarian Endometrioid Adenocarcinoma / Ovarian Seromucinous Carcinoma / Ovarian Serous Adenocarcinoma / Primary Peritoneal Serous Adenocarcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Undifferentiated Fallopian Tube Carcinoma / Undifferentiated Ovarian Carcinoma1
3Active Not RecruitingTreatmentAdenocarcinomas of the Gastroesophageal Junction / Gastric Adenocarcinoma1
3Active Not RecruitingTreatmentAdvanced Gastric Cancer / Esophagogastric Junction Cancer1
3Active Not RecruitingTreatmentAdvanced Non-Small Cell Lung Cancer1
3Active Not RecruitingTreatmentAntimetabolites, Antineoplastic / Digestive System Diseases / Digestive System Neoplasms / Endocrine Gland Neoplasms / Endocrine System Diseases / Gemcitabine / Neoplasms / Neoplasms by Site / Neoplasms, Pancreatic / Pancreatic Diseases1
3Active Not RecruitingTreatmentBMI >30 kg/m2 / Endometrial Clear Cell Adenocarcinoma / Endometrial Serous Adenocarcinoma / Neurotoxicity Syndrome / Stage I Uterine Corpus Cancer / Stage II Uterine Corpus Cancer / Tiredness1
3Active Not RecruitingTreatmentBladder Cancers1
3Active Not RecruitingTreatmentBorderline Ovarian Mucinous Tumor / Ovarian Mucinous Cystadenocarcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Stage IA Fallopian Tube Cancer / Stage IA Ovarian Cancer / Stage IB Fallopian Tube Cancer / Stage IB Ovarian Cancer / Stage IC Fallopian Tube Cancer / Stage IC Ovarian Cancer / Stage IIA Fallopian Tube Cancer / Stage IIA Ovarian Cancer / Stage IIB Fallopian Tube Cancer / Stage IIB Ovarian Cancer / Stage IIC Fallopian Tube Cancer / Stage IIC Ovarian Cancer / Stage IIIA Fallopian Tube Cancer / Stage IIIA Ovarian Cancer / Stage IIIB Fallopian Tube Cancer / Stage IIIB Ovarian Cancer / Stage IIIC Fallopian Tube Cancer / Stage IIIC Ovarian Cancer / Stage IV Fallopian Tube Cancer / Stage IV Ovarian Cancer1
3Active Not RecruitingTreatmentBreast Adenocarcinoma / HER2 Positive Breast Carcinoma / Stage IA Breast Cancer / Stage IB Breast Cancer / Stage IIA Breast Cancer / Stage IIB Breast Cancer / Stage IIIA Breast Cancer1
3Active Not RecruitingTreatmentBreast Cancer Invasive Nos1
3Active Not RecruitingTreatmentCancer, Breast14
3Active Not RecruitingTreatmentCancer, Breast / Neoplasms, Breast1
3Active Not RecruitingTreatmentCancer, Ovarian3
3Active Not RecruitingTreatmentCancer, Ovarian / Neoplasms, Ovarian1
3Active Not RecruitingTreatmentCervical Cancers / Uterine Cervical Cancer / Uterine Cervical Neoplasms1
3Active Not RecruitingTreatmentEndometrial Cancers1
3Active Not RecruitingTreatmentEndometrial Cancers / Recurrent Uterine Corpus Carcinoma / Stage IIIA Uterine Corpus Cancer / Stage IIIB Uterine Corpus Cancer / Stage IIIC Uterine Corpus Cancer / Stage IVA Uterine Corpus Cancer / Stage IVB Uterine Corpus Cancer1
3Active Not RecruitingTreatmentEndometrial Clear Cell Adenocarcinoma / Endometrial Serous Adenocarcinoma / Stage IA Uterine Corpus Cancer / Stage IB Uterine Corpus Cancer / Stage II Uterine Corpus Cancer / Stage IIIA Uterine Corpus Cancer / Stage IIIB Uterine Corpus Cancer / Stage IIIC Uterine Corpus Cancer / Stage IVA Uterine Corpus Cancer1
3Active Not RecruitingTreatmentEsophageal Cancers1
3Active Not RecruitingTreatmentEstrogen Receptor Negative / Estrogen Receptor Positive / HER2/Neu Negative / HER2/Neu Positive / Male Breast Carcinoma / Progesterone Receptor Negative / Progesterone Receptor Positive / Recurrent Breast Carcinoma / Stage IIIC Breast Cancer AJCC v6 / Stage IV Breast Cancer1
3Active Not RecruitingTreatmentEstrogen Receptor Negative / Estrogen Receptor Positive / HER2/Neu Negative / Male Breast Carcinoma / Stage IA Breast Cancer / Stage IB Breast Cancer / Stage IIA Breast Cancer / Stage IIB Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer1
3Active Not RecruitingTreatmentEstrogen Receptor Negative / Estrogen Receptor Positive / HER2/Neu Positive / Progesterone Receptor Negative / Progesterone Receptor Positive / Recurrent Breast Carcinoma / Stage IA Breast Cancer / Stage IB Breast Cancer / Stage IIA Breast Cancer / Stage IIB Breast Cancer / Stage IIIA Breast Cancer / Stage IIIC Breast Cancer1
3Active Not RecruitingTreatmentFallopian Tube Clear Cell Adenocarcinoma / Fallopian Tube Endometrioid Adenocarcinoma / Fallopian Tube Mucinous Adenocarcinoma / Fallopian Tube Serous Adenocarcinoma / Fallopian Tube Transitional Cell Carcinoma / Malignant Ovarian Mixed Epithelial Tumor / Ovarian Brenner Tumor / Ovarian Clear Cell Adenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Mucinous Adenocarcinoma / Ovarian Serous Adenocarcinoma / Ovarian Transitional Cell Carcinoma / Primary Peritoneal Serous Adenocarcinoma / Stage IIIA Fallopian Tube Cancer / Stage IIIA Ovarian Cancer / Stage IIIA Primary Peritoneal Cancer / Stage IIIB Fallopian Tube Cancer / Stage IIIB Ovarian Cancer / Stage IIIB Primary Peritoneal Cancer / Stage IIIC Fallopian Tube Cancer / Stage IIIC Ovarian Cancer / Stage IIIC Primary Peritoneal Cancer / Stage IV Fallopian Tube Cancer / Stage IV Ovarian Cancer / Stage IV Primary Peritoneal Cancer / Undifferentiated Fallopian Tube Carcinoma / Undifferentiated Ovarian Carcinoma1
3Active Not RecruitingTreatmentFallopian Tube Endometrioid Adenocarcinoma / Fallopian Tube Mucinous Adenocarcinoma / Fallopian Tube Transitional Cell Carcinoma / Malignant Ovarian Mixed Epithelial Tumor / Ovarian Brenner Tumor / Ovarian Clear Cell Adenocarcinofibroma / Ovarian Endometrioid Adenocarcinoma / Ovarian Mucinous Adenocarcinoma / Ovarian Serous Adenocarcinoma / Ovarian Transitional Cell Carcinoma / Primary Peritoneal Serous Adenocarcinoma / Stage IIA Fallopian Tube Cancer / Stage IIA Ovarian Cancer / Stage IIB Fallopian Tube Cancer / Stage IIB Ovarian Cancer / Stage IIC Fallopian Tube Cancer / Stage IIC Ovarian Cancer / Stage IIIA Fallopian Tube Cancer / Stage IIIA Ovarian Cancer / Stage IIIA Primary Peritoneal Cancer / Stage IIIB Fallopian Tube Cancer / Stage IIIB Ovarian Cancer / Stage IIIB Primary Peritoneal Cancer / Stage IIIC Fallopian Tube Cancer / Stage IIIC Ovarian Cancer / Stage IIIC Primary Peritoneal Cancer / Stage IV Fallopian Tube Cancer / Stage IV Ovarian Cancer / Stage IV Primary Peritoneal Cancer / Undifferentiated Ovarian Carcinoma1
3Active Not RecruitingTreatmentGastric Cancer Third Line / Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma1
3Active Not RecruitingTreatmentGastroesophageal Junction Cancer / Malignant Neoplasm of Stomach1
3Active Not RecruitingTreatmentHER-2 Positive Breast Cancer / Inflammatory carcinoma of breast stage IV / Inflammatory carcinoma of the breast / Invasive Ductal Breast Carcinoma / Malignant Neoplasm of Female Breast / Mucinous Breast Cancer Stage II / Tubular Breast Cancer Stage II / Tubular Breast Cancer Stage III1
3Active Not RecruitingTreatmentHER2/Neu Positive / Male Breast Carcinoma / Stage IIA Breast Cancer / Stage IIB Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer1
3Active Not RecruitingTreatmentHER2/Neu Positive / Stage IA Breast Cancer / Stage IB Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer1
3Active Not RecruitingTreatmentHead and Neck Carcinoma1
3Active Not RecruitingTreatmentLocally Advanced Malignant Neoplasm / Malignant Neoplasm of Pancreas / Pancreatic Carcinoma Non-resectable1
3Active Not RecruitingTreatmentLung Cancer - Non Small Cell (Squamous) / Lung Cancer Non-Small Cell Cancer (NSCLC)1
3Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)3
3Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Non-Small Cell Lung Carcinoma (NSCLC)1
3Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Non-Small-Cell Lung Carcinoma NSCLC1
3Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Non-Squamous Non-Small Cell Lung Cancer2
3Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Squamous Non-Small Cell Lung Cancer1
3Active Not RecruitingTreatmentLung Cancers / Radiation Toxicity1
3Active Not RecruitingTreatmentMalignant Neoplasm of Stomach1
3Active Not RecruitingTreatmentMalignant Ovarian Mixed Epithelial Tumor / Ovarian Brenner Tumor / Ovarian Clear Cell Cystadenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Mucinous Cystadenocarcinoma / Ovarian Serous Cystadenocarcinoma / Stage IIA Fallopian Tube Cancer / Stage IIA Ovarian Cancer / Stage IIB Fallopian Tube Cancer / Stage IIB Ovarian Cancer / Stage IIC Fallopian Tube Cancer / Stage IIC Ovarian Cancer / Stage IIIA Fallopian Tube Cancer / Stage IIIA Ovarian Cancer / Stage IIIA Primary Peritoneal Cancer / Stage IIIB Fallopian Tube Cancer / Stage IIIB Ovarian Cancer / Stage IIIB Primary Peritoneal Cancer / Stage IIIC Fallopian Tube Cancer / Stage IIIC Ovarian Cancer / Stage IIIC Primary Peritoneal Cancer / Undifferentiated Ovarian Carcinoma1
3Active Not RecruitingTreatmentMetastatic Breast Cancer (MBC)3
3Active Not RecruitingTreatmentMetastatic Breast Cancer, Triple Negative Breast Cancer / Triple Negative Breast Cancer (TNBC)1
3Active Not RecruitingTreatmentMixed Mesodermal (Mullerian) Tumor / Ovarian Carcinosarcoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Recurrent Uterine Corpus Sarcoma / Stage I Ovarian Cancer / Stage IA Fallopian Tube Cancer / Stage IA Ovarian Cancer / Stage IA Uterine Sarcoma / Stage IA Uterine Sarcoma AJCC v7 / Stage IB Fallopian Tube Cancer / Stage IB Ovarian Cancer / Stage IB Uterine Sarcoma / Stage IB Uterine Sarcoma AJCC v7 / Stage IC Fallopian Tube Cancer / Stage IC Ovarian Cancer / Stage IC Uterine Sarcoma / Stage IC Uterine Sarcoma AJCC v7 / Stage II Ovarian Cancer / Stage IIA Fallopian Tube Cancer / Stage IIA Ovarian Cancer / Stage IIA Uterine Sarcoma / Stage IIA Uterine Sarcoma AJCC v7 / Stage IIB Fallopian Tube Cancer / Stage IIB Ovarian Cancer / Stage IIB Uterine Sarcoma / Stage IIB Uterine Sarcoma AJCC v7 / Stage IIC Fallopian Tube Cancer / Stage IIC Ovarian Cancer / Stage IIIA Fallopian Tube Cancer / Stage IIIA Ovarian Cancer / Stage IIIA Primary Peritoneal Cancer / Stage IIIA Uterine Sarcoma / Stage IIIA Uterine Sarcoma AJCC v7 / Stage IIIB Fallopian Tube Cancer / Stage IIIB Ovarian Cancer / Stage IIIB Primary Peritoneal Cancer / Stage IIIB Uterine Sarcoma / Stage IIIB Uterine Sarcoma AJCC v7 / Stage IIIC Fallopian Tube Cancer / Stage IIIC Ovarian Cancer / Stage IIIC Primary Peritoneal Cancer / Stage IIIC Uterine Sarcoma / Stage IIIC Uterine Sarcoma AJCC v7 / Stage IV Fallopian Tube Cancer / Stage IV Ovarian Cancer / Stage IV Primary Peritoneal Cancer / Stage IVA Uterine Sarcoma / Stage IVA Uterine Sarcoma AJCC v7 / Stage IVB Uterine Sarcoma / Stage IVB Uterine Sarcoma AJCC v7 / Uterine Carcinosarcoma1
3Active Not RecruitingTreatmentNeoplasms, Breast3
3Active Not RecruitingTreatmentNon-Squamous Non-Small Cell Lung Cancer2
3Active Not RecruitingTreatmentRecurrent Large Cell Lung Carcinoma / Recurrent Lung Adenocarcinoma / Recurrent Squamous Cell Lung Carcinoma / Stage IV Large Cell Lung Carcinoma / Stage IV Lung Adenocarcinoma / Stage IV Squamous Cell Lung Carcinoma1
3Active Not RecruitingTreatmentRecurrent Ovarian Cancer1
3Active Not RecruitingTreatmentSquamous Cell Carcinoma, Non-Small-Cell Lung1
3Active Not RecruitingTreatmentSquamous Non-Small Cell Lung Cancer1
3Active Not RecruitingTreatmentStage IV or Recurrent Non-Small Cell Lung Cancer1
3Active Not RecruitingTreatmentTriple Negative Breast Cancer (TNBC)1
3Active Not RecruitingTreatmentUnresectable or Metastatic Melanoma1
3Active Not RecruitingTreatmentUrothelial Cancer1
3CompletedPreventionCancers1
3CompletedSupportive CareCancer, Breast1
3CompletedSupportive CareChemotherapeutic Agent Toxicity / Neuropathy / Neurotoxicity Syndrome / Pain / Stage IIIA Fallopian Tube Cancer / Stage IIIA Ovarian Cancer / Stage IIIA Primary Peritoneal Cancer / Stage IIIB Fallopian Tube Cancer / Stage IIIB Ovarian Cancer / Stage IIIB Primary Peritoneal Cancer / Stage IIIC Fallopian Tube Cancer / Stage IIIC Ovarian Cancer / Stage IIIC Primary Peritoneal Cancer / Stage IV Fallopian Tube Cancer / Stage IV Ovarian Cancer / Stage IV Primary Peritoneal Cancer1
3CompletedSupportive CareDrug/Agent Toxicity by Tissue/Organ / Lung Cancers / Oral Complications / Radiation Toxicity1
3CompletedTreatmentAbdominal wall neoplasm / Fallopian Tube Neoplasms / Genital Neoplasms, Female / Neoplasms, Ovarian / Pelvic Neoplasms1
3CompletedTreatmentAbdominal wall neoplasm / Neoplasms, Ovarian1
3CompletedTreatmentAdenocarcinoma of the Cervix / Adenosquamous carcinoma of the cervix / Cervical Squamous Cell Carcinoma / Recurrent Cervical Carcinoma / Stage IVB Cervical Cancer2
3CompletedTreatmentAdenocarcinoma of the Lung / Adenosquamous Cell Lung Cancer / Bronchoalveolar Cell Lung Cancer / Large Cell Lung Cancer / Squamous Cell Carcinoma of Lung / Stage IB Non-small Cell Lung Cancer1
3CompletedTreatmentAdenocarcinoma of the Lung / Adenosquamous Cell Lung Cancer / Large Cell Lung Cancer / Squamous Cell Carcinoma of Lung / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer1
3CompletedTreatmentBladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter / Urethral Cancer2
3CompletedTreatmentBladder Cancers / Urethral Cancer1
3CompletedTreatmentBreast Cancer Nos Metastatic Recurrent1
3CompletedTreatmentCancer of the Fallopian Tube / Cancer, Ovarian / Malignant Peritoneal Neoplasm1
3CompletedTreatmentCancer, Breast24
3CompletedTreatmentCancer, Breast / Chemotherapy, Adjuvant1
3CompletedTreatmentCancer, Breast / Stage IV Breast Cancer1
3CompletedTreatmentCancer, Ovarian7
3CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer3
3CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Peritoneal Cavity Cancer2
3CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cancer1
3CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer2
3CompletedTreatmentCancer, Ovarian / Primary Peritoneal Cavity Cancer4
3CompletedTreatmentCarcinoma, Squamous Cell of the Head and Neck1
3CompletedTreatmentCritical Ischemia1
3CompletedTreatmentEndometrial Adenocarcinomas / Endometrial Adenosquamous Carcinoma / Endometrial Clear Cell Adenocarcinoma / Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation / Endometrial Serous Adenocarcinoma / Stage III Uterine Corpus Cancer1
3CompletedTreatmentEndometrial Cancers2
3CompletedTreatmentFallopian Tube Cancer / Ovarian Epithelial Cancer / Primary Peritoneal Cancer1
3CompletedTreatmentFallopian Tube Clear Cell Adenocarcinoma / Fallopian Tube Endometrioid Adenocarcinoma / Fallopian Tube Mucinous Adenocarcinoma / Fallopian Tube Serous Adenocarcinoma / Fallopian Tube Transitional Cell Carcinoma / Malignant Ovarian Mixed Epithelial Tumor / Ovarian Brenner Tumor / Ovarian Clear Cell Adenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Mucinous Adenocarcinoma / Ovarian Serous Adenocarcinoma / Ovarian Transitional Cell Carcinoma / Primary Peritoneal Serous Adenocarcinoma / Stage IIIA Fallopian Tube Cancer / Stage IIIA Ovarian Cancer / Stage IIIA Primary Peritoneal Cancer / Stage IIIB Fallopian Tube Cancer / Stage IIIB Ovarian Cancer / Stage IIIB Primary Peritoneal Cancer / Stage IIIC Fallopian Tube Cancer / Stage IIIC Ovarian Cancer / Stage IIIC Primary Peritoneal Cancer / Stage IV Fallopian Tube Cancer / Stage IV Ovarian Cancer / Stage IV Primary Peritoneal Cancer / Undifferentiated Fallopian Tube Carcinoma / Undifferentiated Ovarian Carcinoma1
3CompletedTreatmentHER2 Positive Breast Cancers / Inflammatory carcinoma of the breast / Invasive Ductal Breast Carcinoma / Malignant Neoplasm of Female Breast / Mucinous Breast Cancer Stage II / Tubular Breast Cancer Stage II / Tubular Breast Cancer Stage III1
3CompletedTreatmentHER2-Negative Breast Cancer / Her2-Positive Breast Cancer / Recurrent Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer1
3CompletedTreatmentHER2-positive Metastatic Breast Cancer / Human Epithelial Receptor (HER)-2 Positive Breast Cancer1
3CompletedTreatmentHead and Neck Carcinoma2
3CompletedTreatmentIll-defined Sites / Supportive1
3CompletedTreatmentKaposi's Sarcoma AIDS Related1
3CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)11
3CompletedTreatmentLung Cancers14
3CompletedTreatmentMalignant Melanoma1
3CompletedTreatmentMalignant Neoplasm of Stomach1
3CompletedTreatmentMelanoma1
3CompletedTreatmentMetastatic Breast Cancer (MBC)3
3CompletedTreatmentMetastatic Non-Small Cell Lung Cancer1
3CompletedTreatmentMucosal Melanoma / Recurrent Melanoma / Stage IIIA Skin Melanoma / Stage IIIB Skin Melanoma / Stage IIIC Skin Melanoma / Stage IV Skin Melanoma1
3CompletedTreatmentNeoplasm Metastases / Neoplasms, Breast1
3CompletedTreatmentNeoplasms, Breast2
3CompletedTreatmentNeoplasms, Gastrointestinal Tract1
3CompletedTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
3CompletedTreatmentNon-small Cell Lung Cancer Stage I and II / Peri-operative Chemotherapy1
3CompletedTreatmentPancreatic Cancer Metastatic1
3CompletedTreatmentPrimary Peritoneal Carcinoma / Primary Peritoneal Cavity Cancer / Stage III Ovarian Cancer / Stage III Ovarian Epithelial Cancer / Stage IV Ovarian Cancer / Stage IV Ovarian Epithelial Cancer1
3CompletedTreatmentProstate Cancer2
3CompletedTreatmentSarcomas1
3CompletedTreatmentStage IV Gastric Cancer1
3CompletedTreatmentTumors, Solid1
3CompletedTreatmentUnknown Primary Neoplasms1
3CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
3Enrolling by InvitationTreatmentAnus Diseases / Anus Neoplasms / Carcinoma NOS / Neoplasms / Neoplasms, Squamous Cell / Squamous Cell Carcinoma (SCC)1
3Enrolling by InvitationTreatmentCancer, Ovarian / Neoplasms, Ovarian / Ovarian Germ Cell Cancer1
3Enrolling by InvitationTreatmentCancer, Ovarian / Neoplasms, Ovarian / Ovarian Sex Cord Stromal Tumor1
3Not Yet RecruitingTreatmentCervical Cancers2
3Not Yet RecruitingTreatmentGestational Trophoblastic Neoplasms1
3Not Yet RecruitingTreatmentHER2/Neu Positive / Recurrent Breast Carcinoma / Stage IV Breast Cancer / Stage IV Breast Cancer AJCC v6 and v71
3Not Yet RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)3
3Not Yet RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Malignant Hydrothorax1
3Not Yet RecruitingTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
3Not Yet RecruitingTreatmentSquamous Cell Carcinoma of the Penis, Usual Type1
3RecruitingTreatment(FIGO Stage IIB-IVA) / Uterine Cervical Cancer1
3RecruitingTreatmentAbdominal wall neoplasm / Cancer, Ovarian / Fallopian Tube Cancer1
3RecruitingTreatmentAdenocarcinoma of the Oesophago-gastric Junction / Adenocarcinoma of the Oesophagus / Junctional Tumours / Malignant Neoplasm of Esophagus / Oesophageal Tumours1
3RecruitingTreatmentAdenocarcinomas of the Esophagogastric Junction / Esophageal Adenocarcinoma (UICC TNM7)1
3RecruitingTreatmentAdenocarcinomas of the Gastroesophageal Junction / Gastric Adenocarcinoma1
3RecruitingTreatmentAdenocarcinomas of the Gastroesophageal Junction / Neoplasm, Gastric1
3RecruitingTreatmentAdvanced Gastric Cancer2
3RecruitingTreatmentArtery Diseases, Peripheral / Atherosclerosis / Occlusive Arterial Disease / Peripheral Artery Disease (PAD) / Plaque, Atherosclerotic1
3RecruitingTreatmentBRCA Rearrangement / Deleterious BRCA1 Gene Mutation / Deleterious BRCA2 Gene Mutation / Endometrial Undifferentiated Carcinoma / Fallopian Tube Clear Cell Adenocarcinoma / Fallopian Tube Transitional Cell Carcinoma / Malignant Ovarian Mixed Epithelial Tumor / Ovarian Clear Cell Adenocarcinoma / Ovarian Endometrioid Tumor / Ovarian Seromucinous Carcinoma / Ovarian Serous Tumor / Ovarian Transitional Cell Carcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Undifferentiated Fallopian Tube Carcinoma / Undifferentiated Ovarian Carcinoma1
3RecruitingTreatmentBreast Adenocarcinoma / Estrogen Receptor Negative / HER2/Neu Negative / Progesterone Receptor Negative / Stage IB Breast Cancer / Stage IIA Breast Cancer / Stage IIB Breast Cancer / Stage IIIA Breast Cancer / Stage IIIC Breast Cancer / Triple-Negative Breast Carcinoma1
3RecruitingTreatmentCancer, Breast4
3RecruitingTreatmentCancer, Breast / Metastasis1
3RecruitingTreatmentCancer, Ovarian2
3RecruitingTreatmentCancer, Ovarian / Fallopian Tube Cancer / Malignant Peritoneal Neoplasm / Ovarian Epithelial Cancer1
3RecruitingTreatmentCancer, Ovarian / Fallopian Tube Cancer / Ovarian Epithelial Cancer / Primary Fallopian Tube Cancer / Primary Peritoneal Carcinoma1
3RecruitingTreatmentCarcinoma,Non-Small-Cell Lung / Lung Cancer Non-Small Cell Cancer (NSCLC) / Lung Carcinomas, Non-Small-Cell1
3RecruitingTreatmentCervical Cancers4
3RecruitingTreatmentCervical Carcinoma Stage IIB1
3RecruitingTreatmentChildhood Teratoma / Choriocarcinoma / Extragonadal Seminoma / Germ Cell Tumors / Germinoma / Malignant Germ Cell Neoplasm / Mixed Germ Cell Tumor / Non-seminomatous Germ Cell Tumors / Seminoma / Teratoma / Yolk Sac Tumor1
3RecruitingTreatmentEndometrial Cancers1
3RecruitingTreatmentEndometrial Clear Cell Adenocarcinoma / Endometrial Serous Adenocarcinoma / Stage IIIA Uterine Corpus Cancer / Stage IIIB Uterine Corpus Cancer / Stage IIIC Uterine Corpus Cancer / Stage IVA Uterine Corpus Cancer1
3RecruitingTreatmentEsophageal Cancers3
3RecruitingTreatmentEsophagogastric Junction Carcinoma / Oesophageal Carcinoma1
3RecruitingTreatmentFirst Line Non-Small Cell Lung Cancer1
3RecruitingTreatmentHER2-positive Locally Advanced or Metastatic Breast Cancer1
3RecruitingTreatmentIMRT With or Without Concurrent Chemotherapy for Esophageal Cancer1
3RecruitingTreatmentInfection, Human Immunodeficiency Virus I1
3RecruitingTreatmentInflammatory carcinoma of the breast / Invasive Ductal Breast Carcinoma / Mucinous Breast Cancer / Tubular Breast Carcinoma1
3RecruitingTreatmentInvasive Ductal Breast Carcinoma1
3RecruitingTreatmentLocal Advanced Esophageal Squamous Cell Carcinoma / Stage III Esophageal Squamous Cell Carcinoma1
3RecruitingTreatmentLocally Recurrent Breast Cancer / Metastatic Breast Cancer (MBC)1
3RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)9
3RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers1
3RecruitingTreatmentMetastatic Breast Cancer (MBC)3
3RecruitingTreatmentNeoplasms, Breast1
3RecruitingTreatmentNeoplasms, Endometrial1
3RecruitingTreatmentNeoplasms, Esophageal3
3RecruitingTreatmentNeoplasms, Head and Neck1
3RecruitingTreatmentNon Small Cell Lung Carcinoma (NSCLC) / Non Small Cell Lung Carcinoma NSCLC2
3RecruitingTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
3RecruitingTreatmentNon-Squamous Non-Small Cell Lung Cancer2
3RecruitingTreatmentPancreatic Ductal Carcinoma1
3RecruitingTreatmentPrimary Breast Cancer1
3RecruitingTreatmentProsthesis Survival1
3RecruitingTreatmentSquamous Cell Carcinoma of Esophagus1
3RecruitingTreatmentStage IIA Non-small Cell Lung Cancer / Stage IIB Non-small Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer1
3RecruitingTreatmentStage ⅡA Pancreatic Cancer / Stage ⅡB Pancreatic Cancer1
3RecruitingTreatmentStomach Neoplasms1
3RecruitingTreatmentTriple Negative Breast Cancer (TNBC)1
3RecruitingTreatmentTriple Negative Breast Neoplasms1
3RecruitingTreatmentTriple-Negative Breast Cancer (TNBC)2
3TerminatedNot AvailableStage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
3TerminatedTreatmentCancer, Breast1
3TerminatedTreatmentCancer, Ovarian1
3TerminatedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Malignant Peritoneal Neoplasm1
3TerminatedTreatmentCarcinoma, Adenosquamous / Carcinoma, Large Cell / Lung Cancer Non-Small Cell Cancer (NSCLC) / Squamous Cell Carcinoma (SCC)1
3TerminatedTreatmentCarcinoma, Breast / HER2/Neu Positive / Male Breast Carcinoma / Recurrent Breast Carcinoma / Stage IV Breast Cancer1
3TerminatedTreatmentCardiac Toxicity / Inflammatory carcinoma of the breast / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IV Breast Cancer1
3TerminatedTreatmentEndometrial Cancers2
3TerminatedTreatmentExtragonadal Germ Cell Tumor / Testicular germ cell tumour1
3TerminatedTreatmentFirst Line Metastatic Breast Cancer1
3TerminatedTreatmentHead and Neck Carcinoma1
3TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)7
3TerminatedTreatmentLung Cancers2
3TerminatedTreatmentMelanoma2
3TerminatedTreatmentMetastatic Breast Cancer (MBC)1
3TerminatedTreatmentNeoplasms, Breast1
3Unknown StatusDiagnosticCancer, Breast1
3Unknown StatusTreatmentAdvanced Breast Cancer1
3Unknown StatusTreatmentCancer, Breast9
3Unknown StatusTreatmentCarcinoma of Unknown Primary1
3Unknown StatusTreatmentCervix Carcinoma1
3Unknown StatusTreatmentEsophageal Cancers1
3Unknown StatusTreatmentEsophageal Squamous Carcinoma1
3Unknown StatusTreatmentExtragonadal Germ Cell Tumor / Teratoma / Testicular germ cell tumour1
3Unknown StatusTreatmentFallopian Tube Cancer / Ovarian Epithelial Cancer / Primary Peritoneal Cancer1
3Unknown StatusTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
3Unknown StatusTreatmentLung Cancers8
3Unknown StatusTreatmentMalignant Neoplasm of Stomach1
3Unknown StatusTreatmentMelanoma1
3Unknown StatusTreatmentRecurrent, Persistent or Metastasized Cervical Cancer1
3WithdrawnTreatmentAnaplastic Thyroid Cancers1
3WithdrawnTreatmentCervical Cancers1
3WithdrawnTreatmentLung Cancers2
4Active Not RecruitingTreatmentCancer, Ovarian1
4CompletedNot AvailableCancers1
4CompletedTreatmentAdenocarcinomas / Carcinoma NOS / Carcinoma, Large Cell / Lung Cancer Non-Small Cell Cancer (NSCLC) / Neoplasms, Lung / Squamous Cell Carcinoma (SCC)1
4CompletedTreatmentCancer, Breast1
4CompletedTreatmentCarcinoma, Large Cell / Neuroendocrine Tumors1
4CompletedTreatmentInstent Restenosis1
4CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
4RecruitingTreatmentAdenocarcinoma of the Pancreas1
4RecruitingTreatmentCancer, Breast1
4RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
4Unknown StatusTreatmentMetastatic Breast Cancer (MBC)1
4Unknown StatusTreatmentTumors, Solid1
4WithdrawnTreatmentCancer, Breast1
Not AvailableActive Not RecruitingNot AvailableCancer, Breast1
Not AvailableActive Not RecruitingNot AvailableCancer, Breast / Metastatic Breast Cancer (MBC)1
Not AvailableActive Not RecruitingNot AvailableStage I Ovarian Cancer / Stage IA Fallopian Tube Cancer / Stage IB Fallopian Tube Cancer / Stage IC Fallopian Tube Cancer / Stage II Ovarian Cancer / Stage IIA Fallopian Tube Cancer / Stage IIB Fallopian Tube Cancer / Stage IIC Fallopian Tube Cancer / Stage III Ovarian Cancer / Stage III Primary Peritoneal Cancer / Stage IIIA Fallopian Tube Cancer / Stage IIIB Fallopian Tube Cancer / Stage IIIC Fallopian Tube Cancer / Stage IV Fallopian Tube Cancer / Stage IV Ovarian Cancer / Stage IV Primary Peritoneal Cancer1
Not AvailableActive Not RecruitingNot AvailableStage IV Gastric Cancer With Metastasis1
Not AvailableActive Not RecruitingTreatmentCancer, Breast1
Not AvailableActive Not RecruitingTreatmentCancer, Ovarian / Fallopian Tube Cancer / Malignant Peritoneal Neoplasm1
Not AvailableActive Not RecruitingTreatmentCarcinoma, Breast / Pain, Acute / Pain, Neuropathic / Peripheral Neuropathy1
Not AvailableActive Not RecruitingTreatmentOf the Pancreas / Previously Untreated Resectable Adenocarcinoma of the Pancreas / Subjects Must Have Previously Untreated Apparently Resectable Adenocarcinoma1
Not AvailableCompletedNot AvailableCancer, Breast2
Not AvailableCompletedNot AvailableCancer, Breast / Metastatic Cancers1
Not AvailableCompletedNot AvailableCervical Intraepithelial Neoplasia (CIN)2
Not AvailableCompletedNot AvailableLung Cancers2
Not AvailableCompletedNot AvailableMalignant Neoplasm of Pancreas1
Not AvailableCompletedNot AvailableMetastatic Breast Cancer (MBC)1
Not AvailableCompletedNot AvailableNonsquamous Nonsmall Cell Neoplasm of Lung1
Not AvailableCompletedPreventionPeripheral Vascular Disease (PVD)1
Not AvailableCompletedSupportive CareMalignant Airway Obstruction Secondary to Non-small Cell Lung Cancer1
Not AvailableCompletedTreatmentAdenocarcinoma of the Breast / Cancer, Breast1
Not AvailableCompletedTreatmentAngioplasty / Atherosclerosis / Peripheral Arterial Disease (PAD)1
Not AvailableCompletedTreatmentBreast / Cervical / Lung / Ovarian / Renal1
Not AvailableCompletedTreatmentCancer, Breast2
Not AvailableCompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cancer1
Not AvailableCompletedTreatmentHead and Neck Carcinoma1
Not AvailableCompletedTreatmentHypermethylation / Lung Cancers / Non Small Cell Lung Carcinoma (NSCLC)1
Not AvailableCompletedTreatmentLung Cancers1
Not AvailableCompletedTreatmentMalignant Neoplasm of Pancreas1
Not AvailableCompletedTreatmentOvarian Epithelial Cancer1
Not AvailableCompletedTreatmentPancreatic Cysts1
Not AvailableCompletedTreatmentTumors, Solid1
Not AvailableCompletedTreatmentUterine Cervical Neoplasms1
Not AvailableNo Longer AvailableNot AvailableAdenocarcinomas of the Gastroesophageal Junction / Malignant Neoplasm of Stomach1
Not AvailableNot Yet RecruitingDiagnosticLung Cancer Non-Small Cell Cancer (NSCLC)1
Not AvailableNot Yet RecruitingTreatmentAdenocarcinoma of the Pancreas1
Not AvailableNot Yet RecruitingTreatmentAdvanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction1
Not AvailableNot Yet RecruitingTreatmentCancer, Breast / Cyclophosphamide / Epirubicin / Paclitaxel1
Not AvailableRecruitingNot AvailableCancer, Breast3
Not AvailableRecruitingNot AvailableCancer, Ovarian1
Not AvailableRecruitingNot AvailableCognition Disorders / Polyneuropathies1
Not AvailableRecruitingNot AvailableEsophageal Cancers / Lung Cancers1
Not AvailableRecruitingNot AvailableLung Cancer Non-Small Cell Cancer (NSCLC)2
Not AvailableRecruitingNot AvailablePancreatic Cancer Metastatic1
Not AvailableRecruitingDiagnosticNeoplasms, Breast1
Not AvailableRecruitingHealth Services ResearchCancer, Breast1
Not AvailableRecruitingSupportive CareCancer, Breast / Neoplasms, Ovarian / Pain1
Not AvailableRecruitingTreatmentAdenocarcinoma of the Lung / Adenosquamous Cell Lung Cancer / Large Cell Lung Cancer / Recurrent Non-small Cell Lung Cancer / Squamous Cell Carcinoma of Lung / Stage IIA Non-small Cell Lung Cancer / Stage IIB Non-small Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer1
Not AvailableRecruitingTreatmentAtypical Teratoid/Rhabdoid Tumor (AT/RT) / CNS Tumors / Ewing's Family Tumors / Germ Cell Tumors / Hepatoblastomas / Medulloblastomas / Primary Malignant Brain Neoplasms / Renal Tumors / Retinoblastoma / Rhabdomyosarcomas / Soft Tissue Sarcoma (STS) / Supra-tentorial Primative Neuro-Ectodermal Tumor (PNET)1
Not AvailableRecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
Not AvailableRecruitingTreatmentRecurrent Fallopian Tube Cancer / Recurrent Ovarian Cancer / Recurrent Primary Peritoneal Cancer / Recurrent Uterine Corpus Cancer / Stage IIIA Fallopian Tube Cancer / Stage IIIA Ovarian Cancer / Stage IIIA Primary Peritoneal Cavity Cancer / Stage IIIA Uterine Corpus Cancer / Stage IIIB Fallopian Tube Cancer / Stage IIIB Ovarian Cancer / Stage IIIB Primary Peritoneal Cavity Cancer / Stage IIIB Uterine Corpus Cancer / Stage IIIC Fallopian Tube Cancer / Stage IIIC Ovarian Cancer / Stage IIIC Primary Peritoneal Cavity Cancer / Stage IIIC Uterine Corpus Cancer / Stage IV Fallopian Tube Cancer / Stage IV Ovarian Cancer / Stage IV Primary Peritoneal Cavity Cancer / Stage IVA Uterine Corpus Cancer / Stage IVB Uterine Corpus Cancer1
Not AvailableRecruitingTreatmentStage IIA Breast Cancer / Stage IIB Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer1
Not AvailableTerminatedNot AvailableCancer, Breast1
Not AvailableUnknown StatusNot AvailableCancer, Breast / Metastatic1
Not AvailableUnknown StatusNot AvailableLung Cancer Non-Small Cell Cancer (NSCLC)1
Not AvailableUnknown StatusTreatmentCancer, Breast1
Not AvailableUnknown StatusTreatmentPeripheral Arterial Disease (PAD) / Restenosis1
Not AvailableUnknown StatusTreatmentStage IA Uterine Sarcoma / Stage IB Uterine Sarcoma / Stage IC Uterine Sarcoma / Stage IIA Uterine Sarcoma / Stage IIB Uterine Sarcoma / Stage IIIA Uterine Sarcoma / Stage IIIB Uterine Sarcoma / Stage IIIC Uterine Sarcoma / Stage IVA Uterine Sarcoma / Stage IVB Uterine Sarcoma / Uterine Carcinosarcoma1
Not AvailableWithdrawnTreatmentCancer, Breast2
Not AvailableWithdrawnTreatmentCancer, Breast / Elderly Patients Diagnosed With Breast Cancer / HER-2 Positive Breast Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
Injection, powder, for suspensionIntravenous5 mg/ml
Injection, powder, lyophilized, for suspensionIntravenous100 mg/20mL
Powder, for suspensionIntravenous100 mg
InjectionIntravenous100 mg/16.7mL
InjectionIntravenous30 mg/5mL
InjectionIntravenous300 mg/50mL
InjectionIntravenous6 mg/mL
Injection, solutionIntravenous100 mg/16.7mL
Injection, solutionIntravenous30 mg/5mL
Injection, solutionIntravenous300 mg/50mL
Injection, solutionIntravenous6 mg/mL
SolutionIntravenous6 mg
LiquidIntravenous6 mg
Injection, solution, concentrateIntravenous6 mg/ml
Prices
Unit descriptionCostUnit
Abraxane 100 mg vial1119.6USD vial
Taxol 30 mg/5 ml vial35.06USD ml
Onxol 30 mg/5 ml vial34.54USD ml
Onxol 300 mg/50 ml vial34.54USD ml
Paclitaxel 300 mg/50 ml vial5.31USD ml
Paclitaxel 100 mg/16.7 ml vial4.45USD ml
Paclitaxel 30 mg/5 ml vial3.54USD ml
Paclitaxel 150 mg/25 ml vial3.36USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5498421No1993-03-122013-03-12Us
US5439686No1993-02-222013-02-22Us
CA2155947No2007-08-212014-02-22Canada
CA2086874No1998-09-012013-01-07Canada
US7923536No2003-12-092023-12-09Us
US8034375No2006-08-132026-08-13Us
US8138229No2003-12-092023-12-09Us
US8268348No2006-02-212026-02-21Us
US8314156No2003-12-092023-12-09Us
USRE41884No1996-08-142016-08-14Us
US7758891No2006-02-212026-02-21Us
US9101543No2006-02-212026-02-21Us
US7820788No2004-10-272024-10-27Us
US8853260No2000-10-102020-10-10Us
US9597409No2012-03-042032-03-04Us
US9393318No2012-03-042032-03-04Us
US9511046No2014-01-122034-01-12Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)216-217 °CFDA label
water solubilityInsolubleFDA label
logP3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00556 mg/mLALOGPS
logP3.2ALOGPS
logP3.54ChemAxon
logS-5.2ALOGPS
pKa (Strongest Acidic)10.36ChemAxon
pKa (Strongest Basic)-1ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count10ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area221.29 Å2ChemAxon
Rotatable Bond Count14ChemAxon
Refractivity218.29 m3·mol-1ChemAxon
Polarizability87.17 Å3ChemAxon
Number of Rings7ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.914
Blood Brain Barrier-0.9748
Caco-2 permeable-0.8957
P-glycoprotein substrateSubstrate0.8345
P-glycoprotein inhibitor IInhibitor0.5509
P-glycoprotein inhibitor IINon-inhibitor0.7309
Renal organic cation transporterNon-inhibitor0.9349
CYP450 2C9 substrateNon-substrate0.837
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.7278
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8937
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9158
BiodegradationNot ready biodegradable0.9491
Rat acute toxicity2.4391 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9978
hERG inhibition (predictor II)Non-inhibitor0.7982
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-3971000000-2a76bfe38de6d5790a39

Taxonomy

Description
This compound belongs to the class of organic compounds known as taxanes and derivatives. These are diterpenoids with a structure based either on the taxane skeleton, or a derivative thereof. In term of phytochemistry, several derivatives of the taxane skeleton exist: 2(3->20)-abeotaxane, 3,11-cyclotaxane, 11(15->1),11(10->9)-abeotaxane, 3,8-seco-taxane, and 11(15->1)-abeotaxane, among others. More complex skeletons have been found recently, which include the taxane-derived [3.3.3] propellane ring system.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Prenol lipids
Sub Class
Diterpenoids
Direct Parent
Taxanes and derivatives
Alternative Parents
Tetracarboxylic acids and derivatives / Benzoic acid esters / Benzoyl derivatives / Alpha-acyloxy ketones / Fatty acid esters / Tertiary alcohols / Secondary alcohols / Oxetanes / Carboxylic acid esters / Cyclic alcohols and derivatives
show 9 more
Substituents
Taxane diterpenoid / Tetracarboxylic acid or derivatives / Benzoate ester / Benzoic acid or derivatives / Benzoyl / Fatty acid ester / Alpha-acyloxy ketone / Monocyclic benzene moiety / Fatty acyl / Benzenoid
show 25 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
taxane diterpenoid, tetracyclic diterpenoid (CHEBI:45863)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Ubiquitin protein ligase binding
Specific Function
Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells. Regulates cell death by controlling the mitochondrial membrane permeability. Appea...
Gene Name
BCL2
Uniprot ID
P10415
Uniprot Name
Apoptosis regulator Bcl-2
Molecular Weight
26265.66 Da
References
  1. Gan Y, Wientjes MG, Au JL: Expression of basic fibroblast growth factor correlates with resistance to paclitaxel in human patient tumors. Pharm Res. 2006 Jun;23(6):1324-31. Epub 2006 Jun 8. [PubMed:16741658]
  2. Thomadaki H, Talieri M, Scorilas A: Treatment of MCF-7 cells with taxol and etoposide induces distinct alterations in the expression of apoptosis-related genes BCL2, BCL2L12, BAX, CASPASE-9 and FAS. Biol Chem. 2006 Aug;387(8):1081-6. [PubMed:16895478]
  3. Yoshino T, Shiina H, Urakami S, Kikuno N, Yoneda T, Shigeno K, Igawa M: Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6116-24. [PubMed:17062688]
  4. Matsuyoshi S, Shimada K, Nakamura M, Ishida E, Konishi N: Bcl-2 phosphorylation has pathological significance in human breast cancer. Pathobiology. 2006;73(4):205-12. [PubMed:17119350]
  5. Zhang X, Wang Q, Ling MT, Wong YC, Leung SC, Wang X: Anti-apoptotic role of TWIST and its association with Akt pathway in mediating taxol resistance in nasopharyngeal carcinoma cells. Int J Cancer. 2007 May 1;120(9):1891-8. [PubMed:17230521]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Structural constituent of cytoskeleton
Specific Function
Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain (By similarity).
Gene Name
TUBB1
Uniprot ID
Q9H4B7
Uniprot Name
Tubulin beta-1 chain
Molecular Weight
50326.56 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Cheung CH, Chen HH, Kuo CC, Chang CY, Coumar MS, Hsieh HP, Chang JY: Survivin counteracts the therapeutic effect of microtubule de-stabilizers by stabilizing tubulin polymers. Mol Cancer. 2009 Jul 3;8:43. doi: 10.1186/1476-4598-8-43. [PubMed:19575780]
  4. Horwitz SB: Mechanism of action of taxol. Trends Pharmacol Sci. 1992 Apr;13(4):134-6. [PubMed:1350385]
  5. Kovacs P, Csaba G, Pallinger E, Czaker R: Effects of taxol treatment on the microtubular system and mitochondria of Tetrahymena. Cell Biol Int. 2007 Jul;31(7):724-32. Epub 2007 Jan 14. [PubMed:17314054]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Zinc ion binding
Specific Function
Nuclear receptor that binds and is activated by variety of endogenous and xenobiotic compounds. Transcription factor that activates the transcription of multiple genes involved in the metabolism an...
Gene Name
NR1I2
Uniprot ID
O75469
Uniprot Name
Nuclear receptor subfamily 1 group I member 2
Molecular Weight
49761.245 Da
References
  1. Harmsen S, Meijerman I, Beijnen JH, Schellens JH: Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor. Cancer Chemother Pharmacol. 2009 Jun;64(1):35-43. doi: 10.1007/s00280-008-0842-3. Epub 2008 Oct 7. [PubMed:18839173]
Kind
Protein
Organism
Human
Pharmacological action
Yes
General Function
Structural molecule activity
Specific Function
Non-neuronal microtubule-associated protein. Promotes microtubule assembly.
Gene Name
MAP4
Uniprot ID
P27816
Uniprot Name
Microtubule-associated protein 4
Molecular Weight
121003.805 Da
References
  1. McGrogan BT, Gilmartin B, Carney DN, McCann A: Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta. 2008 Apr;1785(2):96-132. Epub 2007 Nov 12. [PubMed:18068131]
Kind
Protein
Organism
Human
Pharmacological action
Yes
General Function
Structural molecule activity
Specific Function
The exact function of MAP2 is unknown but MAPs may stabilize the microtubules against depolymerization. They also seem to have a stiffening effect on microtubules.
Gene Name
MAP2
Uniprot ID
P11137
Uniprot Name
Microtubule-associated protein 2
Molecular Weight
199524.51 Da
References
  1. McGrogan BT, Gilmartin B, Carney DN, McCann A: Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta. 2008 Apr;1785(2):96-132. Epub 2007 Nov 12. [PubMed:18068131]
Kind
Protein
Organism
Human
Pharmacological action
Yes
General Function
Structural constituent of cytoskeleton
Specific Function
Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N-terminus binds neu...
Gene Name
MAPT
Uniprot ID
P10636
Uniprot Name
Microtubule-associated protein tau
Molecular Weight
78927.025 Da
References
  1. McGrogan BT, Gilmartin B, Carney DN, McCann A: Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta. 2008 Apr;1785(2):96-132. Epub 2007 Nov 12. [PubMed:18068131]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Yu L, Shi D, Ma L, Zhou Q, Zeng S: Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro. Biopharm Drug Dispos. 2013 Jul;34(5):278-87. doi: 10.1002/bdd.1842. Epub 2013 Jun 3. [PubMed:23536207]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxygen binding
Specific Function
Catalyzes the formation of aromatic C18 estrogens from C19 androgens.
Gene Name
CYP19A1
Uniprot ID
P11511
Uniprot Name
Aromatase
Molecular Weight
57882.48 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1B1
Uniprot ID
Q16678
Uniprot Name
Cytochrome P450 1B1
Molecular Weight
60845.33 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Details
1. Bile salt export pump
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Transporter activity
Specific Function
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name
ABCB11
Uniprot ID
O95342
Uniprot Name
Bile salt export pump
Molecular Weight
146405.83 Da
References
  1. Wang EJ, Casciano CN, Clement RP, Johnson WW: Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites. Pharm Res. 2003 Apr;20(4):537-44. [PubMed:12739759]
  2. Lecureur V, Sun D, Hargrove P, Schuetz EG, Kim RB, Lan LB, Schuetz JD: Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol Pharmacol. 2000 Jan;57(1):24-35. [PubMed:10617675]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674]
  2. Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5. [PubMed:11716514]
  3. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. [PubMed:14985103]
  4. Jang SH, Wientjes MG, Au JL: Kinetics of P-glycoprotein-mediated efflux of paclitaxel. J Pharmacol Exp Ther. 2001 Sep;298(3):1236-42. [PubMed:11504826]
  5. Li D, Jang SH, Kim J, Wientjes MG, Au JL: Enhanced drug-induced apoptosis associated with P-glycoprotein overexpression is specific to antimicrotubule agents. Pharm Res. 2003 Jan;20(1):45-50. [PubMed:12608535]
  6. Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24. [PubMed:12948019]
  7. Kim S, Kim SS, Bang YJ, Kim SJ, Lee BJ: In vitro activities of native and designed peptide antibiotics against drug sensitive and resistant tumor cell lines. Peptides. 2003 Jul;24(7):945-53. [PubMed:14499271]
  8. Walle UK, Walle T: Taxol transport by human intestinal epithelial Caco-2 cells. Drug Metab Dispos. 1998 Apr;26(4):343-6. [PubMed:9531522]
  9. Lecureur V, Sun D, Hargrove P, Schuetz EG, Kim RB, Lan LB, Schuetz JD: Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol Pharmacol. 2000 Jan;57(1):24-35. [PubMed:10617675]
  10. Collett A, Tanianis-Hughes J, Hallifax D, Warhurst G: Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a(-/-) mice in vivo. Pharm Res. 2004 May;21(5):819-26. [PubMed:15180340]
  11. Kuo CC, Hsieh HP, Pan WY, Chen CP, Liou JP, Lee SJ, Chang YL, Chen LT, Chen CT, Chang JY: BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo. Cancer Res. 2004 Jul 1;64(13):4621-8. [PubMed:15231674]
  12. Li YC, Fung KP, Kwok TT, Lee CY, Suen YK, Kong SK: Mitochondria-targeting drug oligomycin blocked P-glycoprotein activity and triggered apoptosis in doxorubicin-resistant HepG2 cells. Chemotherapy. 2004 Jun;50(2):55-62. [PubMed:15211078]
  13. Kwak JO, Lee SH, Lee GS, Kim MS, Ahn YG, Lee JH, Kim SW, Kim KH, Lee MG: Selective inhibition of MDR1 (ABCB1) by HM30181 increases oral bioavailability and therapeutic efficacy of paclitaxel. Eur J Pharmacol. 2010 Feb 10;627(1-3):92-8. doi: 10.1016/j.ejphar.2009.11.008. Epub 2009 Nov 10. [PubMed:19903471]
  14. Woodahl EL, Crouthamel MH, Bui T, Shen DD, Ho RJ: MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8. doi: 10.1007/s00280-008-0906-4. Epub 2009 Jan 4. [PubMed:19123050]
  15. Tiwari AK, Sodani K, Wang SR, Kuang YH, Ashby CR Jr, Chen X, Chen ZS: Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol. 2009 Jul 15;78(2):153-61. doi: 10.1016/j.bcp.2009.04.002. Epub 2009 Apr 11. [PubMed:19427995]
  16. Noguchi K, Kawahara H, Kaji A, Katayama K, Mitsuhashi J, Sugimoto Y: Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib. Cancer Sci. 2009 Sep;100(9):1701-7. doi: 10.1111/j.1349-7006.2009.01213.x. Epub 2009 May 12. [PubMed:19493273]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Transporter activity
Specific Function
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotre...
Gene Name
ABCC1
Uniprot ID
P33527
Uniprot Name
Multidrug resistance-associated protein 1
Molecular Weight
171589.5 Da
References
  1. Heijn M, Hooijberg JH, Scheffer GL, Szabo G, Westerhoff HV, Lankelma J: Anthracyclines modulate multidrug resistance protein (MRP) mediated organic anion transport. Biochim Biophys Acta. 1997 May 22;1326(1):12-22. [PubMed:9188796]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Atpase activity, coupled to transmembrane movement of substances
Specific Function
ATP-dependent transporter probably involved in cellular detoxification through lipophilic anion extrusion.
Gene Name
ABCC10
Uniprot ID
Q5T3U5
Uniprot Name
Multidrug resistance-associated protein 7
Molecular Weight
161627.375 Da
References
  1. Chen ZS, Hopper-Borge E, Belinsky MG, Shchaveleva I, Kotova E, Kruh GD: Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol Pharmacol. 2003 Feb;63(2):351-8. [PubMed:12527806]
  2. Zhou Y, Hopper-Borge E, Shen T, Huang XC, Shi Z, Kuang YH, Furukawa T, Akiyama S, Peng XX, Ashby CR Jr, Chen X, Kruh GD, Chen ZS: Cepharanthine is a potent reversal agent for MRP7(ABCC10)-mediated multidrug resistance. Biochem Pharmacol. 2009 Mar 15;77(6):993-1001. doi: 10.1016/j.bcp.2008.12.005. Epub 2008 Dec 25. [PubMed:19150344]
  3. Hopper-Borge E, Xu X, Shen T, Shi Z, Chen ZS, Kruh GD: Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epothilone B. Cancer Res. 2009 Jan 1;69(1):178-84. doi: 10.1158/0008-5472.CAN-08-1420. [PubMed:19118001]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotre...
Gene Name
SLCO1B3
Uniprot ID
Q9NPD5
Uniprot Name
Solute carrier organic anion transporter family member 1B3
Molecular Weight
77402.175 Da
References
  1. Smith NF, Acharya MR, Desai N, Figg WD, Sparreboom A: Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther. 2005 Aug;4(8):815-8. [PubMed:16210916]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name
ABCG2
Uniprot ID
Q9UNQ0
Uniprot Name
ATP-binding cassette sub-family G member 2
Molecular Weight
72313.47 Da
References
  1. Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhanel M, Spruss T, Bernhardt G, Graeff C, Farber L, Gschaidmeier H, Buschauer A, Fricker G: Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest. 2002 Nov;110(9):1309-18. [PubMed:12417570]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Organic anion transmembrane transporter activity
Specific Function
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name
ABCC2
Uniprot ID
Q92887
Uniprot Name
Canalicular multispecific organic anion transporter 1
Molecular Weight
174205.64 Da
References
  1. Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhanel M, Spruss T, Bernhardt G, Graeff C, Farber L, Gschaidmeier H, Buschauer A, Fricker G: Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest. 2002 Nov;110(9):1309-18. [PubMed:12417570]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:33